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The human eye is one of our main sensory organs. The cornea and the lens enable us 
to focus images on the retina, the light sensitive part of the eye. Most of the refractive 
power is due the difference in refractive index between air and the cornea that provides 
the refractive power of approximately 43 diopters, but the ciliary muscles controlling the 
curvature of the lens provide the flexible focusing power of the eye. Variation of the lens 
curvature is essential in accommodation, which enables the eye to focus the image of 
objects both far and near on the retina. The retina is a light-sensitive layer covering about 
65 percent the interior surface of the eye. It is composed of three layers of nerve cell 
bodies, two layers of synapses (Figure 1), and a nerve fiber layer. The outer nuclear layer 
contains cell bodies of the photoreceptors, the inner nuclear layer contains cell bodies 
of the amacrine, bipolar and horizontal cells, and the ganglion cell layer contains cell 
bodies of ganglion cells and displaced amacrine cells. The neurons are supported by 
Müller cells, the radial glial cells of the retina. The adherens junctions between Müller 
cells and photoreceptor cell inner segments form the outer limiting membrane (OLM) 
of the retina. The inner limiting membrane (ILM) of the retina is likewise composed of 
laterally contacting Müller cell end feet and associated basement membrane constituents 
(Figure 1). 
The human retina contains two types of photoreceptors: rods and cones. The rods are 
more numerous, totaling 120 million. Rods are more sensitive than cones. The 6 to 7 
million cones provide color sensitivity in bright light conditions; there are red, yellow and 
blue cones for, long, medium and short wavelengths(L, M and S cones), respectively. 
Cones are concentrated in the central retina known as the macula lutea (the yellow spot). 
Visual acuity is formed in the center of the macula at the fovea centralis, a 0.3 mm 
diameter rod-free area with very tightly packed cones.1 The photoreceptors are embedded 
in the retinal pigment epithelium (RPE), a pigmented cell layer that supports the functions 
of the retina.
Figure 1. Structure of the human eye. A small part of the retina is enlarged (right), revealing its cellular layers. The photorecep-
tors lie against a pigmented cells layer called the retinal pigment epithelium (RPE). OLM, outer limiting membrane (modified 
from http://webvision.med.utah.edu).
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Retinal processes
Three important processes can be discerned in photoreceptor cells: 1) ciliary transport, 2) 
phototransduction, and 3) (a part of) the visual cycle. First, ciliary transport is carried out 
by the intraflagellar transport (IFT) machinery, which mediates bidirectional movement 
of axonemal components and proteins along the ciliary axoneme of photoreceptors. 
Second, the phototransduction cascade is the process by which the photoreceptors 
convert the energy of an absorbed photon into a neuronal signal. Finally, the visual 
cycle is a continuous recycling process in which the chromophore (all-trans retinal) that 
plays a role in the start of the phototransduction cascade, is recycled into newly usable 
chromophore (11-cis retinal).
Ciliary transport
The connecting cilium (CC) at the base of the photoreceptor outer segment corresponds 
to the transition zone of a prototypic cilium, a region with increasing relevance for ciliary 
homeostasis. The outer segment, connecting cilium and associated basal body form a 
highly specialized sensory cilium, dedicated to photoreception and subsequent signal 
transduction to the inner retinal layers and, eventually, the brain. The CC is involved 
in bidirectional transport of a plethora of proteins required for the visual process. The 
IFT machinery has been ﬁrst discovered in the unicellular organism Chlamydomonas 
reinhardtii.2,3 IFT involves the transport of cargo associated with large protein complexes 
(IFT particles) along the axoneme by motor proteins. IFT particles transport axonemal 
subunits and structural proteins at the base of the cilium and transfer them to the site 
of cilium synthesis, as it grows. The association of IFT particles forms two multiprotein 
subcomplexes, IFT complex A and B. The IFT particles also interact with motor proteins 
such as heterotrimeric kinesin-2 for anterograde transport towards the cilium, and dynein 
for retrograde transport towards the cell body. The IFT network is highly conserved from 
unicellular organisms to mammals and within different cell types. The cilium transport 
in photoreceptors requires distinct trafficking machinery to target speciﬁc proteins to 
different domains of the outer segment (Figure 2, lower panel).
Phototransduction 
Phototransduction cascade begins when a photopigment in the photoreceptor disks 
absorbs a photon. The photopigment contains the light-absorbing chromophore 11-cis-
retinal (an aldehyde of vitamin A) coupled to one of four opsins that tune the molecule’s 
absorption of light to a particular region of the spectrum. The functional specialization 
of the various photoreceptor types (rods, L, M and S cones) is due to different protein 
components of the photopigments. Most of the knowledge  about the molecular events 
of phototransduction has been gathered from experiments performed in rods, where the 
photopigment is rhodopsin. When the rhodopsin molecule is activated by a photon, its 
conformation  changes from 11-cis-retinal to all-trans retinal. The changes lead to the 
activation of transducin, which activates cGMP specific phosphodiesterase (PDE). All 
of these events take place within the disk membrane. The hydrolysis of cGMP by PDE 
decreases the concentration of cGMP throughout the outer segment, and subsequently, 
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reduces the number of cGMP molecules that are available for binding to the channels in 
the surface of the outer segment membrane, leading to channel closure4 (Figure 2, middle 
panel).
The phototransduction cascade provides an extraordinary signal amplification. A single 
light-activated rhodopsin molecule can activate 800 transducin molecules. The transducin 
molecule in turn activates a phosphodiesterase molecule, that is capable of catalyzing up 
to six cGMP molecules. This complex biochemical cascade, initiated by the rhodopsin 
molecule capturing a photon, results in the closure of more than 200 ion channels (~ 2%) 
in each rod that are open in the dark. Subsequently, this results in a change of about 1 mV 
in the membrane potential of this photoreceptor.4
Visual cycle
The classical visual cycle takes place in the retinal pigment epithelium (RPE) and 
photoreceptor outer segment (OS) and begins with the absorption of a photon by a visual 
pigment molecule. In rods, the outer segments contain stacks of membranous disks 
composed of a lipid bi-layer. Following photon capture, all-trans retinal is dissociated 
from the activated opsin into the disk membranes of the photoreceptor OS and is believed 
to complex with phosphatidylethanolamine (Figure 2, upper panel). The resulting 
N-retinylidine-phosphatidylethanolamine is transported to the cytoplasmic disk surface 
by the retina-specific ATP-binding cassette transporter (ABCA4), and then transferred to 
the cytoplasm as all-trans retinal.5 Once in the cytoplasm, all-trans retinal is reduced to 
all-trans retinol (vitamin A) by retinol dehydrogenase (RDH12) in an NADPH-dependent 
reaction. All-trans retinol is released into the interphotoreceptor matrix a, crosses the 
subretinal space bound to the interphotoreceptor retinoid binding protein (IRBP), and 
enters the retinal pigment epithelium (RPE).6
In the RPE, all-trans retinol is transferred to the cellular retinoid binding protein-1 
(CRBP1) and delivered to lecithin retinol acyl transferase (LRAT).7 LRAT esterifies all-
trans retinol by linking it to phosphatidyl choline in the membrane and generating all-
trans retinyl esters. Additionally, all-trans retinol from blood in the choroidal circulation 
can enter the visual cycle through the basal surface of RPE cells for esterification by LRAT. 
The esters generated by LRAT are the stable and non-cytotoxic  storage form of vitamin A 
in the eye, and their accumulation is thought to be an important force driving subsequent 
reactions in the visual cycle. More importantly, they serve as the substrate for the next 
step of the visual cycle and are required for 11-cis retinal regeneration.8
In the next step, RPE65 hydrolyses and isomerizes all-trans retinyl esters to yield 11-
cis retinol.9 RPE65 is essential for the regeneration of 11-cis retinoids, as there is no 
isomerohydrolase activity in its absence.10 Then, 11-cis Retinol binds the cellular 
retinaldehyde binding protein (CRALBP), a retinoid binding protein with high affinity 
for 11-cis retinoids.11
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Figure 2. Retinal processes. Schematic representation of three major processes in human rod photoreceptor cells and the reti-
nal pigmented epithelium (RPE). Upper panel: The retinoid cycle takes place in rod photoreceptor cells and the RPE. The local-
ization and function of proteins involved in autosomal recessive  and X-linked non-syndromic retinal dystrophies are depicted, 
with the exception of GCAP, a critical Ca2+-binding interactor of GUCY2D, which is mutated in autosomal dominant cone-
rod dystrophy (http://www.sph.uth.tmc.edu/Retnet/home.htm). CRALBP, protein product of RLBP1; IRBP, protein product of 
RBP3; RAL, retinal; RE, retinyl esters; RHOa, photoactivated rhodopsin; ROL, retinol. Middle panel: The phototransduction 
cascade in rod photoreceptors. Upon photoactivation, amplification of the signal is mediated through the α-subunit of trans-
ducin and phosphodiesterase, which results in closure of the cGMP-gated channel, hyperpolarization of the cell, and reduced 
glutamate release at the synapse. SAG, arrestin. Lower panel: Ciliary transport along the connecting cilium. Kinesin II family 
motors mediate transport toward the outer segment; cytoplasmic dynein 2/1b (DYNC2H1) is involved in transport from the 
outer segment towards the inner segment (modified from den Hollander et al., 201017)
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CRALBP delivers 11-cis retinol to 11-cis retinol dehydrogenase (RDH5). 11-cis RDH 
oxidizes 11-cis retinol to 11-cis retinal using NAD as a cofactor, and newly generated 
11-cis retinal. At that time, 11-cis retinal is released from the RPE, crosses the sub-retinal 
space and re-enters the photoreceptors. Again, IRBP is proposed to facilitate this transport 
and to protect 11-cis retinal from isomerization en route to the photoreceptors.6 After 
entering the OS, the newly generated 11-cis retinal  binds to rhodopsin and can initiate 
the phototransduction cascade again (Figure 2, upper panel). 
Besides this ‘classical’ visual cycle in which photoreceptors and the RPE participate, another 
visual cycle recently emerged related to cone photoreceptors. Cones are specialized in 
daytime vision where constant high light levels increase the demand for 11-cis retinal. 
Besides cones, the cone visual cycle is believed to involve the Müller glia cells. In the 
proposed cone visual cycle, all-trans retinol generated in photoreceptors is transported 
to Müller cells and is isomerized to 11-cis retinol by RPE65c isomerase.12 At that time, 
11-cis retinol from Müller cells enters the inner segments of the cone photoreceptors and 
is oxidized to 11-cis retinal for visual pigment formation. Müller cells have the ability 
to generate 11-cis retinol from all-trans retinol.13 Furthermore, IRBP, which colocalizes 
with the microvilli of Müller cells, is a major carrier of 11-cis retinol,11 and is mainly 
concentrated around cone photoreceptors.14-16 A functional relationship between IRBP, 
Müller cells, and cone inner segments in a cone-specific pathway would explain the ability 
of cones to efficiently regenerate visual pigment in constant light conditions.
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Aim of this thesis
The aim of this thesis was to identify and characterize genetic defects underlying retinal 
ciliopathies. Initially, genetic defects were detected by homozygosity mapping using high-
density genome-wide single nucleotide polymorphism (SNP) arrays in combination with 
a positional candidate gene approach. After the advent of next generation sequencing 
technology, the approach shifted to a combination of homozygosity mapping with 
targeted next generation sequencing, which, finally, was replaced by exome sequencing.
Chapter 2 summarizes all genes, mutations and modifier alleles associated with non-
syndromic retinal ciliopathies, the progress that was made in dissecting the associated 
retinal disease mechanisms, and an evaluation of gene augmentation approaches to 
antagonize retinal degeneration.
Chapter 3 describes  mutation analysis of IQCB1 in 226 individuals affected by Leber 
congenital amaurosis (LCA). We identified frameshift and nonsense mutations in 12 
individuals diagnosed with LCA. 
In Chapter 4, we performed restriction fragment length polymorphism analysis of the 
BBS1 p.Met390Arg allele in 2,007 individuals affected by autosomal recessive retinitis 
pigmentosa (RP). We found a significant association between this BBS1 variant and non-
syndromic autosomal recessive RP and relatively mild forms of Bardet-Biedl syndrome 
(BBS). 
Chapter 5A presents C8orf37 as a new gene involved in RP and cone-rod dystrophy. 
In Chapter 5B the interactome of C8orf37 is described and the role of C8orf37 in 
photoreceptors is proposed.
Finally, Chapter 6 is dedicated to the general discussion. 
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Abstract
Homozygosity mapping and exome sequencing have accelerated the discovery of gene 
mutations and modifier alleles implicated in inherited retinal degeneration in humans. 
To date, 158 genes have been found to be mutated in individuals with retinal dystrophies. 
Approximately one-third of the gene defects underlying retinal degeneration affect the 
structure and/or function of the “connecting cilium” in photoreceptors. This structure 
corresponds to the transition zone of a prototypic cilium, a region with increasing 
relevance for ciliary homeostasis. The connecting cilium connects the inner and outer 
segment of the photoreceptor, mediating bi-directional transport of phototransducing 
proteins required for vision. In fact, the outer segment, connecting cilium and associated 
basal body forms a highly specialized sensory cilium, fully dedicated to photoreception 
and subsequent signal transduction to the brain. At least 21 genes that encode ciliary 
proteins are implicated in non-syndromic retinal dystrophies like cone dystrophy (CD), 
cone-rod dystrophy (CRD), Leber congenital amaurosis (LCA), macular degeneration 
(MD) or retinitis pigmentosa (RP). The generation and characterization of vertebrate 
retinal ciliopathy animal models have revealed insights into the molecular disease 
mechanism which are indispensable for the development and evaluation of therapeutic 
strategies. Gene augmentation therapy has proven to be safe and successful in restoring 
long-term sight in mice, dogs and humans suffering from LCA or RP. Here, we present 
a comprehensive overview of the genes, mutations and modifier alleles involved in non-
syndromic retinal ciliopathies, review the progress in dissecting the associated retinal 
disease mechanisms, and evaluate gene augmentation approaches to antagonize retinal 
degeneration in these ciliopathies.
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Introduction 
Up to just a few years ago, identifying the genetic basis of an inherited human disease 
was a long journey, requiring many years of work in ascertainment of families for linkage 
analysis, followed by fine mapping of the locus and, finally, sequencing of candidate genes 
one by one until the likely causative gene was identified. Until now at least 158 genes 
(RetNet; http://www.sph.uth.tmc.edu/retnet/) have been associated with several types 
of inherited retinal dystrophies, and the arrival of new genetic technologies like single 
nucleotide polymorphism (SNP) microarrays and next generation sequencing (NGS) 
have increased the pace of disease gene identification. For example, during the past year 
(2011-2012) the use of SNP arrays and/or NGS have enabled the identification of 10 new 
retinal dystrophy genes. Remarkably, four of these genes (C8orf37,1 IFT140,2 MAK3-4 
and TMEM2375) encode ciliary proteins, which underlines the importance of disrupted 
ciliary processes in the pathogenesis of retinal dystrophies.
The primary cilium is the antenna of the cell, allowing the effective transduction of 
various forms of sensory information from the extracellular environment. The cilium is 
present on cells throughout the human body, and the importance of this organelle in 
biology and in medicine has been highlighted by the growing number of genetic diseases 
that have been linked to primary cilium defects. The connecting cilium at the base of the 
photoreceptor outer segment corresponds to the transition zone of a prototypic cilium, a 
region with increasing relevance for ciliary homeostasis. The connecting cilium connects 
the inner and the outer segment of the photoreceptor cell, mediating bi-directional 
transport of phototransducing proteins required for vision. In fact, the outer segment, 
connecting cilium and associated basal body forms a highly specialized sensory cilium, 
fully dedicated to photoreception and subsequent signal transduction to the brain. Ciliary 
databases, like CiliaProteome6 or Cildb,7 have integrated bioinformatic, genomic and 
proteomic ciliary data from numerous high-throughput studies. Of the 158 identified 
genes implicated in retinal dystrophies, at least 53 (33%) encode proteins that localize to 
the cilium and/or basal body of the cell.
Mutations in these ciliary genes can lead to a wide range of clinical features involving the 
eye, kidney, heart, liver, central nervous system, adipose tissue, gonads and bones. Vari-
ous syndromes have been defined based on the combination of clinical features involving 
these organs.8,9 Syndromic ciliopathies include Alstrom syndrome (ALMS, MIM 203800), 
Bardet-Biedl syndrome (BBS, MIM 209900), Ellis-van Creveld syndrome (EVC, MIM 
225500), asphyxiating thoracic dystrophy (ATD, MIM 208500), Joubert syndrome (JBTS, 
MIM 213300), McKusick-Kaufman syndrome (MKKS, MIM 236700), Meckel-Gruber 
syndrome (MKS, MIM 249000), orofaciodigital syndrome type 1 (OFD1, MIM 311200), 
Senior-Løken syndrome (SLSN, MIM 266900) and Usher syndrome type 2A (USH2A, 
MIM 276901). These syndromes are genetically heterogeneous, involving mutations in a 
large number of genes. They can show considerable clinical and genetic overlap, as muta-
tions in a number of these genes can cause various syndromes.
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Retinal dystrophy can present as one of the clinical features of these syndromes, but is 
more often present as an isolated disease without additional features. One-third of these 
non-syndromic retinal dystrophies involve a defect in a ciliary protein. This group of reti-
nal dystrophies, the non-syndromic retinal ciliopathies, are the scope of this review.
Non-syndromic retinal ciliopathies
Non-syndromic retinal ciliopathies can have various clinical presentations, depending 
on the type of photoreceptors that are primarily affected by the disease. Retinitis pig-
mentosa (RP, MIM 268000) is the most common inherited retinal degeneration with an 
estimated worldwide prevalence of 1:4,000 individuals.10 RP is initially characterized by 
rod photoreceptor dysfunction, giving rise to night blindness, followed by progressive 
midperipheral vision loss, tunnel vision, and at advanced stages when also cones are af-
fected, eventually can progress to blindness. The disease is genetically heterogeneous and 
displays all Mendelian patterns of inheritance. In addition, some cases have been linked 
to mitochondrial mutations or displayed digenic inheritance.11,12
Cone dystrophy is a progressive cone disorder with an estimated prevalence of 1:30,000 
to 1:40,000.13 Patients have normal cone function initially, but show visual loss and color 
vision disturbance in the first or second decade.14 Macular abnormalities can be present, 
and the optic nerve may show a variable degree of temporal pallor. On electroretinogra-
phy (ERG), cone responses progressively deteriorate and rod responses are initially nor-
mal, but can diminish slightly over time. The visual acuity generally diminishes to legal 
blindness before the third or fourth decade of life.
Cone-rod dystrophy (CRD, MIM 120970) has an estimated prevalence of 1:30,000 to 
1:40,000,13 and also displays all types of Mendelian inheritance. CRD is characterized by 
a primary loss of cone photoreceptors and subsequently followed by, or simultaneous 
with, the loss of rod photoreceptors.14 The disease in most cases becomes apparent during 
primary school years. The symptoms include photo-aversion, decreased visual acuity with 
or without nystagmus (pendular or roving eye movements), color vision defects, and de-
creased sensitivity of the central visual field. Since rods are also involved, night blindness 
and peripheral vision loss may occur. The diagnosis of CRD is mainly based on ERG 
recordings, in which cone responses are more severely reduced than, or equally reduced 
as, rod responses.15
Macular dystrophy (MD) affects the central region of the retina called the macula, 
leading to loss of color and sharp vision. Inherited forms of the disease can be transmitted 
through autosomal dominant and autosomal recessive mechanisms. Various forms of 
MD are distinguished based on particular clinical features, such as a dark choroid typical 
for Stargardt disease and a yellow ‘egg-yolk’ appearance of the macula in Best disease, 
while the retinal appearance is essentially normal in occult macular dystrophy. 
Leber congenital amaurosis (LCA, MIM 204000) is the most severe form of early-onset 
Chapter 2
26
retinal blindness and typically becomes evident in the first year of life. The frequency varies 
between 1:30,00016 and 1:81,000.17 Poor visual function is accompanied by nystagmus, 
photophobia, absent pupillary responses, hyperopia, extinguished or severely reduced 
rod and cone signals on ERG, and a highly variable retinal appearance. LCA is generally 
inherited in an autosomal recessive manner.
Genetic heterogeneity
Although CD, CRD, LCA, MD and RP are described as distinct clinical entities, they are 
not always easily distinguished18 (Figure 1) and can have overlapping genetic causes.12 
To date, 74 genes have been associated with these diseases and it is expected that more 
will follow soon, since ~50% of autosomal recessive (ar) RP, 90% of arCD, 60% of arCRD 
and 30% of arLCA cases still need to be solved.18 Of these 74 genes, 21 (~28%) encode 
ciliary proteins (Table 1). As studies involving comprehensive screening of all these genes 
in large cohorts are scarce, it is difficult to calculate the prevalence of mutations in these 
21 genes in retinal dystrophies. Several genes mutations have so far only been described 
in one or a few families. If we assign a frequency of 1% to such cases, we estimate that 
mutations in 16 ciliary genes (ARL6, BBS1, BBS9, C2orf71, C8orf37, CLRN1, FAM161A, 
MAK, OFD1, RP1, RP2, RPGR, TOPORS, TTC8, TULP1, USH2A) represent at least 36% 
of the genetic causes in RP. Among the most frequent causes of RP are mutations in the 
USH2A gene, and in particular the p.Cys759Phe mutation.19
Figure 1. Schematic representation of phenotypic and genetic overlap among non-syndromic retinal ciliopathies. The 
involvement of cone and rod photoreceptors and progression of diseases are shown in order to match the genetic overlap. At 
end stage, CD can hardly be distinguished from CRD. Patients with RP initially display tunnel vision due to rod defects that 
very often progresses to complete blindness when the cones are also affected. In patients with LCA, the defects can occur in 
both types of  photoreceptors, or in RPE cells, and therefore clinical and molecular genetic overlap with CD, CRD, or RP can 
be expected. At early stage MD can show an overlap with CD. RPGR is also associated with MD. CD, cone dystrophy; CRD, 
cone-rod dystrophy; LCA, Leber congenital amaurosis; MD, macular dystrophy; RP, retinitis pigmentosa (modified from den 
Hollander et al., 2010).18
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Mutations in five ciliary genes (CEP290, IQCB1, LCA5, RPGRIP1, TULP1) explain 23% of 
all solved LCA cases. An intronic mutation (c.2991+1655A→G) in CEP290, which creates 
a strong splice-donor site and inserts a cryptic exon into the mRNA, is by far the most 
frequent cause of LCA.20
In CD and CRD, only 4% of the cases are due to mutations in three ciliary genes (C8orf37, 
RPGR, RPGRIP1), which is unexpected considering the high percentage of mutations 
in ciliary genes identified in LCA and RP. Possibly, the number of ciliary genes is 
underrepresented due to the high percentage of unsolved cases in CD and CRD (90% and 
60% respectively).21-25 Mutations in the ciliary RP1L1 gene have only been described in 
Japanese patients with occult MD;26-28 other ciliary genes have so far not been associated 
with MD.
Inheritance patterns 
In genes associated with non-syndromic retinal ciliopathies, the most predominant 
patterns of inheritance are autosomal recessive and X-linked. Only two genes, RP1 and 
TOPORS have been associated with autosomal dominant RP. It is remarkable that just two 
genes of a total of 21 adRP genes encode ciliary proteins.29 An explanation for the small 
number of autosomal dominant non-syndromic retinal ciliopathies could lie in the type 
of mutations and gene function. 
Many non-syndromic retinal ciliopathy genes encode proteins that are part of a 
multiprotein complex, like the BBSome (BBS1, BBS9, TTC8)30 or the IQCB1-CEP290 
complex.31. Haploinsufficiency due to the loss of one allele could potentially be 
compensated by another member of the protein complex. RPGRIP1 forms stable polymers 
in the connecting cilium through the coiled-coil domain.32.
Eight additional non-syndromic retinal ciliopathy proteins are predicted by SMART 
(http://smart.embl-heidelberg.de/) to have coiled-coil domains which, when mutated, 
could affect cell fate through a dominant-negative disease mechanism. Therefore, it is 
possible that dominant-negative mutations in ciliary proteins remain to be identified 
in non-syndromic retinal dystrophies. Mutations in RP1 have been suggested to act in 
a dominant-negative fashion rather than a gain-of-function, as heterozygous mutant 
Rp1 mice did not show any phenotype, opposed to RP patients carrying the mutation 
p.Arg677* in heterozygous state.33-34 On the other hand, TOPORS is inherited as an 
autosomal dominant trait and likely to be due to haploinsufficiency.35
The occurrence of de novo mutations could be relatively frequent, as NGS analysis of 
retinal dystrophy genes identified de novo mutations in 4 (~14%) of 28 isolated cases in 
which causative variants were found.36 De novo mutations have recently been shown to 
play a major role in human diseases with reduced reproductive fitness,37-39 suggesting that 
they may also occur frequently in individuals affected by retinal ciliopathies, particular in 
syndromic forms involving intellectual disorders. 
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Genotype-phenotype correlation
For the majority of mutations, a clear-cut correlation has not been established between 
genotype and phenotype. This holds true for mutations in genes that exclusively cause 
non-syndromic retinal ciliopathies, in which the clinical presentation can partially 
overlap (Figure 1, Table 1). However, among genes that cause both syndromic and non-
syndromic retinal ciliopathies (ARL6, BBS1, BBS9, CLRN1, CEP290, IQCB1, OFD1, 
TTC8, USH2A) there are some interesting examples of genotype-phenotype correlations. 
In TTC8 a splice site mutation, leading to the in-frame skipping of a 30-bp retina-specific 
exon, was identified in a family with non-syndromic RP, whereas most BBS mutations are 
predicted to significantly impact mRNA stability and/or protein function.40 Interestingly, 
an in-frame deletion (p.Glu148_Val234del) in BBS9 has been described to cause non-
syndromic RP in two affected members of the family, while the third affected member 
showed all the primary features of BBS,41 suggesting that additional factors may 
contribute to the disease in the latter individual. Two missense mutations in CLRN1 
identified in RP patients are predicted to have a less severe effect on protein function 
than mutations identified in patients with Usher syndrome.42 A deep intronic mutation in 
the OFD1 gene was identified in a large family with RP, which inserts a cryptic exon into 
the mRNA, but reduced levels of normally spliced gene product remain.43 This disease 
mechanism of reduced expression of a syndromic ciliopathy genes causing isolated retinal 
dystrophy is reminiscent of an intronic mutation in CEP290 that causes LCA,20 suggesting 
that reduced dosage of correctly spliced ciliopathy genes may be a common disease 
mechanism in retinal degenerations.
A vast number of mutations have been identified in CEP290, which can lead to a wide 
phenotypic spectrum ranging from non-syndromic LCA to MKS. The intronic mutation 
c.2991+1655A>G, leading to the insertion of a cryptic exon into the mRNA and 
introduction of a premature stop codon, is the most prevalent mutation in LCA accounting 
for 15-20% of the cases.22 Since a fraction of wild-type CEP290 mRNA remains in patients 
carrying the intronic mutation, it is hypothesized that this hypomorphic character of the 
Table1. Non-syndromic retinal ciliopathies genes
Entrez 
gene 
symbol
Entrez 
gene 
identifier
Localization of the 
encoded protein in 
photoreceptors
Pattern of 
inheritance
Non-syndromic 
disease association
Syndromic 
disease 
association
References
ARL6 84100 Photoreceptor and 
ganglion cell layer, nerve 
fiber layer 
AR RP BBS 98-100
BBS1 582 BB, CC, synapse of the 
plexiform layer
AR RP BBS 53, 101-
102a
BBS9 27241 BB, CC, synapse of the 
plexiform layer
AR RP BBS 41, 103a
C2orf71 388939 CC (putative) AR RP 82, 83
C8orf37 157657 BB, ciliary rootlet AR CRD, RP 1
CEP290 80184 CC AR LCA BBS, JBTS, 
MKS, SLSN
20, 104-
107
CLRN1 7401 CC, IS, ribbon synapses AR RP USH3 42, 108-
110
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FAM161A 84140 Apical part of CC, BB, 
IS, OPL
AR RP 111-112b
IQCB1 9657 CC, OS AR LCA SLSN 67, 113-
114
LCA5 167691 BB, CC AR LCA 71
MAK 4117 CC, OS axoneme AR RP 3-4, 115
OFD1 8481 CC, IS (putative) XL RP JBTS, OFD, 
SGBS2
43, 97, 116-
117
RP1 6101 CC, OS axoneme AD, AR RP 68, 118-
121
RP1L1 94137 CC, OS axoneme AD with 
reduced 
penetrance
MD 26-28, 68
RP2 6102 BB, Golgi, periciliary 
region, PM
XL RP 80, 122-
123
RPGR 6103 BB, CC XL CD, CRD, MD, RP, 
RP and sinorespirato-
ry infections, with or 
without deafness
74, 78, 124-
133
RPGRIP1 57096 CC AR CRD, LCA, RP 24, 32, 134-
136
TOPORS 10210 BB, nuclei of ganglion 
cells, periciliary region
AD RP 35, 72
TTC8 123016 BB, CC, synapse of the 
plexiform layer
AR RP BBS 40, 137a
TULP1 7287 CC, IS, OLM AR LCA, RP 138-142
USH2A 7399 CC, IS, OLM, OPL AR RP USH2 19, 143-
145
For all non-syndromic retinal ciliopathy genes, the gene identifier, localization of the encoded protein in the photoreceptor, the 
type of inheritance, association with non-syndromic and syndromic disease and references are shown. AD, autosomal dominant; 
AR, autosomal recessive; BB, basal body; BBS, Bardet – Biedl syndrome; CC, connecting cilium; CD, cone dystrophy; CRD, cone 
– rod dystrophy; IS, inner segment; JBTS, Joubert syndrome; LCA, Leber congenital amaurosis; MD, macular dystrophy; MKS, 
Meckel – Gruber syndrome; OFD, orofaciodigital syndrome; OLM, outer limiting membrane; OMD, occult macular dystrophy; 
OPL, outer plexiform layer; OS, outer segment; PM, plasma membrane; RP, retinitis pigmentosa; SGBS2, Simpson – Golabi – 
Behmel syndrome type 2; SLSN, Senior–Løken syndrome; USH2, Usher syndrome type 2; USH3, Usher syndrome type 3; XL, 
X-linked. aLocalization of BBS1, BBS9 and TTC8 in the photoreceptor reported by U. Wolfrum (personal communication).
aFAM161A localization at the BB and CC reported by S.A. Di Gioia (personal communication).
mutation could explain why this mutation leads to LCA, instead of a multiorgan disease.20 
However, a number of non-syndromic LCA patients have been described to carry nonsense 
and frameshift mutations on both alleles,44-45 and the question remains why they have not 
developed syndromic features. One possible molecular mechanism was demonstrated for 
the nonsense mutation p.Arg151*, identified in patients with non-syndromic early-onset 
retinal dystrophy. RNA analysis demonstrated that the exon containing this mutation was 
differentially spliced, leading to splice products lacking exon 7 or exons 7 and 8, both 
remaining in frame.46 It was suggested that the different splice products are the result of 
nonsense-associated altered splicing, a putative correction mechanism that recognizes 
an exon with a premature termination codon, and excludes that exon from the mature 
mRNA.47
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Figure 2. Model of the localization of non-syndromic retinal ciliopathy proteins in the ciliary compartment of the photo-
receptor. For each protein, the corre-sponding gene name has been used. At least four protein complexes have been reported in 
literature which localize to the connecting cilium (Table 1). The BBSome consisting of BBS1, BBS9 and TTC8, and recruited by 
ARL6, forms a coat at the base of the CC (63). A complex consisting of nephronophthisis-associated proteins CEP290/IQCB1 
connected to RPGR by RPGRIP1 (96) localizes to CC, like OFD1 bound to lebercilin (97). In the OS axonemes, localization of 
RP1L1 and RP1 is observed (68). BB, basal body; CC, connecting cilium; IS, inner segment; OS, outer segment; PM, plasma 
membrane
Genetic ciliary modifiers for retinal degeneration 
It is presumed that the phenotypic variability of CEP290-associated disease, and also of other 
retinal ciliopathies, might be caused by a modifier allele in a second gene. Two missense 
mutations in AHI1, p.Asn811Lys and p.His758Pro, have been described as neurological 
modifiers of CEP290-associated disease.45 A third mutation in AHI1, p.Arg830Trp, was 
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identified as a modifier allele for retinal degeneration in patients with nephronophthisis, 
independent of a primary NPHP1 mutation.48 A common allele in the RPGRIP1L gene, 
p.Ala229Thr, may be a modifier of retinal degeneration in ciliopathy patients due to other 
mutations.49 Heterozygosity for a truncating PDZD7 allele, p.Arg56Profs*24, aggravates 
retinal disease in a family with Usher syndrome due to USH2A variants.50 Polymorphic 
alleles in IQCB1 (p.Ile393Asn) and RPGRIP1L (p.Arg744Gln) have been associated with 
severe disease in X-linked RP caused by RPGR mutations.51 Intriguingly, a recent study 
demonstrated that knockout of Mkks in Cep290-Rd16 mice improved ciliogenesis and 
sensory functions of the eye and inner ear.52
An alternative explanation for the variable phenotypes associated with retinal ciliopa-
thy alleles could be cis-acting regulators of expression. Different enhancer or promoter 
variants may result in higher or lower mRNA expression levels of the mutated alleles in 
affected individuals, which may be correlated with the severity of the phenotype as was 
suggested for the BBS1 p.Met390Arg allele.53
Transcriptomics 
The majority of the genes that cause retinal dystrophies have been shown to be specifically 
expressed, or highly enriched, in photoreceptors.54 A range of transcription factors have 
been shown to contribute to photoreceptor gene regulation, with crucial roles attributed 
to CRX, NRL, and NR2E3.55-57 CRX is a key photoreceptor regulator required for the ex-
pression of many rod and cone genes, including ~50% of genes known to be mutated in 
retinal dystrophies (RetNet).54,58-60 CRX-binding sites were identified in the promoter of 
13 (~61%) of 21 genes that cause non-syndromic retinal ciliopathies.61 Considering that 
many genes for CD, CRD, LCA, MD and RP have not been identified yet, ciliary genes 
that have CRX-binding sites are excellent candidates genes for the unsolved cases. No-
tably, prioritizing candidate genes in exome data based on these CRX-binding sites was 
recently used successfully to identify MAK as a novel RP-associated gene.4
Proteomics 
Non-syndromic retinal ciliopathy proteins are located at the ciliary base (basal body and 
associated centriole), ciliary axoneme or membrane of the connecting cilium of photo-
receptors (Figure 2). At these specific sites of action, this class of proteins and associat-
ed complexes is essential for photoreceptor function by guiding the transport of new-
ly-formed proteins which reside in vesicles from the Golgi-apparatus towards the base of 
the connecting cilium,62 transport of phototransduction proteins like rhodopsin through 
the connecting cilium towards the outer segment, and the transport of turnover products 
back towards the inner segment of the photoreceptor cell.63,64 Given the specific site of ex-
pression of ciliopathy proteins, quite a few protein-protein interaction studies have been 
carried out to examine the connectivity and mechanism of action on a molecular level. 
This approach has proven to be successful and has led to the identification of multiple 
protein complexes of which the individual molecules functionally overlap and when mu-
tated, result in similar phenotypes in humans. Examples are the BBSome complex which 
is comprised of BBS proteins (BBS1, 2, 4, 5, 7, 9 and TTC830), in which mutations have 
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been identified in BBS65 and non-syndromic forms of RP (BBS1,53 BBS9,41 TTC840), 
and the NPHP-JBTS-MKS complex31 which is composed of proteins involved in NPHP, 
JBTS, MKS66 and non-syndromic forms of LCA (CEP290,20 IQCB167). In addition, 
protein interaction studies have uncovered the biochemical fundament for known ge-
netic interactions between non-syndromic retinal ciliopathy genes (e.g. RP1-RP1L168 or 
IQCB1-CEP29069), and have proven to be a powerful tool in prioritizing candidate dis-
ease genes for syndromic ciliopathies (e.g. ATXN10 and TCTN231) and non-syndromic 
retinal ciliopathies (e.g. RPGRIP170).
Importantly, a comparison between the interactome of full-length and truncated LCA-as-
sociated lebercilin has lead to the identification of the molecular disease mechanism for 
LCA type 564,71. A homozygous mutation in the last exon of LCA5, predicted to escape 
nonsense-medicated decay, results in a truncated protein that displays loss of interac-
tion with the intraflagellar transport (IFT) machinery. This IFT complex bi-directionally 
transports ciliary proteins in all types of cilia, including connecting cilia of the photore-
ceptor, suggesting that defective transport through the connecting cilium is the under-
lying cause for LCA. Studies have shown that transport defects could be an underlying 
cause for RP as well, since RP-associated BBS1, RPGR, and TOPORS, have been found to 
interact with IFT and/or the dynactin complex,72-74 which is required for dynein-depen-
dent retrograde transport.75
Animal studies 
Most of the current knowledge of the biological roles for genes associated with non-syn-
dromic retinal ciliopathies has come from studies using vertebrate animal models, which 
have proven to be powerful tools to study the effect of specific gene inactivation on ver-
tebrate photoreceptor function. In addition, these models have created excellent oppor-
tunities for therapeutic studies. Genetically modified mouse models have been reported 
for the majority of known non-syndromic retinal ciliopathy genes (Table 2). Common 
retinal features in these mice are reduced ERG responses to light stimulation, opsin mis-
localization in photoreceptors and progressive photoreceptor degeneration. The onset 
and progression of photoreceptor degeneration however is variable, which in most cas-
es reflects the human situation. For example, mouse models for non-syndromic LCA in 
humans such as the rd16 mouse model which carries a hypomorphic Cep290 allele, and 
the Lca5 gene-trap mouse model, show early-onset (P14 and P12 respectively) and rapid 
degeneration of outer and inner segments, and the outer nuclear layer accompanied with 
low ERG responses.47,64,76
Compared to this early-onset phenotype of LCA models, mouse models for RP show 
a delayed onset and slower progression of photoreceptor degeneration. The Rd9 mouse 
strain, harbouring a spontaneous frameshift mutation in ORF15 of Rpgr, show mildly 
reduced ERG responses at 6 weeks of age, which develops progressively but slowly over a 
two year period.77 Another mutated Rpgr mouse strain shows normal retinal morphology 
and ERG function at P30. Photoreceptor loss in these mice becomes substantial after 6 
months of age, showing reduced outer segment length, outer nuclear layer thickness and 
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abnormal ERG responses.78
Unfortunately, mouse models for retinal ciliopathy genes do not always match the human 
phenotype, like Clrn1 mutant mice, which do not develop a retinal phenotype79 (Table 
2). Morpholino-mediated silencing of different orthologs for non-syndromic retinal cil-
iopathy genes in zebrafish show largely overlapping retinal phenotypes. Knockdown of 
zebrafish topors, the ortholog for autosomal dominant RP-associated TOPORS,35 shows 
microphthalmia, defective retinal development and failure to form outer segments.72 
Similar phenotypes (microphthalmia, defective retinal lamination and absence of out-
er segments) are observed after rp2 knockdown, the ortholog of X-linked RP-associated 
RP2.80,81 In addition, knockdown of c2orf71, the ortholog for autosomal recessive RP-as-
sociated C2ORF71,82,83 results in microphthalmia and shorter outer segments.83 These 
studies indicate that knockdown of orthologs for retinal ciliopathy genes in zebrafish re-
sult in micropthalmia and loss of outer segments. An overview of published animal mod-
els for each non-syndromic retinal ciliopathy gene is shown in Table 2.
Translational research 
Non-syndromic retinal dystrophies have been considered for long to be incurable. The 
recent identification and characterization of avian, canine, feline and rodent models for 
many of the non-syndromic retinal diseases has provided an excellent platform for trans-
lational research. Translational research has mainly focused on gene augmentation by 
subretinal injection of virus, which appears to be safe and successful in long-term re-
storing of vision in models for non-syndromic retinal dystrophies. The successes of gene 
augmentation studies in a mouse model for childhood blindness84 or in a RPE65 null 
canine model85 have led to ongoing clinical trials of ocular subretinal delivery of ade-
no-associated virus (AAV) serotype 2 carrying human RPE65 in individuals with known 
RPE65 mutations.86 For the non-syndromic retinal ciliopathy genes, the efficacy of gene 
replacement therapy has been evaluated in a Rpgrip1 mutant mouse model (Tm1Tili; 
Table 2). Subretinal delivery of the human replacement construct, packaged in an AAV 
serotype 8 vector, results in the expression of functional RPGRIP1 in connecting cilia of 
photoreceptors, better preservation of rod and cone photoreceptor function and prolongs 
photoreceptor survival.87 In addition, AAV-based gene augmentation therapy of human 
RPGR in two blinding canine models for X-linked RP (XLPRA1 and XLPRA2; Table 2) 
shows preservation of morphology and functionality of rod and cone photoreceptors, 
while post-receptor remodeling was corrected as well.88
AAV-based gene augmentation therapies for large genes, like CEP290 which encodes a 
2,479 amino acid protein and is the most frequently mutated LCA gene, is problematic 
given the size-restriction for the AAV-vector (~5 kb).89 A mini-gene augmentation ther-
apy, which uses only part of the gene important for gene function in the photoreceptor, 
would fulfill the AAV-size limit criteria. A successful mini-gene augmentation approach 
for CEP290 has recently been performed in zebrafish. Expression of only the N-termi-
nal 1,059 amino acids of CEP290 resulted in a rescue of visual impairment in cep290 
morpholino-injected fish.90 Additional studies need to be performed to determine the 
efficiency of mini-gene replacement therapies in higher vertebrate models.
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Promising alternatives for gene augmentation in retinal dystrophies, are therapeutic ap-
proaches using either modified U1 small nuclear (sn)RNAs or antisense oligonucleotides 
to correct mutation-induced splicing defects. Lentiviral treatment of fibroblasts derived 
from individuals with RP who carry a c.479G>A splice donor site mutation in exon 5 of 
BBS1, partially corrected aberrant splicing of endogenously expressed BBS1 transcripts 
in a dose-dependent manner, indicating that U1 snRNAs can correct pathogenic effects 
of splice donor site mutations in recessive RP.91 Similar results were obtained for X-linked 
RP, for which splice-defects in RPGR have been corrected in patient-derived primary 
Table 2. Overview of published vertebrate animal models for non-syndromic retinal ciliopathy genes, including morpholino 
studies in zebrafish
Gene Vertebrate 
model
Gene targeting Reference Eye phenotype
ARL6 mouse deletion of exon 8 (specific for long 
isoform)
100 Late onset, slowly progressive retinal 
degeneration
ARL6 mouse deletion of exons 6 and 7 146 Rapidly progressive retinal degeneration
ARL6 zebrafish morpholino (translation and splice 
blocker)
147 No eye phenotype recorded
ARL6 zebrafish morpholino (splice blocker for long 
isoform and translation blocker)
100 Impaired visual function and opsin mis-
localization for splice blocker; translation 
blocker: no eye phenotype recorded
BBS1 mouse gene-trap in intron 11 148 Retinal degeneration
BBS1 mouse targeted knock-in M390R allele 149 Rapidly progressive photoreceptor 
degeneration
BBS1 zebrafish morpholino (translation and splice 
blocker)
147, 150 No eye phenotype recorded
BBS9 zebrafish morpholino (splice blocker) 151 Defective eye development, smaller eyes
C2orf71 dog spontaneous frameshift mutation 
c.3149_3150insC
152 Late-onset, slowly progressive retinal 
atrophy
C2orf71 zebrafish morpholino (translation blocker) 83 Smaller eyes, shorter outer segments
CEP290 cat (rdAc) IVS50 + 9T>G (creates splice donor 
site)
153 Photoreceptor degeneration
CEP290 mouse 
(Rd16)
spontaneous in frame deletion of 
aa1599-1897
107 Early-onset, rapidly progressive photore-
ceptor degeneration
CEP290 mouse Rd16 crossed with Nrl null (all-cone 
retina)
76 Loss of photoreceptor function
CEP290 zebrafish morpholino (translation and splice 
blocker)
69, 90, 154 Smaller eyes, altered visual function
CLRN1 mouse deletion of exon 1 79, 155 No eye phenotype recorded
IQCB1 zebrafish morpholino (splice blocker) 69 Defective eye development
LCA5 mouse gene-trap in intron 3 64 Early onset, rapidly progressive photore-
ceptor degeneration
MAK mouse deletion of exons 5 to 8 115, 156 Normal photoreceptor development, 
rapidly progressive photoreceptor 
degeneration
OFD1 mouse conditional knock-out; exons 4 and 
5 flanked by loxP sites
157 No eye phenotype recorded
OFD1 zebrafish morpholino (translation and splice 
blocker)
158 Incomplete fusion of the choroid fissure 
of the eye (coloboma)
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RP1 mouse deletion of exons 2 and 3 159 Early onset, rapidly progressive photore-
ceptor degeneration
RP1 mouse truncation after codon 662 in 
exon 4
33 Early onset, rapidly progressive photore-
ceptor degeneration
RP1 mouse 
(tvrm64)
point mutation resulting in R522X 160 Early onset, rapidly progressive photore-
ceptor degeneration
RP1L1 mouse deletion of exons 2-3 and part of 
exon 4
68 Normal photoreceptor development, 
slowly progressive photoreceptor 
degeneration
RP2 zebrafish morpholino (translation and splice 
blocker)
81, 161 Defective lamination, lacking outer 
segments, apoptotic retinal neurons, 
smaller eyes
RPGR dog (XL-
PRA1)
spontaneous 5 bp deletion (del1028-
1032) in exon ORF15
162 Normal photoreceptor development, 
slowly progressive photoreceptor 
degeneration
RPGR dog (XL-
PRA2)
spontaneous 2 bp deletion (del1084-
1085) in exon ORF15
162 Early onset, rapidly progressive photo-
receptor degeneration, early inner retina 
remodeling
RPGR mouse in-frame deletion of exons 4-5-6 78 Normal photoreceptor development, 
slowly progressive photoreceptor 
degeneration
RPGR mouse in-frame deletion of exon 4 163 Normal photoreceptor development, 
slowly progressive photoreceptor 
degeneration
RPGR mouse (Rd9) spontaneous 32 bp duplication in 
exon ORF15
77 Normal photoreceptor development, 
slowly progressive photoreceptor 
degeneration
RPGR zebrafish morpholino (translation blocker) 164 No eye phenotype recorded
RPGR zebrafish morpholino (translation blocker) 165 Abnormal development of the retina 
(lamination defects, failure to form outer 
segments, smaller eyes)
RPGR zebrafish morpholino (translation blocker) 96 Smaller eyes
RP-
GRIP1
dog spontaneous 44 bp insertion in 
exon 2
166 Cone-rod dystrophy
RP-
GRIP1
mouse (tm-
1Tili)
insertion targeting construct 
between exon 14 and 15
32 Early onset, rapidly progressive photore-
ceptor degeneration
RP-
GRIP1
mouse 
(nmf247)
point mutation in splice acceptor 
site in intron 6
167 Early onset, rapidly progressive photore-
ceptor degeneration
TOPORS zebrafish morpholino (translation blocker) 72 Abnormal development of the retina 
(lamination defects, failure to form outer 
segments, smaller eyes)
TTC8 mouse deletion of exons 1 and 2 168 Photoreceptor degeneration
TTC8 zebrafish morpholino (translation blocker) 169 Smaller eyes
TULP1 mouse removal of exons 8-9 170 Early onset, rapidly progressive photore-
ceptor degeneration
TULP1 mouse 
(tvrm124)
point mutation in splice donor site 
in intron 3
160 Early onset, rapidly progressive photore-
ceptor degeneration
USH2A mouse targeted disruption of exon 5 171 Late onset, slowly progressive photore-
ceptor degeneration
USH2A zebrafish morpholino (splice blocker) 50 Abnormal apoptotic photoreceptors
Currently, no vertebrate animal models have been published forC8orf37orFAM161A.
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fibroblasts using U1 snRNAs.92 A recent antisense oligonucleotide-based approach for 
the most frequent LCA-causative mutation (c.2991+1655A>G), which resulted in the in-
clusion of an aberrant exon in CEP290 mRNA, has shown to be successful in almost 
completely redirecting normal CEP290 splicing (dose-dependent, with a high degree of 
sequence specificity) using immortalized lymphoblastoid cells of individuals carrying two 
intronic CEP290 mutations.93
In case gene therapy is not applicable or efficient, pharmacological therapy may offer a 
good alternative to slow down or halt the course of photoreceptor degeneration. Adminis-
tration of ciliary neurotrophic factor through an encapsulated cell technology device has 
shown to be effective in slowing photoreceptor degeneration in animal models of RP, and 
is currently included in clinical trials for RP.94 Another pharmaceutical drug, taurour-
sodeoxycholic acid, has shown to preserve photoreceptors in a variety of mouse models, 
including Bbs1 mutant mice. Subcutaneous administration of tauroursodeoxycholic acid 
twice a week, from P40 to P120, has shown to preserve photoreceptor morphology (outer 
segments and outer nuclear layer) and function in mice with a targeted knock-in of the 
p.Met390Arg variant on both alleles95 (Table 2).
The most frequently mutated non-syndromic retinal ciliopathy genes, such as RPGR and 
USH2A, are associated with disease in ~1:60,000 individuals.11 Other genes associated 
with non-syndromic retinal ciliopathies carry mutations less frequently, which poses a 
challenge to identify sufficient numbers of patients who are eligible for novel treatments, 
and to attract the interest of industry to fund preclinical studies. Most likely these studies 
will take place through public and private funding. Clearly, global efforts are required to 
register clinical and genetic data of patients with retinal ciliopathies. In the mean time, 
large national (e.g. LCA3000 in the USA and RP5000 in the Netherlands) or internation-
al programs (e.g. the European Retinal Disease Consortium, comprising nine groups in 
eight European countries) are required to systematically identify persons with mutations 
in rarely mutated genes. A comprehensive listing of all mutation data in open access cu-
rated databases, such as the Leiden Open Variant Database (http://www.lovd.nl/2.0/) is 
still lacking. Compulsory registration of all genetic data in such databases, as required by 
e.g. Human Mutation, would result in valuable resources for the entire scientific commu-
nity. In addition, there is great need to establish a standardized clinical database that can 
be shared between international groups.
Conclusion
The connecting cilium of photoreceptor cells plays a crucial role in the selective transport 
of proteins and other molecules to and from the outer segments. This cellular structure 
consists of hundreds of proteins, many of which have specialized roles. Approximately 
one-third of the genetic defects associated with inherited retinal dystrophies are located 
in genes encoding ciliary proteins. Protein interaction studies point to the existence of 
key modules governing the complex transport mechanisms. These studies and the use of 
vertebrate animal models are instrumental in the development of an increasing number 
of rational therapies (e.g. based on gene augmentation or the correction of miss-spliced 
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RNAs) for retinal dystrophies. 
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Abstract
Purpose: Leber congenital amaurosis (LCA) is genetically heterogeneous with 15 genes 
identified thusfar, accounting for ~70% of LCA patients. The aim of the current study was 
to identify new genetic causes of LCA.
Method: Homozygosity mapping in >150 LCA patients of worldwide origin was performed 
with high-density SNP microarrays (Affymetrix 250K) to identify new disease-causing 
genes. 
Results: In three isolated LCA patients we identified large homozygous regions on 
chromosome 3 encompassing the IQCB1 gene, which has been associated with Senior-
Loken syndrome (SLSN), characterized by nephronophthisis and retinal degeneration. 
Mutation analysis of IQCB1 in these three patients and a subsequent cohort of 223 
additional LCA patients identified frameshift and nonsense mutations in 12 patients 
diagnosed with LCA. Upon re-inspection of the patient’s disease status, seven were 
found to have developed SLSN, while five maintained the diagnosis of LCA as the kidney 
function remained normal. In one LCA patient we identified one heterozygous frameshift 
mutation in IQCB1 and one heterozygous mutation in CEP290, suggesting a digenic 
inheritance mechanism.
Conclusions: Our results show that the onset of renal failure in patients with IQCB1 
mutations is highly variable, and that mutations are also found in LCA patients without 
nephronophthisis, rendering IQCB1 a new gene for LCA. However, these patients are at 
high risk to develop renal failure, which in early stages is often not recognized and can 
cause sudden death from fluid and electrolyte imbalance. We therefore recommend that 
all LCA patients be screened for IQCB1 mutations, in order to follow them more closely 
for kidney disease. 
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Introduction
Leber congenital amaurosis (LCA [MIM 204000]) is the most severe form of early-onset 
retinal blindness and typically becomes evident in the first year of life. The frequency is 
variably estimated as 1/30,0001 and 1/81,000.2 Poor visual function is accompanied by 
nystagmus (pendular or roving eye movements), photophobia, sluggish or near-absent 
pupillary responses, hyperopia, extinguished or severely reduced rod and cone signals on 
the electroretinogram (ERG), and a highly variable retinal appearance. LCA is generally 
inherited in an autosomal recessive manner and is genetically heterogeneous. Fifteen 
genes have been associated with LCA until now, which explain approximately 70% of the 
patients, while 30% of LCA patients are currently “unsettled” and likely have mutations 
in yet to be discovered genes (RetNet, http://www.sph.uth.tmc.edu/RetNet/). The known 
genes that are causative for LCA participate in a diverse group of functional pathways, 
including photoreceptor development (CRB1 [MIM 604210], CRX [MIM 602225]), 
phototransduction (GUCY2D [MIM 600179], AIPL1 [MIM 604392]), retinoid metabolism 
(RPE65 [MIM 180069], LRAT [MIM 604863], RDH12 [MIM 608830]), ciliary transport 
(CEP290 [MIM 610142], TULP1 [MIM 602280], RPGRIP1 [MIM 605446], LCA5 [MIM 
611408]), guanine synthesis (IMPDH1 [MIM 146690]), and outer segment phagocytosis 
by the retinal pigment epithelium (MERTK [MIM 604705]). Additionally, the functional 
pathways in which RD3 [MIM 180040] and SPATA7 [MIM 609868] participate remain 
unknown.
One of these genes, CEP290 (also known as NPHP6), represents the most common cause 
of LCA identified until now, accounting for 20% of LCA patients of northern European 
descent,3,4 although lower frequencies (5%) have been reported in other populations.5-6 
In addition, CEP290 is also associated with several severe multisystem diseases in which 
blindness due to retinal degeneration is only part of the phenotype, such as Joubert 
(JBTS), Meckel (MKS), Bardet-Biedl (BBS) and Senior-Loken syndromes  (SLSN).7-12 
JBTS is characterized by a mid-hindbrain malformation (called the molar tooth sign on 
imaging studies), hypotonia, developmental delay, retinal dystrophy, and may also be 
associated with nephronophthisis, congenital hepatic fibrosis and polydactyly. MKS is 
an early embryonic multisystem disorder characterized by malformations of the central 
nervous system (typically occipital meningoencephalocele), polydactyly, cystic kidney 
dysplasia, and ductal proliferation in the portal area of the liver. BBS includes progressive 
retinal degeneration, obesity, polydactyly, hypogenitalism, cognitive impairment, and 
kidney dysplasia. Finally, SLSN is an autosomal recessive disease with the main features 
of nephronophthisis (NPHP [MIM 256100]) –a cystic kidney disease– and retinal 
degeneration.
CEP290 has been shown to interact with several centrosomal and microtubule-associated 
proteins,11,13-17 including RPGR (mutated in patients with X-linked retinitis pigmentosa), 
RPGRIP1 (LCA), CC2D2A (JBTS and MKS), and IQCB1 (also known as NPHP5) (SLSN). 
Knockdown studies of CEP290 and IQCB1 in zebrafish reveal similar phenotypes which 
recapitulate some of the characteristics of JBTS, and a synergistic effect on the severity 
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of the phenotype was observed after combined knockdown of zebrafish CEP290 and 
IQCB1.16 CEP290 and IQCB1 both localize to the connecting cilium of the photoreceptor, 
where they form part of a multiprotein complex that regulates the transport of cargo 
molecules to the outer segment of the photoreceptor.13,16,18 All SLSN patients with 
mutations in IQCB1 were shown to suffer from severe retinal dystrophy, while the age of 
onset of the renal disease is variable.18
In our continuing efforts to identify new LCA genes, we have genotyped >150 LCA 
patients by SNP arrays and identified 3 LCA patients with large homozygous regions 
encompassing the IQCB1 gene. This finding together with the reported interaction 
between the IQCB1 and CEP290 proteins,16 and the severe retinal dystrophy seen in SLSN 
patients with IQCB1 mutations (not unlike LCA), prompted us to test the hypothesis 
that mutations in IQCB1 cause non-syndromic LCA. In this study, we report mutation 
analysis of the IQCB1 gene in 226 LCA patients, which revealed mutations in 12 patients 
of 10 families. Upon re-evaluation of the renal function seven patients were subsequently 
diagnosed as SLSN, but five LCA patients did not show signs of renal disease. Our results 
show that IQCB1 mutations can cause LCA without nephronophthisis, although we 
cannot exclude that some patients may develop kidney disease later in life.
Material and methods 
Subjects and clinical evaluation. 
Two hundred twenty-six unrelated LCA patients of worldwide origin were included in 
the study. The diagnosis of LCA was given to patients with blindness or severe visual 
impairment before the age of six months, onset of nystagmus within the first few weeks of 
life, and a nondetectable ERG before the age of one year. Patients were examined by acuity 
testing, slitlamp biomicroscopy, cycloplegic refraction (1% cyclogel drops), funduscopy 
and ERG testing. Acuity testing was done with age-appropriate measures. After the 
diagnosis of LCA was ensured, DNA was collected after informed consents were signed. 
Ethical approval was given to all participating institutions and conformed to the tenets of 
Helsinki. 
In order to exclude known mutations in the LCA genes, all patient samples were analyzed 
with a genotyping microarray based on arrayed primer extension (APEX) technology 
(Asper Ophthalmics, Tartu, Estonia). 19 DNA samples of 93 LCA patients were genotyped 
and analyzed for homozygous regions previously by den Hollander and co-workers 
(2007). Sixty additional DNA samples were analyzed in this study as described previously 
using 250K  NspI SNP microarrays (Affymetrix).20 
Mutation Analysis
Primers for amplification of the coding exons and splice junctions of IQCB1 were 
selected by ExonPrimer (http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html) and 
Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). PCR products were 
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purified with 96-well filter plates (Multiscreen HTS-PCR; Millipore, Bedford, MA) or by 
gel extraction (Qia-Quick Gel Extraction Kit; Qiagen). Sequencing was performed with 
dye terminator chemistry (BigDye Terminator, ver. 3 on a 3100. 3730 or 3730XL  DNA 
Analyzer; Applied Biosystems, Inc., [ABI], Foster City, CA). 
QPCR
SYBR Green-based genomic real-time quantitative PCR (gQPCR) analysis was performed 
on a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) by 
using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer´s instructions. gQPCR primers for all exons of IQCB1 
were developed using the primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi).21 gQPCR quantifications were performed in duplicate on 20 ng/µl 
DNA and included a water control. Copy numbers were measured relative to a reference 
gene, CFTR. DNA copy number differences between two samples were calculated by the 
Ct or 2ΔΔCt method.22,23
Results
Identification of IQCB1 mutations in LCA patients
In a previous and this study we performed genome-wide homozygosity mapping in 
a cohort of >150 LCA patients using SNP microrarrays (20). In two isolated LCA 
patients (42108 and 42109) without known consanguinity and one isolated LCA patient 
from a consanguineous marriage (BE77905), we identified large homozygous regions 
encompassing the IQCB1 gene. The region in patient 42108 spans 17 Mb (1,435 SNPs), 
and is the largest homozygous region identified in this patient’s genome. In patient 
42109 the interval spans 6 Mb (521 SNPs), but several larger homozygous regions were 
identified on other chromosomes (the region encompassing the IQCB1 gene ranks 9th). 
In patient BE77905 the largest homozygous region encompassing the IQCB1 gene spans 
26 Mb (2,337 SNPs). 
Direct sequencing of all 13 coding exons of IQCB1 was therefore performed in patients 
42108, 42109 and BE77905. No mutation was detected in patient 42109. A homozygous 
2-bp deletion in exon 6 (c.424_425delTT) of IQCB1 was identified in patient 42108, which 
introduces a shift in the open reading frame (Table 1). A homozygous 2-bp duplication 
in exon 11 (c.1074_1075dup) was identified in patient BE77905, which also introduces 
a shift in the open reading frame (Table 1). No mutation was detected in patient 42109. 
The two mutations identified in patients 42108 and BE77905 were previously reported by 
Otto et. al. (2005) in patients with SLSN. Because of this finding, we carried out IQCB1 
sequence analysis in 223 additional LCA patients, identifying frameshift and nonsense 
mutations in 10 additional patients of 8 families (Table 1). 
Two of the mutations (p.R502X and p.Q512X) have not been reported before, while all 
other mutations were previously identified in patients with SLSN.18,24 In a Puerto Rican 
family, a homozygous nonsense mutation (p.R461X) segregated in a pseudo-dominant 
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fashion in two affected siblings (MOGL3772 and MOGL3773) and their affected mother 
(MOGL430). The father carries the mutation p.R461X heterozygously.
Patient 12860 was heterozygous for the p.F142PfsX5 mutation in IQCB1, and a second 
mutation was not found. Also, gQPCR studies of IQCB1 did not identify a deletion on the 
second allele of this patient. However, this patient is also heterozygous for the common 
CEP290 mutation (c.2991+1655A>G), while no second mutation was identified in 
CEP290 by sequencing all coding exons, suggesting digenic inheritance in this particular 
LCA patient. Because the parents were deceased, segregation could not be tested. 
Table 1. IQCB1 mutations detected in this study
Patient ID Country
Allele 1 Allele 2
DNA variant Protein defect DNA variant Protein defect
42108 Germany c.424_425del p.F142PfsX5 c.424_425del p.F142PfsX5
12786 Germany c.424_425del p.F142PfsX5 c.1518_1519del p.H506NfsX13
BE77905 Morocco c.1074_1075dup p.A359EfsX3 c.1074_1075dup p.A359EfsX3
13079 Netherlands c.424_425del p.F142PfsX5 c.1535_1536insA-
TAGC
p.Q512X
42125 Germany c.825_828del p.R275SfsX6 c.1069C>T p.Q357X
42110 Germany c.825_828del p.R275SfsX6 c.1518_1519del p.H506NfsX13
MOGL3572 US c.1465C>T p.R489X c.1518_1519del p.H506NfsX13
MOGL430 Puerto Rico c.1381C>T p.R461X c.1381C>T p.R461X
MOGL3773* Puerto Rico c.1381C>T p.R461X c.1381C>T p.R461X
MOGL3772* Puerto Rico c.1381C>T p.R461X c.1381C>T p.R461X
MOGL3309 Italy c.1504A>T p.R502X c.1504A>T p.R502X
12860 Germany c.424_425del p.F142PfsX5 none none
*daughters of MOGL430
Clinical findings
Re-evaluation of the renal function in all 12 patients led to the diagnosis of SLSN in 
seven patients (Table 2). Thus, in five patients, the diagnosis remains non-syndromic 
LCA, despite regular follow-up and inspection of the kidney status. The seven patients 
with SLSN developed nephronophthisis between ages 3 and 50 years. The other patients 
retained normal kidney function up to their current ages (age range 3 – 55 years).
The ocular phenotypes of SLSN and LCA patients with IQCB1 mutations are similar and 
seem to be indistinguishable from each other in this study. The phenotype of LCA patients 
with IQCB1 mutations resembles classical LCA with early onset pendular nystagmus, poor 
fixation at birth, and with a non-detectable rod and cone ERG early in the disease process. 
In addition, all patients in this cohort were found to have high hyperopic refractions 
(+3.00 to +7.50 D). The acuities at later ages were variable and ranged from 20/70 at age 
15 (12786) to light perception at age 10 (MOGL3309). 
Two retinal features of patients with IQCB1 mutations are not typical of the retinal 
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phenotypes associated with the currently known 15 LCA genes. Usually, the initial 
peripheral retinal exam in a 1-2 year old patient with LCA is essentially normal, with 
relatively normal-appearing retinal pigment epithelium (RPE), foveal appearance, optic 
disc and mild narrowing of the retinal arterioles. Pigmentary changes and degeneration 
of the retina often occur much later. Interestingly in one of the youngest patients 
(MOGL3309) retinal changes were already prominent at age 18 months, as we noted a 
striking “lobular” pattern of hypo- and hyperpigmentation outside of the retinal arcades 
(Figure 1A). Secondly, this same pattern of abnormalities was seen in another LCA 
patient (42108) (Figure 1B) with IQCB1 mutations at age 34 years. Patient 42125 also has 
hypo-pigmentation outside of the arcades, but this is not in the clear “lobular” pattern as 
the previous two (Figure 1C). Patient 12786 does not show the lobular changes, but has 
a diffuse RPE atrophy with intra-retinal pigment epithelial changes (Figure 1D). Patient 
12860 has synchysis scintillans, a degenerative condition of the vitreous, which represents 
cholesterol crystals formed in response to a haemorrhage or degeneration of the eye. 
The retina of patient 12860 shows choroidal sclerosis and RPE degeneration beneath the 
crystals (Figure1E). 
One of the 12 patients (13079) in our cohort had cataract and keratoconus. Other ocular 
findings that can be associated with LCA (optic disc pallor, maculopathy, macular 
coloboma) were not seen in these patients. 
Discussion 
In this study, we describe IQCB1 mutations in patients with SLSN and in LCA patients 
without renal failure. This study also confirms the power of genome wide homozygosity 
mapping to identify the genetic defect in non-consanguineous patients with an autosomal 
recessive disease.24-28
The initial diagnosis of LCA in our cohort of patients was made using strict criteria (poor 
fixation at birth or within 6 months of age, pendular nystagmus, amaurotic pupils, non-
detectable or severely diminished rod and cone ERG amplitudes before age one year and 
absence of systemic disease) but a clinical re-evaluation of the 12 patients with IQCB1 
mutations showed manifestation of nephronopthisis in seven of them, prompting a 
change in diagnosis to SLSN. However, five patients maintained normal kidney function 
up to their current ages (age range 3 – 55 years). Considering that the median age 
for the manifestation of end-stage renal disease in infantile, juvenile and adolescent 
nephronopthisis is 1, 13, and 19 years old respectively,29-31 we had expected that if a patient 
with IQCB1 mutations is destined to develop kidney disease and failure, that our patients 
would develop renal failure early (before the age of 19 years). However, Otto et al (24) 
extended the range of ages at which end-stage renal disease commences to between age 8 
and 47, which is consistent with our results ranging from 3 to 50 years of age. Based on the 
wide age range in the onset of end-stage renal disease, and the slightly lower mean age of 
the patients in this study without renal failure compared to those with nephronophthisis 
(23 vs. 28 years), we cannot exclude that some patients identified in our study will develop 
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renal disease at a later age. Consequently, it is of major importance to search for signs of 
nephronophthisis in patients with IQCB1 mutations. Because of the mild symptoms in 
the early stages, there is often a delay in the diagnosis of nephronophthisis. This causes a 
risk for sudden death from fluid and electrolyte imbalance.30 Nephronophthisis patients 
receiving kidney transplants have excellent outcomes that are shown to be better compared 
with the general pediatric transplant population.32 We therefore recommend that all LCA 
patients be screened for IQCB1 mutations in order to follow them more closely for kidney
disease.  
Table 2. Clinical characteristics of patients with IQCB1 mutations.
Patient ID Gen-
der/
Cur-
rent 
age
Kidney 
findings
Visual 
acuity
Refractive 
error
(diopter)
Fundus ERG Perime-
try
42108 F/34 Normal 0.1/0.1 
(20/200)
Hyperopia 
(+6.5)
Vitreous cells,  optic nerve 
normal,  narrowed retinal 
vessels, no foveolar light 
reflex, relatively preserved 
RPE in posterior pole, and 
hypopigmented spots sur-
rounded by hyperpigmented 
areas in a “lobular” pattern 
outside the arcades
ND Con-
centric 
narrow-
ing to 
>5°
BE77905 F/3 Normal 0.01/0.01 Hyperopia 
(+5.0 OD, 
+4.0 OS)
Granular fundus (salt and 
pepper pigmentation); macu-
la and optic disc  normal
ND (1 
y)
NA
12786 F/15 Normal 0.30/0.30 
(20/70)
Esotropia 
of the 
right eye
Granular flecks at the poste-
rior pole, normal optic nerve. 
ND NA
13079 M/38 Nephronoph-
thisis, kidney 
transplant at 
age 33
No light 
percep-
tion
NA Peripheral pigmentations and 
Coat’s like changes
ND (1 
y)
NA
42125 M/28 Nephronoph-
thisis, chronic 
sclerotic tubu-
lo-interstitial 
nephropathy 
with extensive 
tubular atro-
phy; dialysis 
since age 23
0.05/0.05 
(20/400)
Hyperopia 
(+7.5)
Normal optic nerve, slightly 
narrowed and straightened 
retinal vessels, very mild 
macular RPE atrophy, 
peripheral hypo-pigment-
ed areas with mild RPE 
clumping
ND Con-
centric 
narrow-
ing to 5°
42110 F/56 Nephronoph-
thisis; dialysis 
since age 50
0.1/0.2 Hyperopia 
(+5.5 OD, 
+6.0 OS)
NA  Min-
imal 
re-
spons-
es in 
33Hz 
flicker
Con-
centric 
narrow-
ing to 8°
MOGL3572 M/8 Normal Fix and 
follow 
inconsis-
tently
Hyperopia 
(+6.0)
Granular- appearing fundus; 
normal optic nerve 
ND NA
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MOGL430 M/37 Nephronoph-
thisis, kidney 
transplant at 
age 24
Light per-
ception
NA NA ND NA
MOGL3773* F/16 Nephronoph-
thisis, dialysis 
since age 13 
Light per-
ception
NA NA ND NA
MOGL3772* F/12 Nephronoph-
thisis, kidney 
transplant at 
age 9
Light per-
ception
NA NA ND NA
MOGL3309 F/10 Nephro-
nophthisis 
diagnosed at 
age 3
Light per-
ception
Hyperopia 
(+3.0 OD, 
+5.5 OS)
Optic nerve normal-ap-
pearing, the narrowed 
retinal arterioles, relatively 
normal-appearing fovea 
and macula, hypopigment-
ed areas surrounded by 
hyperpigmented areas in a 
“lobular” pattern
ND NA
12860 (1925-
SRP107-2-54)
F/55 Normal Light per-
ception
Hyperopia 
(+5.0)
Synchysis scintillans or 
asteroid hyalosis,  optic nerve 
normal-appearing, narrowed 
retinal vessels, choroidal scle-
rosis, RPE atrophy, patchy 
RPE-clumping
ND NA
* daughters of MOGL430; NA, not available; ND, nondetectable
When we compared the IQCB1 mutations found in patients with SLSN18,24 to those 
with LCA in order to determine possible correlations between type or location of the 
mutations and the resulting phenotypes in our patients, we did not find any significant 
patterns. The mutations that were identified in the five LCA patients without renal 
disease were previously found in patients with SLSN.18,24,32 All IQCB1 mutations were 
deleterious mutations, presumably resulting in non-functional or absent IQCB1 protein. 
The wide variability in onset, or even absence, of the kidney failure suggests the presence 
of unknown genetic and/or environmental modifier effects and factors. In line with this 
hypothesis, a genetic modifier in RPGRIP1L has recently been described to affect the 
severity of retinal degeneration in ciliopathies.33
The retinal dystrophy of our LCA patients who later developed SLSN and those LCA 
patients who did not, is indistinguishable. Of interest is the fact that we found very 
similar retinal phenotypes in three unrelated patients with IQCB1 mutations (Figure 
1A and B). We documented in these three patients a “lobular” pattern of hypo- and 
hyperpigmentation around the vascular arcades. We have not seen this pattern in LCA 
patients with mutations in other LCA genes. We have seen hypopigmented and salt and 
pepper changes in other LCA genetic subtypes but not like the ones we have observed in 
LCA patients with NPHP5 or IQCB1 mutations. Salt and pepper changes are well known 
in patients with LRAT and with RPE65 mutations, but these salt (hypo-pigmented) and 
pepper (pigmented) changes are very fine and subtle.20,34 
The hypo-pigmented changes alternating with hyper pigmented changes observed in 
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LCA patients with IQCB1 mutations are large and lobular (Fig. 1 A, B and D). Further 
genotype-phenotype correlation studies must be performed to confirm this disease 
pattern. Some ocular findings are more often found with certain LCA genotypes and may 
be characteristic for them (35-37). In the cohort of 226 patients that was analyzed in this 
study, IQCB1 mutations were identified in 12 probands of 10 families. When we exclude 
patients that were diagnosed as SLSN after the molecular analysis, the frequency of IQCB1 
mutations in LCA patients is estimated to be 2%. The most frequent mutations identified 
in this study (p.F142PfsX5, p.H506NfsX13, p.R275SfsX6) were found in patients of 
European ancestry, in concordance with previous studies.18,24 This result could suggest a 
core of founder mutations whose origin may be northern Europe (involving Germany, the 
Netherlands and Switzerland). 
Figure 1. Fundus pictures of pa-tients with IQCB1 variants. (A) Ret-cam retinal photograph of the right eye of MOGL3309 
at age 18 months. Note the relatively normal color of the optic disc, the narrowing of the retinal arterioles, and the relatively 
normal-appearing fovea and macula. Outside the arcades are hypopig-mented areas surrounded by hyper-pigmented lesions 
in a “lobular pat-tern.” (B) Retinal photograph of the left eye of patient 42108 at age 34 years old, showing a very similar retinal 
pattern as MOGL3309, with a relatively normal-appearing optic disc and vessels and striking “lobu-lar pattern” of hypo- and 
hyperpig-mentary changes outside the vascu-lar arcade. (C) Retinal photograph of the left eye of patient 42125 at age 28 years 
old, showing a slightly hazy retina, with relatively normal optic disc appearance, an abnormal peripapillary white ring and 
narrow retinal arterioles, and no pigmen-tary changes or lobular retinal changes. (D) The retinal photo-graph of the right eye 
at age 15 years old of patient 12786 shows a relatively small optic disc of good color with a prominent white, peri-papillary 
ring, narrow arterioles, a normal appearing macula, and ab-sence of intraretinal flecks or lobu-lar changes seen in (A) and (B) 
but does clearly show hypopigmented lesions, especially around the vascular arcades. There is diffuse RPE atrophy and beaten 
metal changes, more prominent nasally and superiorly, with a small number of intraretinal pigment changes. There is retinal 
remodelling, with straightening of the retinal vessels.
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In conclusion, this study shows that the onset of renal failure in patients with IQCB1 
mutations is highly variable, and that mutations are also found in LCA patients without 
nephronophthisis. The severity or absence of renal failure might be caused by unknown 
modifier alleles and/or environmental factors. Because of the importance of finding 
kidney disease as early as possible, as early intervention improves patient management 
and clinical outcome, we suggest that LCA patients should be routinely tested for IQCB1 
mutations. Those LCA patients with IQCB1 mutations should then be routinely and 
regularly tested for kidney dysfunction with simple clinical tests. Consequently, we also 
recommend that all known IQCB1 mutations are added to the Asper Ophthalmic LCA 
disease chip,19 and advise ophthalmologists to incorporate this  directive into their clinical 
practices.
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Abstract 
Objective: To investigate the involvement of the BBS1 p.M390R variant in nonsyndrom-
ic autosomal recessive retinitis pigmentosa (RP).
Methods: Homozygosity mapping of an isolated RP patient was followed by BBS1 
sequence analysis. We performed restriction fragment length polymorphism analysis of 
the p.M390R allele in 2,007 isolated or arRP patients and in 1,824 ethnically matched 
controls. Patients with two BBS1 variants underwent extensive clinical and ophthalmo-
logic assessment.
Results: In an RP proband who did not fulfill the clinical criteria for BBS, we identified 
a large homozygous region encompassing the BBS1 gene, which carried the p.M390R 
variant. In addition, this variant was detected homozygously in 10 RP patients and one 
control, compound heterozygously in three patients, and heterozygously in five patients 
and six controls. The 14 patients with two BBS1 variants show an entire clinical spec-
trum from nonsyndromic RP to full blown BBS. In 8 of 14 patients, visual acuity was 
significantly reduced. In patients with electroretinogram responses, a rod-cone pattern 
of photoreceptor degeneration was observed.
Conclusions: BBS1 variants are significantly associated with nonsyndromic autosomal 
recessive RP and relative mild forms of BBS. As exemplified in this study by the iden-
tification of a homozygous p.M390R variant in a control individual and in unaffected 
parents of BBS patients in other studies, cis- or trans-acting modifiers may influence the 
disease-phenotype.
Clinical Relevance: An early diagnosis of mild BBS phenotypes is important to monitor 
patients for possible life threatening conditions. 
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Introduction 
Bardet-Biedl syndrome (BBS) (MIM 20900) is a clinically and genetically heterogeneous 
disorder characterized by a wide spectrum of clinical features. It is considered a 
member of the group of conditions collectively called ciliopathies.1 Primary clinical 
features include retinitis pigmentosa (RP) (MIM 268000), polydactyly, obesity, learning 
disabilities, hypogonadism in males, and renal abnormalities. Secondary clinical features 
include speech disorders, strabismus, brachydactyly or syndactyly, developmental delay, 
polydipsia/polyuria (diabetes insipidus), ataxia, mild spasticity, diabetes mellitus, dental 
crowding or hypodontia, congenital heart diseases, and hepatic fibrosis. The clinical 
diagnosis of BBS is based on the presence of at least four primary features or a combination 
of three primary plus at least two secondary features.2 The clinical phenotypic spectrum 
of BBS is wide, and genotype-phenotype correlations have not been clearly established.3,4 
Some clinical features overlap with those of other ciliopathies like McKusick-Kaufman 
(MKKS; MIM 604896), Alstrom (ALMS; MIM 203800) or Laurence-Moon (MIM 
245800) syndromes which have been describe in families with the BBS6, BBS10 or BBS12 
mutation.5-7 The transmission of the disease is  autosomal recessive,8-10 but a digenic 
inheritance in the form of triallelism has been reported in some families in which either 
three mutations in two BBS genes are required to manifest the phenotype,11,12 or a third 
variant may modulate the expression of the clinical phenotype.13-15
The prevalence of BBS ranges from 1:125,000 to 1: 160,000 in Europe,16-18 1:65,000 in 
the Arab population,15 and a higher incidence was observed in isolated populations of 
Newfoundland (1:13,000),7 Kuwait (1:17,000),20 and the Faroe islands (1:3,700).21
To date, 15 genes have been associated with BBS.12,22 Most BBS proteins can be divided 
in 2 groups. One forms a complex called the BBSome (BBS1, BBS2, BBS4, BBS5, BBS7, 
BBS8, BBS9) which is believed to recruit γ-glutamyl transpeptidase Rab8,23 and the second 
group comprises chaperonin-like proteins24 including BBS6, BBS10 and BBS12. Mutations 
in known BBS genes are detected in approximately 75% of families, of which BBS1 and 
BBS10 each account for 20-25% of families of European descent25,26. Two wide-spread 
mutations resulting from founder effects have been described, p.M390R in BBS1,8,13,27 and 
p.C91fsX95 in BBS10.26 The p.M390R variant is the most common BBS1 mutation and 
has been observed in approximately 80% of families with BBS1-associated disease.8,25
Retinitis pigmentosa is the most common inherited retinal degeneration, with an estimated 
worldwide prevalence of 1:4,000,28 and is characterized by progressive photoreceptor 
dysfunction, followed by photoreceptor cell death. The disease is highly heterogeneous 
and displays all patterns of inheritance, that is, autosomal recessive, autosomal dominant 
or X-linked. In addition there are some cases with mitochondrial mutations and digenic 
inheritance.29,30. Mutations in 36 genes have been identified that cause autosomal recessive 
nonsyndromic RP, and mutations in 51 genes cause autosomal recessive syndromic 
retinal dystrophy, including Bardet-Biedl syndrome (BBS) and Usher syndrome (RetNet, 
http://www.sph.uth.tmc.edu/RetNet/). These genes encode proteins involved in the 
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phototransduction cascade, vitamin A metabolism, cellular or cytoskeletal structure, cell-
to-cell signaling or synaptic interaction, gene expression, phagocytosis, and RNA splicing 
factors.30 Several RP proteins, including approximately half of the BBS proteins, are part of 
the photoreceptor sensory cilium proteome, a large protein complex associated with and 
constituting the connecting cilium.31
Homozygosity mapping has proven to be fruitful to identify defects in known and 
newly identified genes implicated in autosomal recessive retinal degenerations32-34 and to 
establish novel genotype-phenotype correlations.35,36 Using this approach, we identified 
a patient with RP with a large homozygous region encompassing the BBS1 gene. The 
fact that retinal degeneration is consistently seen in BBS patients with BBS1 mutations 
and previous observations that some mutations in BBS3/ARL6, BBS8/TTC8, BBS12 and 
BBS14/CEP290 cause nonsyndromic retinal degeneration or retinal degeneration with 
minimal systemic features37-40 prompted us to screen BBS1 in this patient, and to further 
test the hypothesis whether mutations in BBS1 are also a significant cause of nonsyndromic 
RP. In this study, we analyzed the p.M390R BBS1 mutation in 2,007 patients with RP. We 
identified p.M390R BBS1 mutation in a homozygous or compound heterozygous manner 
in 14 patients with a wide clinical spectrum ranging from nonsyndromic RP to classic 
BBS, as well as in one putative healthy individual.
 
Methods
Patients and clinical evaluation. 
In Canada, Europe, and Israel 2,007 unrelated patients with isolated or autosomal recessive 
RP (80 from Ghent, 96 from Jerusalem, 245 from Madrid, 361 from Montpellier, 343 
from Montreal, 143 from Naples, 215 from Nijmegen, and 524 from Tübingen) and 1,824 
ethnically matched individuals serving as controls (103 from Ghent, 100 from Jerusalem, 
320 from Madrid, 56 from Montpellier, 361 from Montreal, 140 from Naples, 233 from 
Nijmegen, and 511 from Tübingen) were included in the study. The diagnosis of RP was 
based on ophthalmologic examination that included measurement of best-corrected visual 
acuity, Goldmannvisual fields, slitlamp biomicroscopy, dilated indirect ophthalmoscopy 
and fundus photography. In addition, full-field flash electroretinogram (ERG), according 
to the guidelines of the International Society of Clinical Electrophysiology of Vision (41), 
was performed when Goldmann visual fields were measurable and indicated a preserved 
visual field with peripheral limits beyond the pericentral 10°. A broad definition of RP 
was used to avoid excluding patients with atypical features: progressive visual loss, night 
blindness and an abnormal ERG finding in a rod-cone pattern when recordable. Blood 
samples were obtained after informed consent forms were signed. Ethical approval 
was given to all participating institutions and the study conformed to the tenets of the 
Declaration of Helsinki. Participants were evaluated again after the BBS1 gene defects, 
since they had previously received a diagnosis of nonsyndromic RP. Special attention 
was given to identifying features associated with BBS,2 which include primary features 
of RP, polydactyly, obesity, learning disabilities, hypogonadism in males, and renal 
abnormalities; and secondary features of speech disorders, cataract, brachydactyly or 
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syndactyly, developmental delay, polydipsia/polyuria (diabetes insipidus), ataxia, mild 
spasticity, diabetes mellitus, dental crowding or hypodontia, congenital heart diseases, 
and hepatic fibrosis . Where and when appropriate, patients were clinically reexamined 
or their records were again reviewed. Clinical evaluation included best-corrected visual 
acuity and slitlamp biomicroscopy of the anterior segment and retina. Additional 
examinations included kinetic and/or static perimetry and ERG according to the protocol 
of the International Society for Clinical Electrophysiology of Vision.
Homozygosity Mapping and BBS1 Mutation Analysis
Genomic DNAs were isolated from lymphocytes by standard salting-out procedures 
(42). Only the DNA sample of patient 5 was genotyped, usinga microarray that contains 
500,000 single nucleotide polymorphisms (SNPs) (GeneChip Genome-Wide Human 
SNP Array 5.0; Affimetrix). Array experiments were performed according to protocols 
provided by the manufacturer. The 5.0 array data were genotyped (Genotype Console, 
version 2.1, Affimetrix) and, subsequently, regions of homozygosity were identified using 
commercial software (Partek, version 6.1, Partek Inc).
Primers for the amplification of the 17 coding exons and splice junctions of BBS1 were 
designed by Primer344 and are available on request. Polymerase chain reaction (PCR) 
products were purified with 96-well filter plates (Multiscreen HTS-PCR; Millipore, 
Bedford, MA) or by gel extraction (Qia-Quick Gel Extraction Kit; Qiagen). Sequencing 
was performed with dye terminator chemistry (BigDye Terminator, version 3 on a 3100, 
3730 or 3730XL  DNA Analyzer; Applied Biosystems, Inc).
Screening for the BBS1 p.M390R and MGC1203 c.403C>T variants
We developed a restriction enzyme test to screen the patients and the controls for the 
recurrent BBS1 p.M390R mutation, as the c.1169T>G variant in exon 12 introduces an 
AvaII recognition site (G/GWCC). The PCR analysis of exon 12 of BBS1 was performed 
with forward primer 5’-CCTGTCTTGCTTTCCTCTCC-3’ and reverse primer 
5’-TCCTCCTCTTTCCCCAGAAG-3’ using 50 ng of DNA and 10 pmol of each primer 
in a standard 25 μl reaction. PCR amplification was performed (PTC-200 Thermo Cycler, 
MJ Research) under the following conditions: 3 min at 94⁰C, 35 cycles at 94⁰C for 30 s, 
58⁰C for 30 s, 72⁰C for 45 s, and a final extension step at 72⁰C for 10 min. PCR products 
were purified with 96-well filter plates (Multiscreen HTS-PCR; Millipore).Ten µl of the 
PCR product was digested with 2U of AvaII (New England Biolabs) in the appropriate 
buffer at 37⁰C for 2 hours, and size discriminated by agarose gel electrophoresis. After 
detecting the mutations, Sanger sequencing was performed to confirm the presence of 
the mutation.
The presence of  the MGC1203 c.403C>T variant was tested in all patients 
with 2 BBS1 variants and in the control individual with BBS1 p.M390R in 
homozygosity. This was done by sequencing PCR products generated using 
forward primer 5’-ACTGGTGCATAGGCAGATGG-3’ and reverse primer 
5’-CATGGACTGGGCCCTACAG-3’. The PCR products were purified with 96-well filter 
plates (Multiscreen HTS-PCR; Millipore). Sequencing was performed with dye terminator 
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chemistry (BigDye Terminator, ver. 3 on a 3100. 3730 or 3730XL  DNA Analyzer; Applied 
Biosystems, Inc).
In silico assessment of missense substitutions
We employed PolyPhen-2 (44) (http://genetics.bwh.harvard.edu/pph2/index.shtml) and 
SIFT (45) (http://sift.jcvi.org) to predict the functional effect of novel missense substitution 
identified in this study. To asses the evolutionary conservation, amino acids sequences of 
orthologous BBS1 proteins (Pan troglodytes XP_0011719550.1, Sus scrofa NP_001091721, 
Canis lupus familiaris XP_540830.2, Mus musculus NP_001028300, Xenopus tropicalis 
NP_001116276.1, Drosophila melanogaster NP_648080.1, and Caenorhabditis elegans 
NP_740933.1) were obtatined from the NCBI protein database (http:/www.ncbi.nlm.nih.
gov/protein/) and were aligned with the protein sequence of human BBS1 (NP_078925.3) 
using Vector NTI software (version11; Invitrogen).
Results
Identification of BBS1 mutations in RP patients
Upon homozygosity mapping, several homozygous regions were identified in patient 
5, who received a diagnosis of severe RP, the largest of which measured 19 Mb and 
encompassed the BBS1 gene on chromosome 11q13.2. Sequence analysis of all 17 coding 
exons of BBS1 revealed the homozygous c.1169T>G (p.M390R) missense mutation in 
exon 12. To determine whether the p.M390R variant could be a rather frequent cause of 
nonsyndromic RP, we carried out a restriction fragment length polymorphism (RFLP) 
analysis for the p.M390R BBS1 mutation in 2,006 patients with isolated or autosomal 
recessive RP in Canada, Europe, and Israel. We found 8 additional unrelated patients and 
a sib-pair with a homozygous p.M390R mutation (Table 1). Three patients carried the 
p.M390R allele combined with a second BBS1 variant in compound heterozygous state. 
Two of these mutations (c.1163T>C [p.L388P] and c.803G>C [p.R268P], detected in 
patients 2 and 13 respectively) are novel and 1 mutation (c.1130_1134del [p.C377Wfs*36] 
in patient 4) was described previously.27 Alignment of the BBS1 amino acid sequences 
of various orthologs showed that the substituted amino acids (i.e., leucin at position 388 
and arginin at position 268) are highly conserved from human to C. elegans. PolyPhen-2 
predicted that p.L388P and p.R268P variants were probably damaging, and SIFT analysis 
revealed that both are not tolerated.
Analysis using restriction fragment length polymorphism revealed 5 patients with only 
1 p.M390R variant, subsequent sequence analysis of the 17 BBS1 exons did not reveal a 
second allele. In 1,824 ethnically matched control individuals we found 6 heterozygous 
p.M390R carriers and 1 individual who is homozygous for this variant. Because these were 
anonymous healthy individuals, further clinical assessments could not be performed.
Because Badano et al.14 identified a modifier allele for BBS in MGC1203, we tested the 
presence of the c.403C>T variant in all cases and the 1 control individual with two BBS1 
alleles. Using RFLP analysis, this modifier allele was not detected in any of these cases.
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Table 1. Spectrum of Ocular and Extraocular Features of Patients With BBS1 Mutations
Patient
/Sex Country
Primary features Secondary features No. of BBS features
Diagnosis Allele1/Allele2Ocular Extra-ocular Ocular
Extra-
ocular Primary Secondary
Group A
1/M NL RP None Cataract None 1 1 Nonsyn-
dromic RP
M390R/ 
M390R
2/M FR RP None Cataract None 1 1 Nonsyn-
dromic RP
M390R/ 
L388P
3/Fa IT RP None Cataract None 1 1 Nonsyn-
dromic RP
M390R/ 
M390R
Group B
4/M NL RP Mild renal 
cysts with-
out renal 
dysfunction
None None 1 1 Possibly 
nonsyn-
dromic RP 
M390R/ 
C77WfsX36
5/M CA RP Obesity, but 
not truncal
Cataract None 1-2 1 Possibly 
nonsyn-
dromic RP 
M390R/ 
M390R
6/M FR RP Obesity None None 2 0 Possibly 
nonsyn-
dromic RP 
M390R/ 
M390R
7Ma IT RP Obesity Cataract None 2 0 Possibly 
nonsyn-
dromic RP 
M390R/ 
M390R
Group C
8/Mb BE RP None None Light spasm 
and clubfoot
1 1 Mild BBS M390R/ 
M390R
9/F GE RP Learning 
difficulties
None Speech im-
pediment
2 1 Mild BBS M390R/ 
M390R
10/Fc FR RP Obesity Cataract None 2 1 Mild BBS M390R/ 
M390R
11/M IT RP Nephro-
nophtisis
Cataract None 2 1 Mild BBS M390R/ 
M390R
12/F FR RP Obesity / 
learning 
difficulties
Cataract None 3 1 Mild BBS M390R/ 
M390R
13/F NL RP Obesity / 
polydactyly
Cataract None 3 1 Mild BBS M390R/ 
R268P
Group D
14/M GE RP Obesity / 
learning 
difficulties
None Poly-
uria-poly-
dipsia / 
diabetes / 
congeni-
tal heart 
disease
3 2 BBS M390R/ 
M390R
Abbreviations: BBS, Bardet-Biedl syndrome; BE, Belgium; CA, Canada; FR, France; GE, Germany; IT, Italy; NL, the Netherlands; 
RP, retinitis pigmentosa. a Patients 3 and 7 are siblings. b Sister with polydactyly. c Sister with polydactyly and RP.
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Table 2. The ocular findings in the patients with BBS1 mutations.
Patient First 
symptoms
Age at 
examina-
tion
Visual acuity Anterior 
segment
Ophthalmoscopy Perimetry Scotopic/ 
photopic 
ERGOD OS
Group A
1 Night blind-
ness at age 
3, VA loss at 
age 12-15
33 CF CF Polar 
subcapsular 
cataract
Typical RP with 
symmetric atrophy 
in the posterior 
pole
Ringscoto-
ma at age 
12, later in 
life central 
islands 15°
At age 
12:severely 
disturbed 
in rod 
cone-pat-
tern; later 
NR / NR
2 NB at age 18 31 20/50 20/63 Moderate 
cortical 
cataract
Punctate pigment 
deposits and 
peripheral bone 
spicules. Preserved 
maculae.
Central 
islands 10°
NR / NR
3a Nystagmus 
and hem-
eralopia at 
age 1
55 LP LP Unknown Typical RP with 
marked peripheral 
pigmentation
Modest 
temporal 
region of 
remaining 
sensitivity
NR / NR
Group B
4 Night 
blindness at 
age 8
43 LP LP Posterior 
cortical 
opacity
Extensive atrophy, 
striking macular 
atrophy, attenuated 
vessels and irregu-
lar midperipheral 
pigmentations 
(Figure 1)
Patient 
could not 
observe 
targets
NR / NR
5 Night 
blindness at 
age 18
43 HM HM Pseudofakia Severe maculopa-
thy, leopard spots, 
diffuse pigmen-
tation
Patient did 
not observe 
targets
NR / NR
6 Night 
blindness at 
age 10
19 20/50 20/63 No abnor-
malities
Typical RP with 
atrophy at the 
fovea
Central 
islands 5°
Not per-
formed
7a Nystagmus 
and hem-
eralopia at 
age 1
55 LP LP Pseudofakia Typical RP with 
macular involve-
ment
Modest 
temporal 
region of 
remaining 
sensitivity
NR / NR
Group C
8 Night 
blindness at 
age 12
16 20/80 20/160 Unknown Typical RP Severely 
constricted 
(30°)
Severely 
decreased 
cone 
response / 
rod NR
9 Night 
blindness at 
age 5
43 20/200 20/200 Posterior 
cortical 
opacity
RP with diffuse 
pigment clumping 
and depigmenta-
tions
Relative 
central 
scotoma of 
60°, with 
relative and 
abolute 
regions
NR / NR
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10 VA loss 
at age 23, 
moderate 
night blind-
ness
41 HM HM Pseudofakia 
(age 41)
Profound macular 
atrophy, bone spic-
ules and attenuated 
vessels
Large 
central 
scotoma of 
40°
Severely 
decreased 
rods more 
than cones
11 Nystag-
mus since 
infancy
21 LP LP Unknown Typical RP with 
macular involve-
ment
Patient 
could not 
observe 
targets
NR / NR
12 Loss of VA 
at age 10
36 20/63 20/63 Subcapsular 
cataract
Typcial RP, normal 
aspect of macula
Severely 
constricted 
(30°)
Severely 
decreased 
cone 
response / 
rod NR
13 Night 
blindness at 
age 18
38 20/50 20/40 Cortical 
cataract
Typical RP with 
severe atrophy,
Severely 
constricted 
(30-35°)
NR / NR
Group D
14 Visual field 
loss at age 
35
54 LP LP Cataract RP without pig-
mentations, severe 
atrophy central and 
in midperiphery
Severely 
constricted 
fields (20°-
45° OU)
NR / NR
Abbreviations: CF, counting fingers; ERG, electroretinography; HM, hand motion; LP, light perception; NR, nonrecordable; RP, 
retinitis pigmentosa; VA, visual acuity. a Patients 3 and 7 are siblings.
Clinical Findings
The clinical findings of the 14 patients with BBS1 variants are reported in Table 1. Patients 
have been divided into 4 groups. Group A contains the 3 patients who appeared to 
have a nonsyndromic form of RP. In these patients, cataract was the only feature that 
might be related to BBS. Group B consisted of 4 patients who may have a nonsyndromic 
form of RP. These patients showed few extraocular features that may be associated with 
the retinal phenotype. Three of these patients were obese, and, in 1 patient routine 
ultrasound revealed a few mild renal cysts without renal dysfunction. The 6 patients of 
group C demonstrate definite extraocular features commonly associated with BBS but 
insufficient to warrant a diagnosis of classic BBS. Finally, group D included 1 patient who 
fulfilled the criteria for the diagnosis of classic BBS after reevaluation. The results of the 
ophthalmologic examination in the 14 patients with RP or (mild) BBS are summarized in 
Table 2. In most patients, night blindness was the first symptom of retinal degeneration. 
Early photoreceptor dysfunction, at or before the age of 10 years, was observed in 6 of the 
14 patients (including 2 siblings, patients 3 and 7). A visual acuity level of counting fingers 
or less was observed in 8 patients, and none of the patients displayed  visual acuity better 
than 20/40. Figure 1 (patient 4) clearly illustrates the severity of the phenotype in these 
patients. A relative later age at onset did not necessarily reflect positively on the chance 
of encountering severe visual loss, as demonstrated by patient 14 who experienced visual 
field loss at age 35 years, but at age 54 years, her visual acuity was already reduced to light 
perception. In most patients there was extensive loss of the visual field. Four patients 
could not see the largest target or showed only a modest temporal region of remaining 
sensitivity; 6 patients demonstrated severe visual field constriction. When ERG responses 
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could be elicited, a rod-cone pattern of photoreceptor degeneration was observed. In 10 of 
13 patients, the ERG became nonrecordable during the course of their disease.
Comment
Mutations in the BBS1 gene have been associated with BBS,27 and in one study they were 
associated with RP and variable mild systemic features. 46 For some BBS families, a digenic-
triallelic inheritance model has been proposed in which interactions were suggested 
between BBS1 and BBS2 or BBS1 and BBS6,13-15 although this has not been replicated 
Figure 1. The right eye of patient 4 at age 33. This color fundus photograph illustrates the severity of the RP phenotype in many 
of the patients in this study. In addition to the midperipheral bone spicules and the attenuated vessels, there is widespread cho-
rioretinal atrophy. The atrophy is especially severe at the posterior pole. The visual acuity in this patient is only light perception 
and ERG responses are absent.
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in other studies.8-10 We found that the BBS1 variant p.M390R is significantly associated 
with nonsyndromic RP or mild BBS because we identified it in 21 of 4,014 alleles in 
our probands vs 8 of 3,648 alleles in controls (p=0.023 Fischer exact test). Similarly, the 
BBS3/ARL6 variant p.A89V and the BBS12 variant p.S701* have been implicated in both 
nonsyndromic RP and BBS.40,47 A splice mutation affecting a retina-specific exon of BBS8/
TTC8 also causes nonsyndromic RP.48 In other studies considerable variations of systemic 
features have been described in BBS patients.49-51
The phenotype of the BBS1-associated retinal dystrophy in our patient group was more 
severe than previously reported by Azari and coworkers.52 Eight of the 14 patients in 
the current study had visual acuity of counting fingers or lower, whereas Azari and co-
workers observed only 1 patient with a visual acuity below 20/200 in their 10 patients with 
principally classic BBS. In addition, the age of onset was relatively early in our patients and 
nystagmus was present in 3 patients. For the most part, the patients in this study showed a 
classic RP with a relatively homogeneous clinical presentation. In view of the early age of 
onset, the low visual acuity and the extensive visual field loss, the photoreceptor dystrophy 
of the 14 patients in this study should be considered severe.
The disease spectrum of the patients in this study is broad, and any attempt at organisation 
is arbitrary at best. Cataract is commonly found in up to 50% of patients with RP and, in 
many patients cataract surgery is performed at a relative early age.53-55 Consequently, in the 
absence of other primary or secondary signs, we believe the condition in the 3 patients in 
group A should be diagnosed as nonsyndromic RP, despite the presence of the secondary 
feature cataract. The same line of reasoning more or less holds with the primary feature 
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Figure 2. Cis- and trans-acting Bardet-Biedl syndrome (BBS) gene BBS1 expression regulator model. A, Enhancer/promot-
er variants (cis-acting) may modulate the messenger RNA expression levels of BBS1 and thereby determine the penetrance or 
expression of disease. Unaffected individuals carry hypomorphic variants (v1 and v2, such as the p.M390R variant) on 1 or 2 
highly () expressed BBS1 alleles; moderately () expressed BBS1 alleles result in nonsyndromic retinitis pigmentosa (RP) or mild 
BBS, and low (/−) expressed BBS1 alleles result in BBS. B, A trans-acting third variant (v3) present in an interactor of BBS1 or a 
transcription factor negatively regulating the expression of BBS1 may contribute to the phenotype.
BBS1 mutations underlie a wide spectrum of phenotypes ranging from non-syndromic 
retinitis pigmentosa to Bardet-Biedl syndrome 
79
of obesity in the patients in group B. Obesity is a rather nonspecific finding in current 
Western society and perhaps even more so in patients with retinal degeneration who are 
prone to physical inactivity.56 In addition to RP, the patients in group B have few primary 
and/or secondary features that could be associated with BBS but may also be coincidental. 
The isolated presence of moderate obesity, especially without truncal distribution and 
in combination with parental obesity, is not necessarily an indication of extraocular 
abnormalities due to BBS1 mutations, so that nonsyndromic RP is at least a possibility. 
Following this approach, 3 of our 14 patients (group A) exhibit nonsyndromic RP, and 4 
patients (group B) demonstrate a form of RP that may very well be nonsyndromic.
Despite the inclusion criterion of autosomal recessive and/or isolated RP, 7 patients 
showed syndromic features that seem to be associated with the retinal phenotype. In one 
patient (group D), a previously undiagnosed classic form of BBS was discovered. The 
extra digits were removed shortly after birth in this patient, emphasizing the importance 
of obtaining a complete history in RP patients. In the remaining 6 patients (group C) 
extraocular features were present, but these abnormalities were insufficient to warrant 
the diagnosis classic BBS. Extra-ocular features in these 6 patients were highly divergent, 
making correct identification of this milder form of BBS challenging. In patient 11, RP 
was associated with nephronophtisis (NPHP), a combination known as the Senior-Løken 
syndrome. This syndrome has been associated with mutations in the NPHP genes and 
not, to our knowledge, with BBS1 mutations. The observation that BBS1 mutations may 
cause milder BBS phenotypes has been reported in a case history of two brothers.46 The 
danger of a misdiagnosis of patients with milder BBS phenotypes is important in view of 
the potentially severe consequences of life threatening conditions associated with BBS1 
mutations, as well as the accuracy of genetic counseling.
The presence of a presumed unaffected individual with two p.M390R variants in our study 
is not unprecedented as Badano and coworkers reported 2 families with 2 p.M390R alleles 
in BBS patients and their unaffected fathers.13 The differential penetrance of BBS1 alleles 
in one of these families was subsequently explained by the detection of a heterozygous 
trans-acting epistatic allele (MGC1203; c.430C>T) in the BBS patient but not in the 
unaffected father.14 The MGC1203 encodes a pericentriolar protein that interacts with 
BBS1, BBS2, BBS4, BBS5, BBS6, BBS7, BBS8, and colocalizes with BBS1 and BBS4. The 
MGC1203 variant c.430C>T enhances the use of a cryptic splice acceptor site, causing the 
introduction of a premature stop codon and the reduction of MGC1203 mRNA levels. 
An alternative explanation for the variable phenotypes associated with BBS1 alleles could 
be cis-acting regulators of expression. We did not find this modifier in our cases and 
control with two BBS1 alleles. Different enhancer or promoter variants may result in 
higher mRNA expression levels of the BBS1 p.M390R alleles in unaffected individuals, 
which may compensate for the reduced activity of the p.M390R-carrying BBS1 protein 
(Figure 2A, cis-acting modifier). Alternatively, as shown in Figure 2B, mild BBS or BBS 
can also be caused by a combination of 2 BBS1 variants and a negatively acting trans-
acting modifier, such as the MGC1203 variant c.430C>T.
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In conclusion, by analysing a very large cohort of isolated or autosomal recessive RP 
patients, we identified BBS1 variants in individuals with a wide clinical spectrum ranging 
from nonsyndromic RP (mild BBS) to classic BBS.
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Abstract
Cone-rod dystrophy (CRD) and retinitis pigmentosa (RP) are clinically and genetically 
overlapping heterogeneous retinal dystrophies. By using homozygosity mapping in an 
individual with autosomal-recessive (ar) RP from a consanguineous family, we identi-
fied three sizeable homozygous regions, together encompassing 46 Mb. Next-generation 
sequencing of all exons, flanking intron sequences, microRNAs, and other highly con-
served genomic elements in these three regions revealed a homozygous nonsense muta-
tion (c.497T>A [p.Leu166*]) in C8orf37, located on chromosome 8q22.1. This mutation 
was not present in 150 ethnically matched control individuals, single nucleotide poly-
morphism databases or the 1000 Genomes database. Immunohistochemical studies re-
vealed C8orf37 localization at the base of the primary cilium of human retinal pigment 
epithelium cells and at the base of connecting cilia of mouse photoreceptors. C8orf37 
sequence analysis of individuals who had retinal dystrophy and carried conspicuously 
large homozygous regions encompassing C8orf37 revealed a homozygous splice-site mu-
tation (c.156-2A>G) in two siblings of a consanguineous family, and homozygous mis-
sense mutations (c.529C>T [p.Arg177Trp]; c.545A.G [p.Gln182Arg]) in siblings of two 
other consanguineous families. The missense mutations affect highly conserved amino 
acids, and in silico analyses predicted that both variants are probably pathogenic. Clinical 
assessment revealed CRD in four individuals, and RP with early macular involvement in 
two individuals. The two CRD siblings with the c.156-2A>G mutation also showed uni-
lateral postaxial polydactyly. These results underline the importance of disrupted ciliary 
processes in the pathogenesis of retinal dystrophies.
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Retinitis pigmentosa (RP [MIM 268000]) is the most common inherited retinal  degen-
eration and has an estimated worldwide prevalence of 1/4,000 individuals.1 RP initially 
is characterized by rod photoreceptor dysfunction, giving rise to night blindness, which 
is followed by progressive rod and cone photoreceptor dystrophy, resulting in midpe-
ripheral vision loss, tunnel vision and sometimes blindness. The disease is genetically 
highly heterogeneous and displays all Mendelian patterns of inheritance. In addition 
there are some cases with mitochondrial mutations and digenic inheritance.2,3 Thus far, 
mutations in 34 genes have been associated with nonsyndromic autosomal-recessive (ar) 
RP (RetNet).3
In contrast to RP, cone-rod dystrophy (CRD [MIM 120970]) is characterized by a 
primary loss of cone photoreceptors and subsequent  or simultaneous  the loss of rod 
photoreceptors.4,5 The disease in most cases becomes apparent during primary-school 
years. The symptoms include photoaversion, a decrease in visual acuity with or without 
nystagmus, color-vision defects, and decreased sensitivity of the central visual field. 
Because rods are also involved, night blindness and peripheral vision loss can occur. 
The diagnosis of CRD is mainly based on electroretinogram (ERG) recordings, in which 
cone (photopic) responses are more severely reduced than, or equally reduced as, rod 
(scotopic) responses.5,6 CRD occurs in 1/40,000 individuals,4,5 and also displays all types 
of Mendelian inheritance. Mutations in five genes i.e. ABCA4 (MIM *601691), ADAM9 
(MIM *602713), CDHR1 (MIM *609502), CERKL (MIM *608381), and RPGRIP1 (MIM 
*605446) have thus far been implicated in nonsyndromic arCRD.7-11
Genes harboring arCRD- and arRP-associated mutations encode proteins that are involved 
in phototransduction, vitamin A (retinoid) metabolism, transport along the connecting 
cilium, cell-to-cell signaling or synaptic interaction, gene regulation, and phagocytosis.3 
Mutations in these genes are estimated to underlie ~50% of the cases.
We aimed to identify the genetic defect associated with retinal dystrophies and to  clinically 
investigate individuals with RP and CRD. The tenets of the Declaration of Helsinki were 
followed, and, in accordance with approvals gathered from the appropriate institutiona 
review boards, informed consent was obtained from all participating individuals prior to 
donation of the blood samples.
Homozygosity mapping has proven to be a fruitful method to identify mutations 
underlying autosomal-recessive retinal diseases,12-16 and to establish novel genotype-
phenotype correlations.17,18 To identify the genetic defect in a consanguineous family with 
RP (family 1; Figure 1A), we analized the DNA of individual IV:1 by using an Affymetrix 
GeneChip Human Mapping 250K SNP array (Affymetrix, Santa Clara, CA, USA) and 
analyzed the SNP data by using Partek Genomic Suite software (Partek Inc., St. Louis, 
MO, USA). The analysis showed three large homozygous regions of 7.7 Mb (4q34.3-q35.1, 
rs2128423 - rs59156350), 31.6 Mb (8q22.1-q24.13, rs279475 - rs7013593) and 7.0 Mb 
(11p11.2-q11; rs11039487 – rs17494990). Because more than 261 genes were present 
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in these three chromosomal regions, a targeted next-generation sequencing  (NGS) 
approach was used. Sequence capture was done on a 385k sequence-capture array (Roche 
NimbleGen, Madison, WI, USA). The array design comprised all coding and non-coding 
exons of these regions, including surrounding sequences that covered the splice sites. The 
array design harbored additional targeted regions used for similar analysis of homozygous 
regions in two other families. In total, the design included 4,952 targets, comprising 
1,903,789 bp. Sequence capture was done according to manufacturer’s (Roche NimbleGen) 
instructions with the Titanium optimized protocol as described by Hoischen et al.19 The 
enriched DNA regions of individual IV:1 from family 1 were sequenced on one of four 
lanes of a Roche 454 sequencing run, yielding 86 Mb of sequence data. Approximately 
86% of the sequences mapped back to unique regions of the human genome (hg18, NCBI 
build 36.1), with the use of the Roche Newbler software (version 2.3). Of all mapped 
reads, 91% were located on or near the targeted regions (i.e., within 500 bp). This was 
sufficient to reach an average of 19.3-fold coverage for all target regions. For the region 
of interest, less than 2.6% of all targeted sequences were not covered, and only 22% of 
the target sequence was covered fewer than ten times. The Roche 454 software detected 
a total of 2,755 high-confidence variants, i.e. it identified the variants in at least three 
reads. We used a custom-made data-analysis pipeline as described elsewhere19 to annotate 
detected variants with various types of information, including known SNPs, amino acid 
substitutions, genomic location, and evolutionary conservation. A total of 2,573 variants 
were found to represent known SNPs or overlapped with a known polymorphic region 
(dbSNP129); they were therefore considered not likely to be disease-causing variants.
The remaining 182 variants included 39 nongenic variants, 32 untranslated-regions 
variants, 74 intronic variants, two potential splice-site variants, and 35 exonic variants. The 
exonic variants consisted of three synonymous coding variants and 32 nonsynonymous 
coding variants. Of the latter 32 variants, only two were called as homozygous variants 
(i.e., > 80% variant reads), whereas the remaining 30 variants appeared heterozygous. The 
finding of  heterozygous variants in homozygous regions possibly can be explained by the 
existence of pseudogenes that are changing the ratio of variant reads to reference reads.20
The two homozygous nonsynonymous variants (c.2483T>C in C4orf41 [NM_199053.1] 
and c.497T>A in C8ORF37 [NM_177965.2]) were chosen for further candidate analysis. 
SIFT predicted that the c.2483T>C (p.Val828Ala) variant in C4orf41 would be tolerated, 
and PolyPhen predicted that it would be benign. In addition, this variant was found in the 
1000 Genomes database and in a heterozygous state in 3 out of 133 individuals, who were 
analyzed via exome NGS. On the basis of the latter finding, this variant would be present 
in a homozygous state in ~1/8,000 individuals, a ratio that is 2 orders of magnitude higher 
than for other RP-associated variants. Together, these data strongly suggest that the 
C4orf41 variant is not associated with RP in family 1. The second candidate variant was 
a homozygous c.497T>A variant in C8orf37 in the 31.6-Mb region of 8q22.1 (Figures 1A 
and B) and resulted in a premature stop codon (p.Leu166*) (Figures 2C and 2D). Sanger 
sequencing confirmed the homozygous presence of this variant in IV:1 (Figure 2D) and 
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its presence as a heterozygous change in both parents (Figure 1A). This mutation was not 
detected in 300 chromosomes of ethnically matched control individuals or in the 1000 
Genomes database.
Family 1
(M1: c.497T>A; p.Leu166*)
Family 2
(M2: c.156-2A>G; splice defect)
Family 3
(M3: c.529C>T; p.Arg177Trp)
Family 4
(M4: c.545A>G; p.Gln182Arg)
I:2I:1
II:1 II:3II:2 II:4
M3/M3 M3/M3
IV:1 IV:2 IV:3
III:1 III:2
I:4I:3 I:2I:1
II:1 II:3II:2 II:4
M4/M4 M4/M4
IV:1 IV:2 IV:3
III:1 III:2
M4/+
M4/+ M4/+
M4/M4
IV:4
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2
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5
I:2I:1
II:1 II:3II:2 II:4
M1/+M1/+
Human           HKLKAKLIKKKGTRAYACQCSWRTIEEVTD  193 
Rat             HKLKTKLIEKKGARAYACQCSWRTVEELTD  196 
Mouse           HKLKTKLIEKKGARAYACQCSWRTVEELTD  195 
Chicken         SKLRAKMIKKKGSRAYACQCSWRSIDELTD  271 
Frog            SKLRPKLIRKKGARAYACQCSWRSVQELTN  183 
Sea urchin      QKLRAKLRKKKDCRAYACQCCWRSLKAQTD  152 
Chlamydomonas   EKLAPKMRSRQGSVAYCCQCSWLNSTEQAK  240 
Phytophthora    AKLRVKMEIAPDFTAYACQCKWLSICSQTR  193 
Figure 2
Figure 1. Pedigrees with C8orf37 Mutations and Partial Align-ment of C8orf37 Orthologs (A) Schematic representation 
of the four consanguineous families in which homozygous C8orf37variants were identified. The respective mutations (M1–
M4) are indicated above the pedigrees. In family 1, a protein-truncating mutation (p.Leu166*) was identi-fied; in family 2, the 
c.1562A>Gvariant affects one of the canon-ical nucleotides of a splice-acceptor site. Affected individuals in families 3 and 4 car-
ry C8orf37missense mutations that are located in close proximity (see B). Theþsymbol represents wild-type. Dia-mond-shaped 
symbols representmale(s) or female(s); the numbers in the symbols indicate the numbers of individuals. Blackened symbols 
represent affected individuals. Symbols with slashes depict deceased individuals. (B) Evolutionary conservation of the part of 
the C8orf37 polypep-tide that contains the missense mutations p.Arg177Trp and p.Gln182Arg, which are identified in families 
3 and 4, respectively. The alignment was performed via ClustalW2 with the following protein sequences: human (NP_808880.1), 
rat (NP_001007747.1), mouse (NP_680281.3), chicken (Xp_418346.2), frog (XP_002931575.1), sea urchin (XP_001194284), 
Phytophtora (XP_002904228.1), and Chlamydomonas (XP_001697126.1). Amino acid residues that are identical in all sequences 
are white on a black background, whereas amino acids that are similar but not identical are black on a light gray background. 
Nonconser-vative changes are indicated in black on a white background.
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C8orf37 spans 23,203 nucleotides of genomic DNA and consists of six exons, that encode a 
polypeptide that is 207 amino acid long (Figure 2B). The function of C8orf37 is unknown, 
and, because it lacks known functional protein domains, it is difficult to predict its role in 
the retina. In adult human tissues, C8orf37 is expressed ubiquitously and there are high 
levels of mRNA expression in brain, heart, and retinae (Figure 3A). Immunohistochemical 
studies on hTERT-RPE1 cells with anti-C8orf37 (rabbit polyclonal, Sigma-Aldrich, MO, 
USA), which was tested for specificity in cow retinal extracts (Figure S1, available online), 
suggested that C8orf37 is localized in the cytoplasm (data not shown). However, after 
inducing cilia formation by serum starvation,21 C8orf37 was localized at the base of the 
primary cilium, as indicated by partial colocalization with polyglutaminated tubulin 
antibody GT335 (mouse monoclonal, ab-cam, Cambridge, UK), a ciliary marker (Figure 
3B). Similar results were observed when the ciliary marker antiacetylated α-tubulin 
(mouse monoclonal, Sigma-Aldrich, MO, USA) and anti-γ-tubulin (mouse monoclonal, 
Sigma-Aldrich, MO, USA) were used in combination with anti-C8orf37 (Figures 3C and 
3D). Immunolocalization studies with the same antibodies in postnatal day 30 mouse 
retinal sections (Figures 3E-3G) also revealed an intense C8orf37 staining at the base of the 
photoreceptor connecting cilia. In addition, staining was observed in the photoreceptor 
inner segments, this staining possibly represents the rootlets.
c. 497T>A; p.Leu166*
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Figure 2. Homozygous Region in Individual IV:1 of Family 1,C8orf37Exon-Intron Structure, and Sequence Variant. (A) 
The 31.6 Mb homozygous region encompassing the flanking SNPs andC8orf37on part of chromosome 8q in IV:1 of family 1. 
(B) Genomic structure of C8orf37, which consists of six exons, all of which are protein coding. (C) Next-generation sequence 
traces for the reads covering theC8orf37c.497T>A variant (minus strand), which results in a premature stop codon (p.Leu166*). 
Twenty five reads, all of which show the c.497T>A change (visible in antisense direction as c.497A>T), encompass cDNA nucle-
otide 497. The visibility of this mutation is hampered in the five reads at the bottom, probably because of the mononucleotide 
stretches around the mutation. These stretches most likely lead to either sequencing or mapping problems when the Roche 454 
sequencing technology is used. The homozygosity of this variant was confirmed by traditional Sanger sequencing (see D). The 
abbreviation wt represents the wild-type anti-sense sequence. (D) Sanger sequencing confirmation of the c.497T>A variant in 
individual IV:1 of family 1.
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Figure 3. mRNA and Protein-Expression Characteristics of C8orf37 (A) mRNA expression of C8orf37 in adult human tis-
sues is the highest in the heart and the brain, followed by the retinae. The y axis shows the relative expression of C8orf37 in 
comparison to the lowest expression detected in the liver. For liver expression, the DDCt value was set at 0, resulting in an 
arbitrary expression of 1.33,34 The x axis shows the adult human tissues that were tested for C8orf37 expression. (B–D) Im-
munohistochemical staining of ciliated hTERT-RPE1 cells with antibodies against human C8orf37 (in green), and (in red) the 
ciliary markers GT335 (antipolyglutamylated tubulin) (B), antiacetylated a-tubulin (C), and anti-g-tubulin (D) revealed that 
endogenous C8orf37 localizes to the base of the primary cilia. Nuclei were stained with DAPI (in blue). Insets show selected 
magnifications. (E–G) Immunohistochemical staining in mouse retinal sections (P30). The most intense labeling for C8orf37 
(in green) was noted at the base of the photoreceptor connecting cilia which partially colocalized with (in red) the connecting 
cilium markers GT335 (antipolyglutamylated tubulin) (E), antiacetylated a-tubulin (F), and anti-g-tubulin (G). C8orf37 also 
stains structures that extend from the base of the cilium toward the inner segments, suggestive of ciliary rootlets. Abbreviations 
are as follows: CC, connecting cilia; IS, photoreceptor inner segments; and OS, photoreceptor outer segments. The scale bars 
represent the following: (B–D), 20 mm and (E–G), 10 mm.
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To determine whether mutations in C8orf37  are more widely involved in retinal 
dystrophies, we assessed ~400 unrelated individuals who had arCRD, arRP and Leber 
congenital amaurosis (LCA [MIM 204000]) and who had significant homozygous regions, 
i.e. >2 Mb for individuals in nonconsanguineous, and >4 Mb for individuals in 
consanguineous families, were assessed.13,14,16,20,22 In 15 consanguineous families and in 
none of the nonconsanguineous families, C8orf37 was located in conspicuously large 
homozygous regions, and sequence analysis of the C8orf37 coding exons revealed DNA 
variants in three additional consanguineous families (Figure 1A). Two affected siblings in 
Family 2 carried a homozygous splice site mutation (c.156-2A>G); whereas in Families 3 
and 4, all affected siblings carried the missense mutations p.Arg177Trp (c.529C>T) and 
p.Gln182Arg (c.545A>G), respectively. When available, additional affected and unaffected 
family members were analyzed, revealing that in each family, mutations fully cosegregated 
with the disease if one assumed an autosomal-recessive mode of inheritance (Figure 1A). 
The c.156-2A>G and c.529C>T variants were not found in 179 ethnically matched control 
individuals, dbSNP129, or the 1000 Genomes database. The c.545A>G mutation that was 
detected in a family of Israeli origin was found to be heterozygous in 2 out of 91 
ethnicallymatched control individuals of Druze origin;this finding is in line with previous 
carrier-frequency data reported for other mutations that were identified in this 
population.23 The splice mutation c.156-2A>G affects one of two canonical nucleotides 
of the 3’ splice site and hence potentially leads to the skipping of exon 2, introducing a 
frameshift and a premature truncation of the protein. Alignment of the C8orf37 amino- 
acid sequences of various orthologs showed that the substituted amino acids, i.e. arginine 
at position 177 and glutamine at position 182, are highly conserved (Figure 1B). Gln-182 
is fully conserved up to Chlamydomonas and Phytophtora, whereas Arg1-77 is conserved 
up to sea urchin. PolyPhen predicted that p.Arg177Trp is probably damaging, and SIFT 
analysis revealed that it is not tolerated. PolyPhen predicted that p.Gln182Arg is probably 
damaging, and SIFT analysis revealed that it is tolerated.
The clinical characteristics of six patients with C8orf37 variants are summarized in Table 
1. The age of onset varied from infancy to the end of the second decade. All affected 
individuals showed early involvement of the macula, resulting in a loss of central vision at 
an early age. Visual acuity in these patients did not exceed 20/60 and was as low as light 
perception in one individual. Figure 4 shows a representative fundus image of patient V:2 
of family 2. It shows atrophy with a beaten-bronze aspect at the center of the macula. The 
optic disc shows temporal pallor and there is a gliosis over the posterior pole. The retinal 
arterioles are mildly attenuated. The optical coherence tomography of this person shows 
a section of the central retina that includes the fovea: the retina is atrophic and much 
thinner compared to a normal retina.
The retinal phenotypes in four of the affected individuals (V:1 and V:2from family 2, IV:2 
and IV:3 from family 3) were classified as CRD in view of the initial symptoms, including 
photophobia and visual loss, the ophthalmoscopic abormalities that involved the macula 
rather than the periphery, and a cone pattern that was more reduce than the rod pattern 
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on the ERG in IV:2 and IV:3. In the remaining four affected individuals, the deterioration 
of the rod and cone systems appeared to occur simultaneously. Besides a loss of visual 
acuity, these individuals also experienced night blindness in the early stage of their 
disease. Whether the photoreceptor dystrophy in these persons should be classified as 
CRD or rather as RP with early macular involvement seems largely academic. However, 
the phenotype in these individuals is more severe than that of the four individuals with 
classic CRD, considering the more severe visual loss and the retinal abnormalities that 
spread into the far periphery.
Table 1. Summary of the Clinical Data of Six Individuals with C8orf37-Associated Retinal Dystrophies
Family Pa-
tient 
ID
Gen-
der
*Age 
at 
onset
Visual 
acuity*
Ophthalmoscopy Full field 
ERG 
(ODS)
Diagno-
sis
Homozygous 
mutation
OD OS
1 IV:1 M Infan-
cy
LP LP Macular atrophy, bone 
spicules pigmentations, 
attenuated retinal 
vessels.
nonrecord-
able
RP (with 
early 
macular 
involve-
ment)
c.497T>A; 
p.Leu166*
2 V:1 F 17 CF CF Atrophy of the central 
macula with gliosis. 
Temporal pallor of 
optic disc. Moderate 
attenuations of retinal 
arterioles. Some pe-
ripheral pigmentations.
nonrecord-
able
CRD c.156-2A>G 
V:2 M 10 0,16 0,16 Severe atrophy of the 
central macula with 
gliosis. Temporal pallor 
of optic disc. Mild 
attenuations of retinal 
arterioles
nonrecord-
able
CRD c.156-2A>G 
3 IV:2 M Infan-
cy
0,08 0,05 Peripapillar atrophy 
and temporal optic disc 
pallor, central isolated 
macular RPE atrophy 
pigment clumping. 
Attenuation of retinal 
vessels.
nonrecord-
able cone 
pattern,  
severe re-
duced   rod 
recording 
CRD c.529C>T; 
p.Arg177Trp
IV:3 M Infan-
cy
0,33 0,05 Central isolated macu-
lar atrophy. Attenuation 
of retinal vessels. No 
pigment clumping 
associated with the 
retinal dystrophy
nonrecord-
able cone 
pattern,  
severe re-
duced   rod 
recording 
CRD c.529C>T; 
p.Arg177Trp
4 IV:1 F 18 HM HM Waxy optic disc polar; 
grayish atrophic chang-
es in maculas with 
pigmentation. Bone 
spicules-like pigmenta-
tion and heavy pigment 
in mid-periphery.
nonrecord-
able
RP (with 
early 
macular 
involve-
ment)
c.545A>G; 
p.Gln182Arg
Abbreviations are as follows: CF, counting fingers; CRD, cone-rod dystrophy; F, female; HM, hand movements; LP, light 
perception; M, male; OD, right eye; OS, left eye; ODS, both eyes; and RP, retinitis pigmentosa. a Fraction measured at 20 feet.
b Age at which the affected individuals of families 2 and 4 first noticed visual abnormalities; retinal abnormalities could have 
been present earlier.
Mutations in C8orf37, encoding a ciliary protein, are associated with autosomal 
recessive retinal dystrophies with early macular involvement 
95
Interestingly, two siblings (V:1 and V:2 from family 2) also demonstrated a postaxial 
polydactyly at birth, with an extra finger or toe on the  right hand or foot respectively. 
Given that  polydactyly is one of the features of Bardet-Biedl syndrome (BBS [MIM 
20900])24 (a ciliopathy which includes retinal dystrophy), it is unlikely that this is a 
coincidental finding. Therefore, C8orf37 mutations might also contribute to extraocular 
abnormalities.
In this study, one nonsense, one splice site and two missense mutations were identified 
in 4 of 15 families with conspicuously large homozygous regions encompassing C8orf37, 
two of which (p.Leu166* and c.156-2A>G) have an unequivocal pathogenic effect. The 
two missense mutations (p.Arg177Trp and p.Gln182Arg) have been subjected to in silico 
prediction analysis, which suggested a pathogenic effect. Further functional studies are 
warranted to confirm an impact of these missense mutations on the function of C8orf37.
On the basis of the data presented above, it is difficult to deduce a genotype-phenotype 
correlation. The individuals with CRD and postaxial polydactyly from family 2 carry a 
splice-site mutation that most likely results in the skipping of exon 2, yielding a frameshift 
Figure 4. Fundus Photograph and Optical Coherence Tomography of the Left Eye of Individual V:2 of Family 2 at age 27. 
The upper panel of the fundus photograph shows atrophy with a beaten-bronze aspect at the center of the macula. The optic 
disc shows temporal pallor, and there is a gliosis over the posterior pole. The retinal arterioles are mildly attenuated. The opti-
cal coherence tomography in the lower panel shows a section of the central retina that includes the fovea; the retina is atrophic 
and much thinner than a normal retina.
Chapter 5A
96
and truncation of the 154 carboxy-terminal amino acids. Moreover, nonsense-mediated 
decay (NMD) could reduce the amount of mutant RNA, effectively resulting in a null 
allele. On the other hand, the p.Leu166* mutation identified in family 1 resides in exon 
6, the last exon of C8orf37, and thereby is not predicted to give rise to NMD. In theory, 
only the 42 carboxy-terminal amino acids would be truncated, which could result in a 
partially functional protein. The precise effect of the missense mutations p.Arg177Trp 
and p.Gln182Arg on the function of the C8orf37 protein in families 3 and 4 cannot be 
predicted.
Given the  extraocular clinical features of t the siblings in family 2, one could argue 
that they are the most severely affected. This, however, is not the case for their retinal 
phenotypes as the age of onset of retinal disease in these patients was in their teens (that 
of affected individuals from families 1 and 3 was in infancy). Postaxial polydactyly is 
one of the cardinal clinical features of BBS (24). To date, 15 genes have been associated 
with BBS (RetNet),25 but DNA variants in BBS1 (MIM 209901)25,26 (A.E.-C., A.I.d.H., 
F.P.M.C., unpublished data), ARL6 (MIM 608845),28 BBS12 (MIM 610683),29 CEP290 
(MIM 610142),30,31 and TTC8 (MIM 608132)32 have also been associated with mild BBS 
or non-syndromic retinal dystrophies. Therefore, it is very  possible that C8orf37 is also 
implicated in full blown BBS or in other ciliopathies. In view of the recent identification 
of a genetic modifier that was enriched in ciliopathies with an ocular phenotype,32 it is 
possible that the affected persons in family 2 carry a genetic modifier that, together with 
the C8orf37 variants, influenced hand and foot development.
In conclusion, we have identified mutations in a ciliary-expressed gene, C8orf37, and 
have found that these mutations are associated with arCRD and arRP with early macular 
involvement. Large-scale mutation analysis in the future will reveal its pathologic burden 
of C8orf37 mutations in these diseases.
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Western blot of bovine retinal extract and hTERT RPE1 cell extracts using anti-C8orf37. hTERT RPE1 cell extract (lane 1), 
hTERT RPE1 cells transfected with fused mRFP-C8orf37 (lane 2), and bovine retinal extracts (lane 3) were subjected to immu-
noblot analysis using anti-C8orf37 (rabbit polyclonal, Sigma-Aldrich, MO, USA). C8orf37 cDNA constructs were generated 
by PCR, using IMAGE clones of C8orf37 (clone 5520656), and were cloned in pDEST733 from the Gateway cloning system 
(Invitrogen), resulting in N-terminally fused mRFP-C8orf37. hTERT RPE1 cells were transfected with pDEST733-C8orf37 by 
using Effectene (Qiagen) according to the manufacturer’s instructions and lysed as describe previously.1 Bovine retinal extracts 
were prepared as describe previously.2 The immunoblot revealed a predicted band of ~23.4 kDa (**) for bovine c8orf37 (lane 3) 
and a predicted band of ~53.4 kDa (*) for the fused RFP-C8orf37 protein. Some additional bands are present in the immunoblot 
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RPE1 extracts (lane 1).
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Abstract
C8orf37, encoding a ciliary protein with an unknown function, is mutated in autosomal 
recessive cone-rod dystrophy and retinitis pigmentosa. In order to reveal the ciliary role 
of C8orf37 and gain insight in the molecular mechanisms underlying C8orf37-associated 
retinal degeneration, we applied an affinity proteomics approach to dissect its interac-
tome. We identified that C8orf37 binds to a core of retinal ciliopathy-associated proteins 
at the base of the photoreceptor cilium, as well as to proteins essential for ciliary transport. 
A member of this protein cluster is NINL, which links the retinal disorders Usher syn-
drome and Leber congenital amaurosis by its direct interaction with USH2A and lebercil-
in. The identification of a direct interaction with IFT74, part of the intraflagellar transport 
complex, supports the position of C8orf37 in the ciliary machinery. This interaction along 
with the presence of C8orf37 at the basal body and at the proximal side of the photore-
ceptor connecting cilium strengthens the view that C8orf37 is involved in trafficking and 
ciliary transport of proteins in photoreceptors. Interestingly, the interaction of C8orf37 
with CEP164, a centrosomal protein involved in DNA damage response, provides an al-
ternative pathogenetic mechanism. These results underline the importance of disrupted 
ciliary processes in the pathogenesis of retinal dystrophies.
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Introduction
Retinitis pigmentosa (RP; MIM 268000]) is the most common inherited retinal degener-
ation with an estimated worldwide prevalence of 1:4,000 individuals.1 RP is a progressive 
disorder, initially characterized by night blindness due to rod photoreceptor dysfunction, 
and typically followed by midperipheral vision loss, tunnel vision, and eventually com-
plete blindness due to degeneration of the rod and cone photoreceptors. In contrast to 
RP, cone-rod dystrophy (CRD, MIM 120970) is characterized by a primary loss of cone 
photoreceptor cells, followed by, or simultaneous with, the loss of rod photoreceptors.2,3 
The disease in most cases becomes apparent during primary school years. The symptoms 
include photo-aversion, a decrease in visual acuity with or without nystagmus, color vi-
sion defects, and decreased sensitivity of the central visual field. Because rods are also 
involved, night blindness and peripheral vision loss can occur. The diagnosis of CRD is 
mainly based on electroretinogram (ERG) recordings, in which cone responses are more 
severely reduced than, or equally reduced as, rod responses.2,4
RP and CRD are highly heterogeneous diseases that can display all Mendelian patterns 
of inheritance. Out of the 39 identified genes implicated in autosomal recessive RP and 
CRD, at least 12 (30%) encode proteins that localize to the cilium and/or basal body.5 This 
class of proteins and their associated complexes are essential for photoreceptor function 
by regulating transport across the cilium: vesicular transport of newly formed proteins 
from the Golgi apparatus towards the base of the connecting cilium,6 transport of pho-
totransduction proteins such as rhodopsin through the connecting cilium towards the 
outer segment, and the transport of turnover products back towards the inner segment of 
the photoreceptor cell.7,8 Given the specific site of action of ciliopathy-associated proteins, 
quite a few protein–protein interaction studies have been carried out to examine their 
connectivity and mechanisms of action at a molecular level.9 This approach has been 
successful and has led to the identification of multiple protein complexes that consist of 
functionally related components which, when mutated, result in similar or overlapping 
phenotypes in humans.10,11
Mutations in C8orf37 have recently been associated with autosomal recessive CRD and 
RP with early macular involvement. This gene encodes a strongly conserved polypeptide 
of 207 amino acids that is expressed ubiquitously in adult human tissues.12 The C8orf37 
protein localizes to the base of the primary cilium of human retinal pigment epithelium 
cells and to the base of connecting cilia of mouse photoreceptors,12 but its function and 
the molecular mechanism of disease caused by mutations in this gene remain unknown.
In this study, we set out to identify the ciliary role of C8orf37 by dissecting its associated 
protein complex. We found that it binds to a core of retinal ciliopathy-associated proteins 
at the base of the photoreceptor cilium, as well as to proteins essential for ciliary transport. 
This strengthens the view that disrupted transport across the cilium underlies a growing 
group of inherited retinal degenerations.
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Results
Analysis of the C8orf37 interactome 
To determine the repertoire of C8orf37-binding proteins, we followed an affinity proteom-
ics approach, employing Strep-Flag tandem affinity purification (SF-TAP) in combination 
with mass spectrometry (MS). This analysis resulted in the identification of 94 proteins 
that interact directly or indirectly with C8orf37 (Table1). In order to obtain functional 
clues about the C8orf37 module we applied the DAVID tool to the interacting protein 
data set, which enabled clustering based on functional annotation.13 The clustering analy-
sis identified 18 microtubule- and/or cytoskeleton- associated proteins (ACTB, ACTR1A, 
ALDOA, CAP1, CCT3, CEP170, CFL1, TTN, MAD2L1, NEB, NINL, NME1, NME2, 
TCP1, TUBA1B, TUBA1C, TUBB, TUBB2C, YWHAZ),14-20 suggesting that C8orf37-in-
teracting protein clusters are most prominently active in microtubule-based movement. 
The fact that these proteins are also annotated in the ciliary protein database,21 empha-
sizes their relevance for ciliary function.  Among the membrane-bound vesicle proteins 
identified in the cluster analysis, IFT74 has the best known ciliary relevance, as it is part of 
the intraflagellar transport (IFT) complex B. In addition to a clear ciliary relevance, some 
groups of C8orf37 interactors are predicted to be linked to peroxidase activity, apoptosis, 
glycolysis, or are known as biotin-binding proteins or heat-shock proteins (Supplemen-
tary Table 1).
The potential direct interaction between C8orf37 and ciliary proteins was evaluated using 
a dedicated yeast two-hybrid binding assay, assessing 95 ciliary proteins (or fragments 
thereof) for direct interaction (Supplementary Table 2). This analysis showed that C8orf37 
directly binds to CEP164 and to a specific fragment of the USH2A- and NINL-interactor 
SPAG5 (Figure 1, Supplementary Table 2), emphasizing the relevance of this connection 
in relation to the retinal phenotype.
C8orf37 colocalizes with NINL and CEP164 at the base of the primary cilium
To further explore the interaction of C8orf37 with NINL and CEP164 in an unbiased way, 
we performed immunofluorescence staining of the endogenous proteins. Staining of cili-
ated hTERT-RPE1 cells with anti-C8orf37, and with antibodies directed against the ciliary 
markers polyglutaminated tubulin (GT335) and acetylated α-tubulin, confirmed C8orf37 
localization at the ciliary base. Similar results were observed when hTERT-RPE1 cells 
were stained with anti-CEP164 and anti-NINL in combination with the ciliary markers 
described above: endogenous CEP164 and NINL localize in the same region as C8orf37 
at the base of the primary cilium (Figure 2).
C8orf37 and NINL colocalize at the murine photoreceptor basal body
Next we determined the subcellular co-localization of C8orf37 and NINL in adult mouse 
photoreceptors cells. By using polyclonal anti-C8orf37, polyclonal anti-NINL, and the 
polyglutaminated tubulin antibody, we observed C8orf37 in the region of the connecting 
cilium of photoreceptors cells. More specifically, C8orf37 stained the basal body and its 
accessory centriole at the very base of the connecting cilium, but it also stained to a weak-
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er extent the distal part of the connecting cilium (Figure 3-A). NINL was detected at the 
connecting cilium and in the inner segment of photoreceptors (Figure 3-B). Both C8orf37 
and NINL co-localize with polyglutaminated tubulin at the photoreceptor connecting cil-
ium, and thus share the same subcellular site of action. C8orf37 also seems to localize to 
the outer plexiform layer (OPL), the relevance of which is unclear.
Table 1. TAP and MS analysis of the C8orf37 interactome in HEK293 cells
Entrez gene 
symbol
Ensembl ID Entrez gene fullname NTAP 
seq cov
NTAP 
pep-
tide 
count
CTAP 
seq 
cov
CTAP 
pep-
tide 
count
ACACA ENSG00000132142 acetyl-Coenzyme A carboxylase alpha 0.15 31 0.3 52
ACTB ENSG00000075624 actin, beta 0.38 10 0.55 14
ACTR1A ENSG00000138107 ARP1 actin-related protein 1 homolog 
A, centractin alpha (yeast)
0.043 2 - -
AHCY ENSG00000101444 adenosylhomocysteinase 0.12 5 0.12 4
ALDOA ENSG00000149925 aldolase A, fructose-bisphosphate 0.06 2 - -
ATXN2L ENSG00000168488 ataxin 2-like 0.037 4 - -
BLVRA ENSG00000106605 biliverdin reductase A - - 0.11 3
CAD ENSG00000084774 carbamoyl-phosphate synthetase 
2, aspartate transcarbamylase, and 
dihydroorotase
0.0076 2 0.02 3
CAP1 ENSG00000131236 CAP, adenylate cyclase-associated 
protein 1 (yeast)
0.057 2 0.084 3
CAPN2 ENSG00000162909 calpain 2, (m/II) large subunit 0.099 6 0.067 4
CAPNS1 ENSG00000126247 calpain, small subunit 1 0.086 3 0.071 2
CASP14 ENSG00000105141 caspase 14, apoptosis-related cysteine 
peptidase
- - 0.14 3
CCT2 ENSG00000166226 chaperonin containing TCP1, subunit 
2 (beta)
0.16 5 0.27 10
CCT3 ENSG00000163468 chaperonin containing TCP1, subunit 
3 (gamma)
0.16 5 0.22 9
CCT4 ENSG00000115484 chaperonin containing TCP1, subunit 
4 (delta)
0.25 9 0.24 10
CCT5 ENSG00000150753 chaperonin containing TCP1, subunit 
5 (epsilon)
0.11 6 0.17 7
CCT6A ENSG00000146731 chaperonin containing TCP1, subunit 
6A (zeta 1)
0.092 5 0.18 7
CCT7 ENSG00000135624 chaperonin containing TCP1, subunit 
7 (eta)
0.05 2 0.21 7
CCT8 ENSG00000156261 similar to chaperonin containing 
TCP1, subunit 8 (theta); chaperonin 
containing TCP1, subunit 8 (theta)
0.1 5 0.37 17
CEP170 ENSG00000143702 centrosomal protein 170kDa 0.02 2 - -
CFL1 ENSG00000172757 cofilin 1 (non-muscle) 0.2 2 0.25 3
COL5A1 ENSG00000130635 collagen, type V, alpha 1 - - 0.024 2
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EEF1A1 ENSG00000156508 eukaryotic translation elongation 
factor 1 alpha-like 7; eukaryotic trans-
lation elongation factor 1 alpha-like 
3; similar to eukaryotic translation 
elongation factor 1 alpha 1; eukaryotic 
translation elongation factor 1 alpha 1
0.063 3 - -
EEF1B2 ENSG00000114942 eukaryotic translation elongation 
factor 1 beta 2; eukaryotic translation 
elongation factor 1 beta 2-like
- - 0.12 2
EEF2 ENSG00000167658 eukaryotic translation elongation 
factor 2
0.028 2 0.023 2
ENO1 ENSG00000074800 enolase 1, (alpha) 0.058 2 - -
FASN ENSG00000169710 fatty acid synthase - - 0.017 3
FLG2 ENSG00000143520 filaggrin family member 2 - - 0.012 2
GAPDH ENSG00000111640 glyceraldehyde-3-phosphate 
dehydrogenase-like 6; hypothetical 
protein LOC100133042; glyceralde-
hyde-3-phosphate dehydrogenase
0.17 5 0.24 5
GLO1 ENSG00000124767 glyoxalase I - - 0.098 2
HMCN2 ENSG00000148357 hemicentin 2 0.002 2 - -
HNRNPCL1 ENSG00000179172 heterogeneous nuclear ribonucleop-
rotein C-like; heterogeneous nuclear 
ribonucleoprotein C-like 1; similar to 
Heterogeneous nuclear ribonucleopro-
tein C-like dJ845O24.4 (hnRNP core 
protein C-like)
0.11 2 - -
HSP90AA1 ENSG00000080824 heat shock protein 90kDa alpha (cy-
tosolic), class A member 2; heat shock 
protein 90kDa alpha (cytosolic), class 
A member 1
0.056 4 - -
HSP90AB1 ENSG00000096384 heat shock protein 90kDa alpha (cyto-
solic), class B member 1
0.08 3 0.088 6
HSPA1A ENSG00000215328 heat shock 70kDa protein 1A; heat 
shock 70kDa protein 1B
0.54 23 0.7 35
HSPA1B ENSG00000215328 heat shock 70kDa protein 1A; heat 
shock 70kDa protein 1B
0.54 23 0.7 35
HSPA4 ENSG00000170606 heat shock 70kDa protein 4 0.12 8 0.34 22
HSPA4L ENSG00000164070 heat shock 70kDa protein 4-like - - 0.24 11
HSPA5 ENSG00000044574 hypothetical gene supported by 
AF216292; NM_005347; heat shock 
70kDa protein 5 (glucose-regulated 
protein, 78kDa)
0.49 24 0.46 23
HSPA8 ENSG00000109971 heat shock 70kDa protein 8 0.45 26 0.68 33
HSPA9 ENSG00000113013 heat shock 70kDa protein 9 (mortalin) 0.23 11 0.34 16
HSPD1 ENSG00000144381 heat shock 60kDa protein 1 (chapero-
nin) pseudogene 5; heat shock 60kDa 
protein 1 (chaperonin) pseudogene 6; 
heat shock 60kDa protein 1 (chapero-
nin) pseudogene 1; heat shock 60kDa 
protein 1 (chaperonin) pseudogene 
4; heat shock 60kDa protein 1 (chap-
eronin)
0.052 2 - -
HSPH1 ENSG00000120694 heat shock 105kDa/110kDa protein 1 0.059 3 0.24 16
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IFT74 ENSG00000096872 intraflagellar transport 74 homolog 
(Chlamydomonas)
- - 0.043 2
IMPG1 ENSG00000112706 interphotoreceptor matrix proteo-
glycan 1
0.025 2 - -
KCNQ2 ENSG00000075043 potassium voltage-gated channel, 
KQT-like subfamily, member 2
0.072 2 - -
LANCL1 ENSG00000115365 LanC lantibiotic synthetase component 
C-like 1 (bacterial)
- - 0.17 5
LDHA ENSG00000134333 lactate dehydrogenase A 0.093 2 - -
LDHB ENSG00000111716 lactate dehydrogenase B 0.093 3 - -
LRP4 ENSG00000134569 low density lipoprotein receptor-relat-
ed protein 4
- - 0.026 2
MAD2L1 ENSG00000164109 MAD2 mitotic arrest deficient-like 1 
(yeast)
- - 0.26 5
MDN1 ENSG00000112159 MDN1, midasin homolog (yeast) 0.0029 2 - -
NEB ENSG00000183091 nebulin 0.0051 2 - -
NINL ENSG00000101004 ninein-like 0.093 14 - -
NME1 ENSG00000011052 non-metastatic cells 1, protein 
(NM23A) expressed in; NME1-NME2 
readthrough transcript; non-metastatic 
cells 2, protein (NM23B) expressed in
0.38 5 0.41 5
NME2 ENSG00000011052 non-metastatic cells 1, protein 
(NM23A) expressed in; NME1-NME2 
readthrough transcript; non-metastatic 
cells 2, protein (NM23B) expressed in
- - 0.36 2
NPEPPS ENSG00000141279 hypothetical protein FLJ11822; amino-
peptidase puromycin sensitive
- - 0.077 6
PAICS ENSG00000128050 phosphoribosylaminoimidazole car-
boxylase, phosphoribosylaminoimid-
azole succinocarboxamide synthetase
0.049 2 - -
PARP14 ENSG00000173193 poly (ADP-ribose) polymerase family, 
member 14
0.013 2 - -
PC ENSG00000173599 pyruvate carboxylase 0.051 5 0.087 8
PCCA ENSG00000175198 propionyl Coenzyme A carboxylase, 
alpha polypeptide
0.19 9 0.37 20
PCCB ENSG00000114054 propionyl Coenzyme A carboxylase, 
beta polypeptide
0.19 8 0.39 15
PCMT1 ENSG00000120265 protein-L-isoaspartate (D-aspartate) 
O-methyltransferase
- - 0.3 3
PHGDH ENSG00000092621 phosphoglycerate dehydrogenase - - 0.058 3
PPIA ENSG00000196262 similar to TRIMCyp; peptidylprolyl 
isomerase A (cyclophilin A); pepti-
dylprolyl isomerase A (cyclophilin 
A)-like 3
0.26 4 0.33 5
PRDX1 ENSG00000117450 peroxiredoxin 1 0.19 4 - -
PRDX3 ENSG00000165672 peroxiredoxin 3 0.25 4 0.086 2
PRDX4 ENSG00000123131 peroxiredoxin 4 0.23 3 0.44 8
PRDX5 ENSG00000126432 peroxiredoxin 5 - - 0.2 3
PRMT5 ENSG00000100462 protein arginine methyltransferase 5 - - 0.23 9
RBM26 ENSG00000139746 RNA binding motif protein 26 - - 0.013 2
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RUVBL2 ENSG00000183207 RuvB-like 2 (E. coli) - - 0.071 3
RYR3 ENSG00000198838 ryanodine receptor 3 0.0053 2 - -
SDHA ENSG00000073578 succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp)
- - 0.062 3
SET ENSG00000119335 SET nuclear oncogene; similar to SET 
translocation
0.17 4 0.18 4
SYCP2 ENSG00000196074 synaptonemal complex protein 2 0.031 2 - -
TCP1 ENSG00000120438 hypothetical gene supported by 
BC000665; t-complex 1
0.054 3 0.16 7
TTN ENSG00000155657 titin 0.00084 2 - -
TUBA1B ENSG00000123416 hypothetical gene supported by 
AF081484; NM_006082; tubulin, 
alpha 1b
0.19 6 0.34 3
TUBA1C ENSG00000167553 tubulin, alpha 1c - - 0.22 7
TUBB ENSG00000196230 tubulin, beta; similar to tubulin, beta 
5; tubulin, beta pseudogene 2; tubulin, 
beta pseudogene 1
0.16 4 0.35 10
TUBB2C ENSG00000188229 tubulin, beta 2C - - 0.32 2
UBA52 ENSG00000221983 ubiquitin A-52 residue ribosomal 
protein fusion product 1
0.36 5 0.29 4
USP11 ENSG00000102226 ubiquitin specific peptidase 11 0.045 4 0.21 17
USP7 ENSG00000187555 ubiquitin specific peptidase 7 (herpes 
virus-associated)
0.061 7 0.12 13
WDR77 ENSG00000116455 WD repeat domain 77 - - 0.17 4
XRCC5 ENSG00000079246 X-ray repair complementing defective 
repair in Chinese hamster cells 5 
(double-strand-break rejoining)
- - 0.15 7
XRCC6 ENSG00000196419 X-ray repair complementing defective 
repair in Chinese hamster cells 6; simi-
lar to ATP-dependent DNA helicase II, 
70 kDa subunit
0.077 4 0.14 7
YWHAB ENSG00000166913 tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
beta polypeptide
- - 0.31 3
YWHAE ENSG00000108953 similar to 14-3-3 protein epsilon 
(14-3-3E) (Mitochondrial import 
stimulation factor L subunit) (MSF L); 
tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
epsilon polypeptide
0.21 5 0.66 14
YWHAG ENSG00000170027 tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
gamma polypeptide
- - 0.3 4
YWHAH ENSG00000128245 tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
eta polypeptide
- - 0.37 5
YWHAQ ENSG00000134308 tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
theta polypeptide
- - 0.45 10
YWHAZ ENSG00000164924 tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
zeta polypeptide
- - 0.62 10
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Discussion
The analysis of C8orf37-binding proteins identified several distinct clusters based on 
functional annotation. The identification of microtubule- and/or cytoskeleton- associ-
ated proteins interacting directly or indirectly with C8orf37 suggests the involvement of 
C8orf37 in transport along the ciliary axoneme. A member of the C8orf37-protein cluster 
is NINL, a protein that is present at the basal bodies and centrioles of the ciliary apparatus 
of photoreceptors, and it is known to be involved in anchoring, nucleation, and outgrowth 
of microtubules. Most interestingly, NINL links the retinal disorders Usher syndrome 
(USH, deaf-blindness) and Leber congenital amaurosis (LCA, congenital blindness) by 
its direct interaction with USH2A and lebercilin.22 The clinical similarities between USH 
and LCA suggest a significant overlap in the pathogenic mechanisms underlying both 
diseases, which are likely to include ciliary dysfunction. NINL is possibly involved in cy-
toplasmic trafficking and ciliary transport of proteins involved in photoreception. NINL 
could function as a molecular hinge connecting cytoplasmic transport mechanisms to 
IFT machinery, suggesting an important role for NINL in photoreceptor cell function.22 
As NINL function has been shown to be controlled by Plk1 phosphorylation,23 the iden-
tification of CEP170 in the same protein module is very interesting. CEP170 is associated 
with the centrosome in interphase and with the spindle apparatus during mitosis, is in-
volved in the control of cell morphology and, most importantly, also interacts with and 
is phosphorylated by Plk1.15 The identification of a direct interaction of C8orf37 with 
SPAG5, a protein that binds both USH2A and NINL,24 validates and further strengthens 
this connection.
Figure 1. Binding of C8orf37 to SPAG5 and CEP164 assessed with a Yeast two-hybrid assay. Yeast cells (PJ69-4α) co-ex-
pressing full length C8orf37 (pAD-C8orf37 full-length) and a fragment of SPAG5 (pBD-SPAG5 aa973-1034) (Panel A) or full 
length CEP164 (pBD-CEP164 full-length) (Panel B) are shown. Omission of leucine, tryptophan and histidine (-LWH) from 
yeast media selected for co-transformants, and additional omission of adenine (-LWHA) selected for binary protein-protein in-
teractions based on the expression of the HIS3 and ADE2 reporter genes. Colonies growing under this selection were tested for 
α- and β-galactosidase activity; blue staining indicates MEL1 and  LacZ reporter gene activation upon positive protein-protein 
interaction, respectively (-LWH α-galactosidase and -LWHA α -galactosidase).
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Figure 2. Immunohistochemical analysis of the C8orf37 module. Ciliated hTERT-RPE1 cells incubated with antibodies 
against human CEP164 (in green), and (in red) the ciliary markers anti-polyglutaminated tubulin (GT335) (A) or anti-acetylat-
ed α-tubulin (D) revealed that endogenous CEP164 localizes to the base of primary cilia. 
Similar results were observed when hTERT-RPE1 cells were stained with anti-NINL (B and E) and anti-C8orf37 (C and F) in 
combination with the ciliary markers described above: these results suggest colocalization of a module containing CEP164, 
NINL and C8orf37 at the base of the primary cilium. Arrows point to regions enlarged in insets. Nuclei were stained with DAPI 
(in blue). The scale bars represent 5 μm.
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The presence of chaperonins, heat shock proteins and apoptosis-associated protein clus-
ters seems interesting, but they might represent false-positive hits since these proteins 
have previously been identified as artifacts due to effects of bait-protein overexpres-
sion in the TAP approach.25 Similarly, the group of 14-3-3 proteins (YWHAB, YWHAE 
,YWHAG, YWHAH, YWHAQ, YWHAZ), a family of conserved regulatory molecules, 
participate in a wide range of cellular processes through interactions with hundreds of 
structurally and functionally diverse proteins,26 and were therefore considered less infor-
mative to pinpoint cilium-specific functions.
The identification of IFT74, however, does further specify the position of C8orf37 in the 
ciliary machinery. This interaction along with the presence of C8orf37 in the basal body 
and at the proximal side of the photoreceptor connecting cilium (Figure 2) strengthens 
the view that C8orf37 is involved in trafficking and ciliary transport of proteins in photo-
receptors. IFT74 is part of the intraflagellar transport (IFT) complex B, which is responsi-
ble for the kinesin-mediated anterograde movement of particles from the cell body to the 
distal tip of the cilia. The core complex contains IFT88, IFT81, IFT74/72, IFT52, IFT46, 
IFT27 and IFT25. Complex B subunits, IFT172, IFT80, IFT57, and IFT20 are not required 
for the core subunits to stay associated. However, IFT81 and IFT74/72 form a tetrameric 
complex, which serves as a scaffold for the formation of the intact IFT complex B. Simi-
lar analysis of the vertebrate IFT81 and IFT74/72 homologues revealed that this interac-
tion is evolutionarily conserved.27,28 IFT74 and IFT88 govern the function of lebercilin, a 
protein associated with LCA.29 The introduction of two LCA-causing mutations (p.Pro-
493Thrfs*1 and p.Gln297*) in lebercilin abolishes the interaction with the complex B pro-
teins, implicating a specific disruption of IFT-dependent protein transport.7 In general, 
dysfunctions of the components of the IFT transport complex lead to retinal degeneration 
due to mislocalization of structural proteins involved in the phototransduction.30-31 This 
is supported by the development of retinal degeneration and polycystic kidney disease 
in mice with a hypermorphic mutation in IFT88.31,32 In addition, photoreceptor-specific 
silencing of KIF3A leads to mislocalization of opsin and arrestin, proteins involved in 
phototransduction.30 Our results extend this knowledge, and suggest the existence of a 
retinal degeneration-related module, involving USH2A, SPAG5, NINL, lebercilin and, as 
we identify here, CEP170 and C8orf 37, possibly regulated by Plk1 phosphorylation, and 
associated with IFT-B driven transport across the photoreceptor cilium.
Next to this concept, the interaction of C8orf37 with CEP164, which we identified in 
the yeast two-hybrid analysis, provides an alternative pathogenetic mechanism. CEP164 
is a centrosomal protein involved in the cell’s DNA damage response, as it was identi-
fied as a chromatin-binding mediator protein functioning in ataxia telangiectasia mu-
tated and rad3 related kinase (ATR)-mediated checkpoint activation upon UV damage; 
when CEP164 was knocked down, the cell survival upon UV damage was shown to be 
compromised.33 Nonsense mutations in CEP164 cause nephronoptisis-related ciliopa-
thies (NPHP-RC) which affect the kidney, retina, brain and liver, and a non-stop change 
(p.*1460Trpext*57) was identified in an individual affected by LCA. Regarding the ques-
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tion why degeneration occurs in specific organs and characteristic sites, it is tempting to 
speculate that these tissues or cell types are more strongly exposed to genotoxins. Retinal 
degeneration could consequently be caused by postnatal accumulation of UV light-in-
duced DNA damage,34 and potentially C8orf37, in connection to CEP164, could be in-
volved in this process.
Basal bodies and associated centrioles are found at the base of cilia and serve as a nucle-
ation site for the axonemal and cytoplasmic microtubules, respectively.35,36 The photore-
ceptor cell outer segment is regarded as a highly specialized cilium corresponding to the 
ciliary shaft of a prototypic cilium.35-36 The connecting cilium correlates with the short 
junction between the basal body and the axoneme of a prototypic cilium, the transition 
zone.36 C8orf37 now joins other ciliopathy-associated proteins like CEP290, lebercilin, 
RP1, RPGR, and RPGRIP1, involved in non-syndromic retinal dystrophies that have been 
shown to exert their function in transport across the connecting cilium of photoreceptor 
cells, emphasizing the role of impaired cilia function in the pathogenesis of retinal degen-
eration.29,37-41 Studies have demonstrated that at the early stages of the disease, individuals 
with mutations in these genes show some preservation of retinal structures required for 
vision: photoreceptors, inner retina, and retinal pigment epithelium.42-46 This is a critical 
condition for developing therapies aiming the restoration of retinal function, such as gene 
replacement therapy.47 The relatively slow progression rate in patients with C8orf37 muta-
tions opens a significant window of opportunity for such therapies in the future.
Figure 3. Colocalization of C8orf37 and Ninl at the mouse connecting cilium. (A) C8orf37 (in green) was detected at the 
inner segment and the base of photoreceptor connecting cilia, which partially colocalized with the connecting cilium marker 
anti-polyglutaminated tubulin (GT335, in red). C8orf37 stains the accessory centriole but it also stains structures at the distal 
side of the connecting cilium. (B) NINL was detected at the connecting cilium and in the inner segment in photoreceptors. 
Both C8orf37 and NINL co-localize with anti-polyglutaminated tubulin at the photoreceptor connecting cilium, and thus 
share the same subcellular site of action. C8orf37 is also detected at the OPL. The scale bars represent 10 μm. INL: inner nucle-
ar layer; OPL: outer plexiform layer; ONL: outer nuclear layer; IS: inner segment; CC: connecting cilium; OS: outer segment; 
RPE: retinal pigment epithelium; BB: basal body; AC: accessory centriole.
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Materials and methods
Animals and tissues
Mature C5BL/6J mice were housed in standard cages and received water and food ad libi-
tum. Animal experiments were conducted in accordance with international and industrial 
guidelines. Bovine retinas were dissected from eyes obtained from a local slaughterhouse.
DNA constructs
Entry clones encoding full-length C8orf37 (NCBI Reference Sequence: NM_177965.3 
[gene]; NP_808880.1 [protein]) were generated by PCR using cDNA IMAGE clone 
IRAKp961O0678Q (Source BioScience LifeSciences, Berlin, Germany) as template. The 
CEP164 full-length construct was previously described by Chaki et. al.34 The NINLisoB 
full-length (aa1-1033) construct was previously described by van Wijk et al.22 Expression 
constructs were created from entry clones using Gateway technology (Invitrogen, Leek, 
The Netherlands) according to the manufacturer’s instructions. The sequence of all entry 
clones was verified by nucleotide sequencing.
Immunocytochemistry
C8orf37 localization was evaluated in ciliated hTERT-RPE1 retinal pigment epithelium 
cells, which were cultured on coverslips, and after 24 hours of culture, cells were se-
rum-starved for 24 hours to induce cilium formation, as previously described.48 Cov-
erslips were fixed in icecold methanol for 10 min, treated with 1% Triton X-100 in PBS 
for 5 minutes and blocked in 2% bovine serum albumin (BSA) in PBS for 20 minutes. 
For the microtubule-association experiment, cells were treated for 2 hours with 20 μM 
nocodazole prior to fixation. Coverslips were incubated for 1 hour with anti-C8orf37, 
anti-NINLisoB, or rabbit anti-CEP164 (SDIX, Newark, USA) in combination with anti 
α-polyglutaminated tubulin (GT335, kindly donated by Dr. Carsten Janke, CNRS Cen-
tre de Recherches en Biochimie Macromoléculaire, Montpellier, France), or acetylated 
α-tubulin antibody, diluted 1:1500 in 2% BSA in PBS. After washing in PBS, the cov-
erslips were incubated with the secondary antibody (goat-α-rabbit) Alexa 568 or 488, 
Invitrogen, Leek, The Netherlands) for 45 minutes. The coverslips were washed again in 
PBS and shortly in milliQ-purified water, after which they were mounted in Vectashield 
containing DAPI (Vector Laboratories, Burlingame, CA, USA). The localization of the ex-
pressed proteins was analyzed on a Zeiss Axio Imager Z1 fluorescence microscope (Zeiss, 
Oberkochen, Germany), equipped with a 63x objective lens. Optical sections were gener-
ated through structured illumination by inserting an ApoTome slider into the illumina-
tion path. Images were processed using Axiovision 4.3 (Zeiss) and Adobe CS4 Photoshop 
(Adobe Systems, San Jose, CA, USA).
Immunohistochemistry
Unfixed adult mouse eyes were collected and frozen in melting isopentane. Seven mi-
crometer cryosections were cut and treated with 0.01% Tween in PBS for 20 minutes 
and subsequently blocked in blocking buffer (0.1% ovalbumin and 0.5% fish gelatin in 
PBS). After the blocking step, the cryosections were incubated overnight with rabbit-an-
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ti-C8orf37 (1:500, Sigma-Aldrich, Zwijndrecht, the Netherlands) or rabbit-anti-NINL 
(previously described)- in combination with GT335, diluted in blocking buffer. Alexa 
Fluor 488- and 568-conjugated secondary antibodies were also diluted in blocking buffer 
and incubated for 1 hour in the dark. Staining of cell nuclei was performed with DAPI 
(1:8000). Prolong Gold Anti-fade (Molecular Probes, Leiden, the Netherlands) was used 
for embedding the sections. Pictures were made with a Zeiss Axio Imager Z1 fluorescence 
microscope (Zeiss), equipped with a 63x objective lens and an ApoTome slider. Images 
were processed using Axiovision 4.3 (Zeiss) and Adobe CS4 Photoshop (Adobe Systems). 
Procedures followed were in accordance with the ethical standards of the responsible 
committee on animal experimentation.
Yeast two-hybrid analysis
The GAL4-based yeast two-hybrid system (HybriZAP, Stratagene, La Jolla, USA) was 
used for the identification of ciliary protein interaction partners of C8orf37. Constructs 
encoding full-length C8orf37 fused to the GAL4 DNA-binding domain (GAL4-BD) were 
used as baits to screen full length or fragments of a collection of ciliary proteins (Table 
2) fused to the GAL4 activation domain (GAL4-AD). The yeast strain PJ69-4A, which 
carries the HIS3 (histidine), ADE2 (adenine), MEL1 (α-galactosidase) and LacZ (β-ga-
lactosidase) reporter genes, was used as a host. Interactions were analyzed by assessment 
of reporter gene activation based on growth on selective media (HIS3 and ADE2 reporter 
genes) and  α-galactosidase colorimetric plate assays (MEL1 reporter gene). For dedi-
cated yeast two-hybrid assays, combinations of pAD- and pBD-fusion constructs were 
co-transformed in PJ69-4α. Interactions were analyzed as described for the yeast two-hy-
brid screen.
Tandem affinity purification (TAP) and mass spectrometry (MS) analysis
Human embryonic kidney 293-T cells (HEK293T) were transfected with plasmids en-
coding full-length C8orf37 protein fused to an N- and C-terminal SF-TAP-tag  using PEI 
(PolySciences, Warrington, PA, USA) as a transfection reagent. Cells were transfected 
for 48 hours and lysed in lysis buffer containing 30 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 0.5% Nonidet-P40, protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
Germany) and phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) for 20 minutes at 4 °C. The Streptavidin- and FLAG-based tandem affinity 
purification steps were performed as previously described.49 5% of the final elute samples 
was separated by SDS-PAGE and stained with silver according to standard protocols. The 
rest of the sample was subjected to protein precipitation with chloroform and methanol. 
Protein precipitates were stored at -80 °C. Further processing of protein precipitates, MS 
analysis and peptide identification was carried out as reported by Coene et al.25
Gene Ontology analysis
We predicted the most likely Gene Ontology (GO) biological process using the complete 
list of proteins identified using the DAVID tool (http://david.abcc.ncifcrf.gov/home.jsp).
The annotation terms are clustered based on the share of common genes by using Kappa 
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statistics and Fuzzy heuristic clustering algorithms.13
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Supplementary Table 1. Yeast two-hybrid mating assay. Interaction of AD-C8orf37 with 
the indicated selection of BD-fused ciliary proteins was assessed.
# BD- -LWH -LWHA
1 MAEA - -
2 C20orf11 - -
3 YPEL5 - -
4 MKLN1 - -
5 SMU1 - -
6 RANBP10 - -
7 RMND5B - -
8 RMND5A - -
9 CDR2 - -
10 MAPRE1 - -
11 SPAG5 aa 774-862 - -
12 SPAG5 aa 774-1193 - -
13 SPAG5 aa 973-1034 + +
14 SPAG5 aa 1115-1190 - -
15 SPAG5 aa 973-1193 - -
16 hEPS8 aa 551-end - -
17 hEPS8 aa 551-616 - -
18 hEPS8 aa 182-533 - -
19 hEPS8 aa 182-248 - -
20 hEPS8 aa 1-211 - -
21 hEPS8 L329P - -
22 hEPS8 fl - -
23 Espin fl - -
24 Cacna1D - -
25 IFT20 - -
26 IFT27 - -
27 IFT52 - -
28 IFT54 - -
29 IFT57 - -
30 IFT74 - -
31 IFT81 - -
32 IFT88 - -
33 TTC30A - -
34 IFT140 - -
35 IFT144 - -
36 IFT43 - -
37 NPHP4 7850-7851 - -
38 NPHP4 7850-7853 - -
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39 NPHP4 7852-7851 - -
40 NPHP4 7852-7853 - -
41 NPHP4 12041-12042 - -
42 NPHP4 12041-12043 - -
43 NPHP4 12044-12045 - -
44 NPHP4 12038-12039 - -
45 NPHP4 12038-12040 - -
46 NPHP4 fl - -
47 BBS5 front - -
48 BBS5 middle - -
49 BBS5 back - -
50 BBS5 PH-B2 - -
51 SDCCAG8 fl - -
52 SDCCAG8 fr.1 - -
53 SDCCAG8 fr.2 - -
54 SDCCAG8 fr.3 - -
55 SDCCAG8 short - -
56  C8orf37 fl - -
57 RPGRIP1 C2short - -
58 RPGRIP1 C2long - -
59 RPGRIP1 C2N - -
60 bRPGRIP1 "fl" + coiled coil - -
61 RPGRIP1L C2short - -
62 RPGRIP1L C2C + C2N - -
63 RPGRIP1L C2N - -
64 RPGRIP1L RID - -
65 RPGRIP1L - -
66 hKIAA1345 coiled coil - -
67 hKIAA1345 naC2-end - -
68 hKIAA1345 Cterm - -
69 hKIAA1345 C2 fragment - -
70 hKIAA1345 Nterm - -
71 hKIAA1345 C2-end - -
72 hCRB1-icd - -
73 bCRB1-icd - -
74 hCRB2-icd - -
75 Cep164 fl + +
76 Cep164 1-550 - -
77 Cep164 551-1100 - -
78 Cep164 1101-end - -
79 DCTN1 iso2 (p135) - -
80 DCTN2 (p50) - -
81 LCA5-like Fr1      - -
The retinitis pigmentosa-associated protein C8orf37 associates with a ciliary transport 
module and expands the molecular link of cone-rod dystrophy and retinitis pigmentosa
125
82 LCA5-like Fr2     - -
83 LCA5-like FL     - -
84 BBS1 fl     - -
85 BBS2 fl        - -
86 BBS3 fl      - -
87 BBS4 fl      - -
88 BBS5 fl      - -
89 BBS6 fl        - -
90 BBS7 fl   - -
91 BBS8 fl      - -
92 BBS9 fl        - -
93 BBS10 fl        - -
94 BBS11 fl      - -
95 BBS12 fl      - -
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Supplementary Table 2. Gene Ontology analysis. Gene Ontology (GO) was predicted 
using the complete list of proteins identified using the DAVID tool (http://david.abcc.
ncifcrf.gov/home.jsp). The p-values associated with each terms inside the clusters is the 
Fisher Exact p-values as the same as ones in regular chart report, which represent the 
“degree of enrichment” of the annotation term with your input gene list.
Annotation 
Cluster 1
Enrichment Score: 
9.1448006
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0000166~nucle-
otide binding
44 2.399128 8.71E-12 XRCC5, HSP90AB1, LDHB, TUB-
B2C, XRCC6, CCT2, HSPA1A, CAD, 
CCT3, HSPA1B, TTN, HSPH1, TUBB, 
ACTR1A, HNRNPCL1, HSPA4, HSPA5, 
TUBA1B, GAPDH, MDN1, TUBA1C, 
HSPA8, HSPA9, RBM26, ACTB, 
EEF1A1, TCP1, HSP90AA1, ACACA, 
EEF2, CCT6A, SDHA, CCT7, NME2, 
CCT5, CCT4, NME1, CCT8, HSPA4L, 
PHGDH, RUVBL2, HSPD1, PAICS, 
PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0017076~purine 
nucleotide binding
39 2.126499 1.15E-10 XRCC5, HSP90AB1, TUBB2C, XRCC6, 
HSPA1A, CCT2, CAD, HSPA1B, CCT3, 
TTN, HSPH1, TUBB, ACTR1A, HSPA4, 
HSPA5, TUBA1B, MDN1, TUBA1C, 
HSPA8, HSPA9, ACTB, EEF1A1, TCP1, 
HSP90AA1, ACACA, EEF2, CCT6A, 
SDHA, CCT7, NME2, CCT5, CCT4, 
NME1, CCT8, HSPA4L, RUVBL2, 
HSPD1, PAICS, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0032553~ribonu-
cleotide binding
38 2.071974 1.43E-10 XRCC5, HSP90AB1, TUBB2C, XRCC6, 
HSPA1A, CCT2, CAD, HSPA1B, CCT3, 
TTN, HSPH1, TUBB, ACTR1A, HSPA4, 
HSPA5, TUBA1B, MDN1, TUBA1C, 
HSPA8, HSPA9, ACTB, EEF1A1, TCP1, 
HSP90AA1, ACACA, EEF2, CCT6A, 
CCT7, NME2, CCT5, CCT4, NME1, 
CCT8, HSPA4L, RUVBL2, HSPD1, 
PAICS, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0032555~purine 
ribonucleotide binding
38 2.071974 1.43E-10 XRCC5, HSP90AB1, TUBB2C, XRCC6, 
HSPA1A, CCT2, CAD, HSPA1B, CCT3, 
TTN, HSPH1, TUBB, ACTR1A, HSPA4, 
HSPA5, TUBA1B, MDN1, TUBA1C, 
HSPA8, HSPA9, ACTB, EEF1A1, TCP1, 
HSP90AA1, ACACA, EEF2, CCT6A, 
CCT7, NME2, CCT5, CCT4, NME1, 
CCT8, HSPA4L, RUVBL2, HSPD1, 
PAICS, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0005524~ATP 
binding
32 1.74482 3.40E-09 HSP90AB1, XRCC5, XRCC6, HSPA1A, 
CCT2, CAD, HSPA1B, CCT3, TTN, 
HSPH1, ACTR1A, HSPA4, HSPA5, 
MDN1, HSPA8, HSPA9, ACTB, TCP1, 
HSP90AA1, ACACA, CCT6A, CCT7, 
NME2, CCT5, CCT4, NME1, CCT8, 
HSPA4L, RUVBL2, HSPD1, PAICS, 
PCCB, PCCA, PC
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GOTERM_
MF_FAT
GO:0030554~adenyl 
nucleotide binding
33 1.799346 3.92E-09 HSP90AB1, XRCC5, XRCC6, HSPA1A, 
CCT2, CAD, HSPA1B, CCT3, TTN, 
HSPH1, ACTR1A, HSPA4, HSPA5, 
MDN1, HSPA8, HSPA9, ACTB, TCP1, 
HSP90AA1, ACACA, CCT6A, SDHA, 
CCT7, NME2, CCT5, CCT4, NME1, 
CCT8, HSPA4L, RUVBL2, HSPD1, 
PAICS, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0032559~adenyl 
ribonucleotide binding
32 1.74482 4.71E-09 HSP90AB1, XRCC5, XRCC6, HSPA1A, 
CCT2, CAD, HSPA1B, CCT3, TTN, 
HSPH1, ACTR1A, HSPA4, HSPA5, 
MDN1, HSPA8, HSPA9, ACTB, TCP1, 
HSP90AA1, ACACA, CCT6A, CCT7, 
NME2, CCT5, CCT4, NME1, CCT8, 
HSPA4L, RUVBL2, HSPD1, PAICS, 
PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0001883~purine 
nucleoside binding
33 1.799346 5.71E-09 HSP90AB1, XRCC5, XRCC6, HSPA1A, 
CCT2, CAD, HSPA1B, CCT3, TTN, 
HSPH1, ACTR1A, HSPA4, HSPA5, 
MDN1, HSPA8, HSPA9, ACTB, TCP1, 
HSP90AA1, ACACA, CCT6A, SDHA, 
CCT7, NME2, CCT5, CCT4, NME1, 
CCT8, HSPA4L, RUVBL2, HSPD1, 
PAICS, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0001882~nucleo-
side binding
33 1.799346 6.76E-09 HSP90AB1, XRCC5, XRCC6, HSPA1A, 
CCT2, CAD, HSPA1B, CCT3, TTN, 
HSPH1, ACTR1A, HSPA4, HSPA5, 
MDN1, HSPA8, HSPA9, ACTB, TCP1, 
HSP90AA1, ACACA, CCT6A, SDHA, 
CCT7, NME2, CCT5, CCT4, NME1, 
CCT8, HSPA4L, RUVBL2, HSPD1, 
PAICS, PCCB, PCCA, PC
Annotation 
Cluster 2
Enrichment Score: 
5.9749226
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0042470~mela-
nosome
11 0.599782 1.05E-10 HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, CCT4, YWHAB, FASN, 
HSPA5, PRDX1, YWHAE, HSPA8
GOTERM_
CC_FAT
GO:0048770~pigment 
granule
11 0.599782 1.05E-10 HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, CCT4, YWHAB, FASN, 
HSPA5, PRDX1, YWHAE, HSPA8
GOTERM_
CC_FAT
GO:0031988~mem-
brane-bounded vesicle
14 0.763359 2.67E-05 ALDOA, HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, YWHAB, YWHAE, PRDX1, 
CCT4, FASN, HSPD1, HSPA5, HSPA8, 
IFT74
GOTERM_
CC_FAT
GO:0016023~cytoplas-
mic membrane-bound-
ed vesicle
13 0.708833 8.94E-05 HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, YWHAB, YWHAE, PRDX1, 
CCT4, FASN, HSPD1, HSPA5, HSPA8, 
IFT74
GOTERM_
CC_FAT
GO:0031982~vesicle 14 0.763359 1.44E-04 ALDOA, HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, YWHAB, YWHAE, PRDX1, 
CCT4, FASN, HSPD1, HSPA5, HSPA8, 
IFT74
GOTERM_
CC_FAT
GO:0031410~cytoplas-
mic vesicle
13 0.708833 3.76E-04 HSP90AB1, YWHAZ, AHCY, 
HSP90AA1, YWHAB, YWHAE, PRDX1, 
CCT4, FASN, HSPD1, HSPA5, HSPA8, 
IFT74
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Annotation 
Cluster 3
Enrichment Score: 
5.2464722
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0042981~regula-
tion of apoptosis
18 0.981461 5.11E-06 XRCC5, YWHAZ, TUBB2C, YWHAB, 
PRDX5, HSPA1A, HSPA1B, PRDX3, 
YWHAE, PRDX1, TUBB, NME2, 
CASP14, NME1, CFL1, GLO1, HSPA5, 
HSPD1, UBA52, HSPA9
GOTERM_
BP_FAT
GO:0043067~regula-
tion of programmed 
cell death
18 0.981461 5.83E-06 XRCC5, YWHAZ, TUBB2C, YWHAB, 
PRDX5, HSPA1A, HSPA1B, PRDX3, 
YWHAE, PRDX1, TUBB, NME2, 
CASP14, NME1, CFL1, GLO1, HSPA5, 
HSPD1, UBA52, HSPA9
GOTERM_
BP_FAT
GO:0010941~regula-
tion of cell death
18 0.981461 6.12E-06 XRCC5, YWHAZ, TUBB2C, YWHAB, 
PRDX5, HSPA1A, HSPA1B, PRDX3, 
YWHAE, PRDX1, TUBB, NME2, 
CASP14, NME1, CFL1, GLO1, HSPA5, 
HSPD1, UBA52, HSPA9
Annotation 
Cluster 4
Enrichment Score: 
5.0055058
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0043066~negative 
regulation of apoptosis
12 0.654308 8.96E-06 XRCC5, YWHAZ, PRDX5, HSPA1A, 
PRDX3, HSPA1B, NME2, NME1, CFL1, 
GLO1, HSPD1, HSPA5, UBA52, HSPA9
GOTERM_
BP_FAT
GO:0043069~negative 
regulation of pro-
grammed cell death
12 0.654308 1.02E-05 XRCC5, YWHAZ, PRDX5, HSPA1A, 
PRDX3, HSPA1B, NME2, NME1, CFL1, 
GLO1, HSPD1, HSPA5, UBA52, HSPA9
GOTERM_
BP_FAT
GO:0060548~negative 
regulation of cell death
12 0.654308 1.05E-05 XRCC5, YWHAZ, PRDX5, HSPA1A, 
PRDX3, HSPA1B, NME2, NME1, CFL1, 
GLO1, HSPD1, HSPA5, UBA52, HSPA9
Annotation 
Cluster 5
Enrichment Score: 
4.1522149
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0034622~cellu-
lar macromolecular 
complex assembly
12 0.654308 3.22E-06 TCP1, TUBB, HSP90AA1, SET, PRMT5, 
TUBB2C, WDR77, HSPA4, HSPD1, 
TTN, TUBA1B, TUBA1C
GOTERM_
BP_FAT
GO:0043623~cellu-
lar protein complex 
assembly
9 0.490731 5.98E-06 TCP1, TUBB, HSP90AA1, TUBB2C, 
HSPA4, HSPD1, TTN, TUBA1B, 
TUBA1C
GOTERM_
BP_FAT
GO:0034621~cellu-
lar macromolecular 
complex subunit 
organization
12 0.654308 9.71E-06 TCP1, TUBB, HSP90AA1, SET, PRMT5, 
TUBB2C, WDR77, HSPA4, HSPD1, 
TTN, TUBA1B, TUBA1C
GOTERM_
BP_FAT
GO:0065003~mac-
romolecular complex 
assembly
14 0.763359 1.69E-04 TCP1, HSP90AA1, TUBB2C, YWHAB, 
TTN, TUBB, SET, PRMT5, WDR77, 
HSPA4, HSPD1, MDN1, TUBA1B, 
TUBA1C
GOTERM_
BP_FAT
GO:0043933~mac-
romolecular complex 
subunit organization
14 0.763359 3.20E-04 TCP1, HSP90AA1, TUBB2C, YWHAB, 
TTN, TUBB, SET, PRMT5, WDR77, 
HSPA4, HSPD1, MDN1, TUBA1B, 
TUBA1C
GOTERM_
BP_FAT
GO:0006461~protein 
complex assembly
11 0.599782 9.22E-04 TCP1, TUBB, HSP90AA1, TUBB2C, 
YWHAB, HSPA4, HSPD1, TTN, 
TUBA1B, MDN1, TUBA1C
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GOTERM_
BP_FAT
GO:0070271~protein 
complex biogenesis
11 0.599782 9.22E-04 TCP1, TUBB, HSP90AA1, TUBB2C, 
YWHAB, HSPA4, HSPD1, TTN, 
TUBA1B, MDN1, TUBA1C
Annotation 
Cluster 6
Enrichment Score: 
2.7137009
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0016885~ligase 
activity, forming car-
bon-carbon bonds
4 0.218103 1.03E-05 ACACA, PCCB, PCCA, PC
GOTERM_
MF_FAT
GO:0009374~biotin 
binding
3 0.163577 4.48E-04 ACACA, PCCA, PC
GOTERM_
MF_FAT
GO:0033293~mono-
carboxylic acid binding
3 0.163577 0.051791215 ACACA, PCCA, PC
GOTERM_
MF_FAT
GO:0019842~vitamin 
binding
4 0.218103 0.058267406 ACACA, FASN, PCCA, PC
Annotation 
Cluster 7
Enrichment Score: 
2.6720893
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0006096~gly-
colysis
5 0.272628 1.83E-04 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0006007~glucose 
catabolic process
5 0.272628 4.15E-04 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0019320~hexose 
catabolic process
5 0.272628 8.04E-04 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0046365~mono-
saccharide catabolic 
process
5 0.272628 8.95E-04 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0046164~alcohol 
catabolic process
5 0.272628 0.001463924 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0044275~cellular 
carbohydrate catabolic 
process
5 0.272628 0.001749312 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0006006~glucose 
metabolic process
6 0.327154 0.002349582 ALDOA, LDHB, LDHA, GAPDH, PC, 
ENO1
GOTERM_
BP_FAT
GO:0016052~carbohy-
drate catabolic process
5 0.272628 0.00430778 ALDOA, LDHB, LDHA, GAPDH, ENO1
GOTERM_
BP_FAT
GO:0019318~hexose 
metabolic process
6 0.327154 0.006173511 ALDOA, LDHB, LDHA, GAPDH, PC, 
ENO1
GOTERM_
BP_FAT
GO:0005996~mono-
saccharide metabolic 
process
6 0.327154 0.01117024 ALDOA, LDHB, LDHA, GAPDH, PC, 
ENO1
GOTERM_
BP_FAT
GO:0006091~gen-
eration of precursor 
metabolites and energy
6 0.327154 0.041361641 SDHA, ALDOA, LDHB, LDHA, GAP-
DH, ENO1
Annotation 
Cluster 8
Enrichment Score: 
2.2652035
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0042267~natural 
killer cell mediated 
cytotoxicity
3 0.163577 9.93E-04 TUBB, TUBB2C, PRDX1
GOTERM_
BP_FAT
GO:0002228~natural 
killer cell mediated 
immunity
3 0.163577 9.93E-04 TUBB, TUBB2C, PRDX1
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GOTERM_
BP_FAT
GO:0001909~leu-
kocyte mediated 
cytotoxicity
3 0.163577 0.001582599 TUBB, TUBB2C, PRDX1
GOTERM_
BP_FAT
GO:0002449~lym-
phocyte mediated 
immunity
4 0.218103 0.008777322 TUBB, TUBB2C, HSPD1, PRDX1
GOTERM_
BP_FAT
GO:0001906~cell 
killing
3 0.163577 0.009187572 TUBB, TUBB2C, PRDX1
GOTERM_
BP_FAT
GO:0045087~innate 
immune response
3 0.163577 0.203877097 TUBB, TUBB2C, PRDX1
Annotation 
Cluster 9
Enrichment Score: 
2.2503325
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0051920~peroxire-
doxin activity
4 0.218103 1.64E-05 PRDX4, PRDX5, PRDX3, PRDX1
GOTERM_
MF_FAT
GO:0004601~peroxi-
dase activity
4 0.218103 0.001294745 PRDX4, PRDX5, PRDX3, PRDX1
GOTERM_
MF_FAT
GO:0016684~ox-
idoreductase activity, 
acting on peroxide as 
acceptor
4 0.218103 0.001294745 PRDX4, PRDX5, PRDX3, PRDX1
GOTERM_
MF_FAT
GO:0016209~antioxi-
dant activity
4 0.218103 0.003934277 PRDX4, PRDX5, PRDX3, PRDX1
GOTERM_
BP_FAT
GO:0045454~cell 
redox homeostasis
4 0.218103 0.006563085 PRDX4, PRDX5, PRDX3, PRDX1
GOTERM_
BP_FAT
GO:0034614~cellular 
response to reactive 
oxygen species
3 0.163577 0.014144859 PRDX5, PRDX3, PRDX1
GOTERM_
BP_FAT
GO:0034599~cellular 
response to oxidative 
stress
3 0.163577 0.027914632 PRDX5, PRDX3, PRDX1
GOTERM_
BP_FAT
GO:0000302~response 
to reactive oxygen 
species
3 0.163577 0.07584235 PRDX5, PRDX3, PRDX1
GOTERM_
BP_FAT
GO:0006979~response 
to oxidative stress
3 0.163577 0.262026278 PRDX5, PRDX3, PRDX1
Annotation 
Cluster 10
Enrichment Score: 
2.0414211
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0030069~lysogeny 3 0.163577 9.93E-04 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0019047~provirus 
integration
3 0.163577 9.93E-04 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0015074~DNA 
integration
3 0.163577 0.006424643 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0019059~initiation 
of viral infection
3 0.163577 0.00775004 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0019058~viral 
infectious cycle
3 0.163577 0.027914632 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0022415~viral 
reproductive process
3 0.163577 0.054321712 XRCC5, PPIA, XRCC6
GOTERM_
BP_FAT
GO:0016032~viral 
reproduction
3 0.163577 0.068963122 XRCC5, PPIA, XRCC6
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Annotation 
Cluster 11
Enrichment Score: 
1.8711821
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0004197~cyste-
ine-type endopeptidase 
activity
5 0.272628 0.001427138 USP7, CAPNS1, CASP14, USP11, 
CAPN2
GOTERM_
MF_FAT
GO:0008234~cyste-
ine-type peptidase 
activity
5 0.272628 0.015392372 USP7, CAPNS1, CASP14, USP11, 
CAPN2
GOTERM_
MF_FAT
GO:0004175~endo-
peptidase activity
6 0.327154 0.110836377 USP7, CAPNS1, CASP14, USP11, 
CAPN2, ENO1
Annotation 
Cluster 12
Enrichment Score: 
1.7657925
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0002443~leu-
kocyte mediated 
immunity
5 0.272628 0.001826277 YWHAZ, TUBB, TUBB2C, HSPD1, 
PRDX1
GOTERM_
BP_FAT
GO:0002449~lym-
phocyte mediated 
immunity
4 0.218103 0.008777322 TUBB, TUBB2C, HSPD1, PRDX1
GOTERM_
BP_FAT
GO:0002252~immune 
effector process
5 0.272628 0.008874935 YWHAZ, TUBB, TUBB2C, HSPD1, 
PRDX1
GOTERM_
BP_FAT
GO:0006955~immune 
response
5 0.272628 0.607765177 YWHAZ, TUBB, TUBB2C, HSPD1, 
PRDX1
Annotation 
Cluster 13
Enrichment Score: 
1.6190999
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0043065~positive 
regulation of apoptosis
8 0.436205 0.015343903 TUBB, CASP14, TUBB2C, YWHAB, 
HSPD1, PRDX1, YWHAE, UBA52
GOTERM_
BP_FAT
GO:0043068~positive 
regulation of pro-
grammed cell death
8 0.436205 0.015884368 TUBB, CASP14, TUBB2C, YWHAB, 
HSPD1, PRDX1, YWHAE, UBA52
GOTERM_
BP_FAT
GO:0010942~positive 
regulation of cell death
8 0.436205 0.016252155 TUBB, CASP14, TUBB2C, YWHAB, 
HSPD1, PRDX1, YWHAE, UBA52
GOTERM_
BP_FAT
GO:0006917~induc-
tion of apoptosis
6 0.327154 0.044764339 TUBB, CASP14, TUBB2C, PRDX1, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0012502~induc-
tion of programmed 
cell death
6 0.327154 0.045263821 TUBB, CASP14, TUBB2C, PRDX1, 
YWHAE, UBA52
Annotation 
Cluster 14
Enrichment Score: 
1.5665492
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0032269~negative 
regulation of cellular 
protein metabolic 
process
6 0.327154 0.004712427 HSP90AB1, MAD2L1, SET, YWHAB, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0051248~negative 
regulation of protein 
metabolic process
6 0.327154 0.00553067 HSP90AB1, MAD2L1, SET, YWHAB, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0031400~negative 
regulation of protein 
modification process
5 0.272628 0.005875192 MAD2L1, SET, YWHAB, YWHAE, 
UBA52
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GOTERM_
BP_FAT
GO:0031399~regula-
tion of protein modifi-
cation process
5 0.272628 0.104070547 MAD2L1, SET, YWHAB, YWHAE, 
UBA52
GOTERM_
BP_FAT
GO:0010605~negative 
regulation of macro-
molecule metabolic 
process
8 0.436205 0.156338575 HSP90AB1, MAD2L1, SET, YWHAB, 
YWHAQ, YWHAE, UBA52, ENO1
GOTERM_
BP_FAT
GO:0032268~regula-
tion of cellular protein 
metabolic process
6 0.327154 0.160053807 HSP90AB1, MAD2L1, SET, YWHAB, 
YWHAE, UBA52
Annotation 
Cluster 15
Enrichment Score: 
1.5662678
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0051258~protein 
polymerization
4 0.218103 0.003235437 TUBB, TUBB2C, TUBA1B, TUBA1C
GOTERM_
BP_FAT
GO:0007018~microtu-
bule-based movement
4 0.218103 0.031213968 TUBB, TUBB2C, TUBA1B, TUBA1C
GOTERM_
BP_FAT
GO:0007017~microtu-
bule-based process
4 0.218103 0.198113665 TUBB, TUBB2C, TUBA1B, TUBA1C
Annotation 
Cluster 16
Enrichment Score: 
1.5176824
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0030017~sarco-
mere
4 0.218103 0.02052817 ALDOA, NEB, TTN, ENO1
GOTERM_
CC_FAT
GO:0030016~myofibril 4 0.218103 0.028351581 ALDOA, NEB, TTN, ENO1
GOTERM_
CC_FAT
GO:0044449~contrac-
tile fiber part
4 0.218103 0.029677277 ALDOA, NEB, TTN, ENO1
GOTERM_
CC_FAT
GO:0043292~contrac-
tile fiber
4 0.218103 0.035303348 ALDOA, NEB, TTN, ENO1
GOTERM_
CC_FAT
GO:0031674~I band 3 0.163577 0.042307787 ALDOA, NEB, TTN
Annotation 
Cluster 17
Enrichment Score: 
1.4828515
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0003924~GTPase 
activity
6 0.327154 0.014259322 EEF1A1, TUBB, TUBB2C, EEF2, 
TUBA1B, TUBA1C
GOTERM_
MF_FAT
GO:0005525~GTP 
binding
7 0.381679 0.040461695 EEF1A1, NME2, TUBB, NME1, TUB-
B2C, EEF2, TUBA1B, TUBA1C
GOTERM_
MF_FAT
GO:0019001~guanyl 
nucleotide binding
7 0.381679 0.045053179 EEF1A1, NME2, TUBB, NME1, TUB-
B2C, EEF2, TUBA1B, TUBA1C
GOTERM_
MF_FAT
GO:0032561~guanyl 
ribonucleotide binding
7 0.381679 0.045053179 EEF1A1, NME2, TUBB, NME1, TUB-
B2C, EEF2, TUBA1B, TUBA1C
Annotation 
Cluster 18
Enrichment Score: 
1.4271908
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0043027~caspase 
inhibitor activity
3 0.163577 0.002400938 PRDX5, PRDX3, HSPA5
GOTERM_
MF_FAT
GO:0043028~caspase 
regulator activity
3 0.163577 0.01637744 PRDX5, PRDX3, HSPA5
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GOTERM_
MF_FAT
GO:0004869~cyste-
ine-type endopeptidase 
inhibitor activity
3 0.163577 0.025944958 PRDX5, PRDX3, HSPA5
GOTERM_
MF_FAT
GO:0004866~endo-
peptidase inhibitor 
activity
3 0.163577 0.257845979 PRDX5, PRDX3, HSPA5
GOTERM_
MF_FAT
GO:0030414~pepti-
dase inhibitor activity
3 0.163577 0.277974725 PRDX5, PRDX3, HSPA5
Annotation 
Cluster 19
Enrichment Score: 
1.3594918
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0051960~regula-
tion of nervous system 
development
5 0.272628 0.029190122 XRCC5, YWHAG, YWHAH, XRCC6, 
UBA52
GOTERM_
BP_FAT
GO:0060284~regula-
tion of cell develop-
ment
5 0.272628 0.035859344 XRCC5, YWHAG, YWHAH, XRCC6, 
UBA52
GOTERM_
BP_FAT
GO:0050767~regula-
tion of neurogenesis
4 0.218103 0.079741811 XRCC5, YWHAG, YWHAH, XRCC6
Annotation 
Cluster 20
Enrichment Score: 
1.2271851
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0003746~transla-
tion elongation factor 
activity
3 0.163577 0.011379535 EEF1A1, EEF1B2, EEF2
GOTERM_
BP_FAT
GO:0006414~transla-
tional elongation
4 0.218103 0.023386523 EEF1A1, EEF1B2, EEF2, UBA52
GOTERM_
MF_FAT
GO:0008135~trans-
lation factor activity, 
nucleic acid binding
3 0.163577 0.14263892 EEF1A1, EEF1B2, EEF2
GOTERM_
BP_FAT
GO:0006412~trans-
lation
4 0.218103 0.325036018 EEF1A1, EEF1B2, EEF2, UBA52
Annotation 
Cluster 21
Enrichment Score: 
1.1778002
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0070013~intracel-
lular organelle lumen
17 0.926936 0.056593933 ACTB, XRCC5, XRCC6, YWHAB, 
CCT2, CAD, CCT5, SET, CFL1, RU-
VBL2, HSPD1, HSPA5, PCCB, UBA52, 
PCCA, HSPA9, PC
GOTERM_
CC_FAT
GO:0043233~organelle 
lumen
17 0.926936 0.067016196 ACTB, XRCC5, XRCC6, YWHAB, 
CCT2, CAD, CCT5, SET, CFL1, RU-
VBL2, HSPD1, HSPA5, PCCB, UBA52, 
PCCA, HSPA9, PC
GOTERM_
CC_FAT
GO:0031974~mem-
brane-enclosed lumen
17 0.926936 0.077205747 ACTB, XRCC5, XRCC6, YWHAB, 
CCT2, CAD, CCT5, SET, CFL1, RU-
VBL2, HSPD1, HSPA5, PCCB, UBA52, 
PCCA, HSPA9, PC
Annotation 
Cluster 22
Enrichment Score: 
1.1079973
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0006605~protein 
targeting
6 0.327154 0.009817918 YWHAZ, YWHAG, YWHAB, YWHAQ, 
YWHAE, HSPA9
GOTERM_
BP_FAT
GO:0006886~intracel-
lular protein transport
7 0.381679 0.025862563 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
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GOTERM_
BP_FAT
GO:0034613~cellular 
protein localization
7 0.381679 0.03840184 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
GOTERM_
BP_FAT
GO:0070727~cellu-
lar macromolecule 
localization
7 0.381679 0.039563175 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
GOTERM_
BP_FAT
GO:0015031~protein 
transport
7 0.381679 0.315271629 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
GOTERM_
BP_FAT
GO:0045184~estab-
lishment of protein 
localization
7 0.381679 0.322830394 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
GOTERM_
BP_FAT
GO:0008104~protein 
localization
7 0.381679 0.446709755 YWHAZ, YWHAG, YWHAH, YWHAB, 
YWHAQ, YWHAE, HSPA9
Annotation 
Cluster 23
Enrichment Score: 
1.0753661
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0031980~mito-
chondrial lumen
5 0.272628 0.046126237 HSPD1, PCCB, PCCA, PC, HSPA9
GOTERM_
CC_FAT
GO:0005759~mito-
chondrial matrix
5 0.272628 0.046126237 HSPD1, PCCB, PCCA, PC, HSPA9
GOTERM_
CC_FAT
GO:0044429~mito-
chondrial part
6 0.327154 0.279257849 SDHA, HSPD1, PCCB, PCCA, PC, 
HSPA9
Annotation 
Cluster 24
Enrichment Score: 
1.0526542
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0030863~cortical 
cytoskeleton
3 0.163577 0.034273667 ACTB, CFL1, CAP1
GOTERM_
CC_FAT
GO:0005938~cell 
cortex
4 0.218103 0.056140122 HMCN2, ACTB, CFL1, CAP1
GOTERM_
CC_FAT
GO:0044448~cell 
cortex part
3 0.163577 0.087278982 ACTB, CFL1, CAP1
GOTERM_
BP_FAT
GO:0000902~cell 
morphogenesis
4 0.218103 0.366639725 ACTB, CFL1, CAP1, UBA52
Annotation 
Cluster 25
Enrichment Score: 
0.9303132
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0004003~ATP-de-
pendent DNA helicase 
activity
3 0.163577 0.012315035 XRCC5, XRCC6, RUVBL2
GOTERM_
MF_FAT
GO:0003678~DNA 
helicase activity
3 0.163577 0.029992442 XRCC5, XRCC6, RUVBL2
GOTERM_
MF_FAT
GO:0008094~D-
NA-dependent ATPase 
activity
3 0.163577 0.057021591 XRCC5, XRCC6, RUVBL2
GOTERM_
MF_FAT
GO:0008026~ATP-de-
pendent helicase 
activity
3 0.163577 0.14263892 XRCC5, XRCC6, RUVBL2
GOTERM_
MF_FAT
GO:0070035~purine 
NTP-dependent heli-
case activity
3 0.163577 0.14263892 XRCC5, XRCC6, RUVBL2
GOTERM_
MF_FAT
GO:0004386~helicase 
activity
3 0.163577 0.245278034 XRCC5, XRCC6, RUVBL2
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GOTERM_
BP_FAT
GO:0006281~DNA 
repair
3 0.163577 0.516411045 XRCC5, XRCC6, RUVBL2
GOTERM_
BP_FAT
GO:0006974~response 
to DNA damage 
stimulus
3 0.163577 0.66508467 XRCC5, XRCC6, RUVBL2
Annotation 
Cluster 26
Enrichment Score: 
0.8995977
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0007015~actin 
filament organization
3 0.163577 0.070662617 ALDOA, CFL1, TTN
GOTERM_
BP_FAT
GO:0030036~actin cy-
toskeleton organization
4 0.218103 0.157525901 ALDOA, CFL1, CAP1, TTN
GOTERM_
BP_FAT
GO:0030029~actin 
filament-based process
4 0.218103 0.179748451 ALDOA, CFL1, CAP1, TTN
Annotation 
Cluster 27
Enrichment Score: 
0.8972121
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0006941~striated 
muscle contraction
3 0.163577 0.031625289 ALDOA, RYR3, TTN
GOTERM_
BP_FAT
GO:0006936~muscle 
contraction
3 0.163577 0.237309447 ALDOA, RYR3, TTN
GOTERM_
BP_FAT
GO:0003012~muscle 
system process
3 0.163577 0.271027973 ALDOA, RYR3, TTN
Annotation 
Cluster 28
Enrichment Score: 
0.8141857
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0004175~endo-
peptidase activity
6 0.327154 0.110836377 USP7, CAPNS1, CASP14, USP11, 
CAPN2, ENO1
GOTERM_
MF_FAT
GO:0070011~pepti-
dase activity, acting on 
L-amino acid peptides
7 0.381679 0.16826224 USP7, CAPNS1, CASP14, USP11, 
NPEPPS, CAPN2, ENO1
GOTERM_
MF_FAT
GO:0008233~pepti-
dase activity
7 0.381679 0.193541352 USP7, CAPNS1, CASP14, USP11, 
NPEPPS, CAPN2, ENO1
Annotation 
Cluster 29
Enrichment Score: 
0.7811043
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0009165~nucle-
otide biosynthetic 
process
4 0.218103 0.103365067 ALDOA, NME2, NME1, CAD, PAICS
GOTERM_
BP_FAT
GO:0034654~nu-
cleobase, nucleoside, 
nucleotide and nucleic 
acid biosynthetic 
process
4 0.218103 0.112223788 ALDOA, NME2, NME1, CAD, PAICS
GOTERM_
BP_FAT
GO:0034404~nucleo-
base, nucleoside and 
nucleotide biosynthetic 
process
4 0.218103 0.112223788 ALDOA, NME2, NME1, CAD, PAICS
GOTERM_
BP_FAT
GO:0044271~nitrogen 
compound biosynthet-
ic process
5 0.272628 0.134684558 ALDOA, NME2, NME1, PHGDH, CAD, 
PAICS
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GOTERM_
BP_FAT
GO:0009152~purine 
ribonucleotide biosyn-
thetic process
3 0.163577 0.158242646 ALDOA, NME2, NME1, PAICS
GOTERM_
BP_FAT
GO:0009260~ribonu-
cleotide biosynthetic 
process
3 0.163577 0.173245059 ALDOA, NME2, NME1, PAICS
GOTERM_
BP_FAT
GO:0009150~purine 
ribonucleotide meta-
bolic process
3 0.163577 0.203877097 ALDOA, NME2, NME1, PAICS
GOTERM_
BP_FAT
GO:0009259~ribo-
nucleotide metabolic 
process
3 0.163577 0.223883551 ALDOA, NME2, NME1, PAICS
GOTERM_
BP_FAT
GO:0006164~purine 
nucleotide biosynthetic 
process
3 0.163577 0.226117165 ALDOA, NME2, NME1, PAICS
GOTERM_
BP_FAT
GO:0006163~purine 
nucleotide metabolic 
process
3 0.163577 0.311448697 ALDOA, NME2, NME1, PAICS
Annotation 
Cluster 30
Enrichment Score: 
0.6930984
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0048167~reg-
ulation of synaptic 
plasticity
3 0.163577 0.057469227 YWHAG, YWHAH, UBA52
GOTERM_
BP_FAT
GO:0050804~reg-
ulation of synaptic 
transmission
3 0.163577 0.199459504 YWHAG, YWHAH, UBA52
GOTERM_
BP_FAT
GO:0051969~regula-
tion of transmission of 
nerve impulse
3 0.163577 0.223883551 YWHAG, YWHAH, UBA52
GOTERM_
BP_FAT
GO:0031644~regula-
tion of neurological 
system process
3 0.163577 0.237309447 YWHAG, YWHAH, UBA52
GOTERM_
BP_FAT
GO:0044057~regula-
tion of system process
3 0.163577 0.56218669 YWHAG, YWHAH, UBA52
Annotation 
Cluster 31
Enrichment Score: 
0.5732492
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0016477~cell 
migration
4 0.218103 0.234478405 CFL1, CAP1, YWHAE, COL5A1
GOTERM_
BP_FAT
GO:0051674~localiza-
tion of cell
4 0.218103 0.28515088 CFL1, CAP1, YWHAE, COL5A1
GOTERM_
BP_FAT
GO:0048870~cell 
motility
4 0.218103 0.28515088 CFL1, CAP1, YWHAE, COL5A1
Annotation 
Cluster 32
Enrichment Score: 
0.4509219
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0000793~con-
densed chromosome
3 0.163577 0.178716809 MAD2L1, TTN, SYCP2
GOTERM_
BP_FAT
GO:0000279~M phase 4 0.218103 0.321704004 TUBB, MAD2L1, TTN, SYCP2
GOTERM_
BP_FAT
GO:0000280~nuclear 
division
3 0.163577 0.386309511 TUBB, MAD2L1, TTN
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GOTERM_
BP_FAT
GO:0007067~mitosis 3 0.163577 0.386309511 TUBB, MAD2L1, TTN
GOTERM_
BP_FAT
GO:0000278~mitotic 
cell cycle
4 0.218103 0.389793658 TUBB, MAD2L1, TTN, UBA52
GOTERM_
BP_FAT
GO:0000087~M phase 
of mitotic cell cycle
3 0.163577 0.394910526 TUBB, MAD2L1, TTN
GOTERM_
BP_FAT
GO:0048285~organelle 
fission
3 0.163577 0.405586422 TUBB, MAD2L1, TTN
GOTERM_
BP_FAT
GO:0022403~cell cycle 
phase
4 0.218103 0.461014477 TUBB, MAD2L1, TTN, SYCP2
Annotation 
Cluster 33
Enrichment Score: 
0.4322231
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0006915~apop-
tosis
6 0.327154 0.301134547 CASP14, YWHAB, HSPD1, SYCP2, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0012501~pro-
grammed cell death
6 0.327154 0.31189036 CASP14, YWHAB, HSPD1, SYCP2, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0008219~cell 
death
6 0.327154 0.442837107 CASP14, YWHAB, HSPD1, SYCP2, 
YWHAE, UBA52
GOTERM_
BP_FAT
GO:0016265~death 6 0.327154 0.448849854 CASP14, YWHAB, HSPD1, SYCP2, 
YWHAE, UBA52
Annotation 
Cluster 34
Enrichment Score: 
0.4179279
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0002520~immune 
system development
4 0.218103 0.234478405 XRCC5, XRCC6, PRDX3, HSPD1
GOTERM_
MF_FAT
GO:0043566~struc-
ture-specific DNA 
binding
3 0.163577 0.257845979 XRCC5, XRCC6, HSPD1
GOTERM_
MF_FAT
GO:0043565~se-
quence-specific DNA 
binding
3 0.163577 0.922046823 XRCC5, XRCC6, HSPD1
Annotation 
Cluster 35
Enrichment Score: 
0.2581462
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0031175~neuron 
projection develop-
ment
3 0.163577 0.461611922 ACTB, PHGDH, UBA52
GOTERM_
BP_FAT
GO:0030182~neuron 
differentiation
4 0.218103 0.498420974 ACTB, TUBB, PHGDH, UBA52
GOTERM_
BP_FAT
GO:0048666~neuron 
development
3 0.163577 0.612994208 ACTB, PHGDH, UBA52
GOTERM_
BP_FAT
GO:0030030~cell pro-
jection organization
3 0.163577 0.657787079 ACTB, PHGDH, UBA52
Annotation 
Cluster 36
Enrichment Score: 
0.2304703
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0006511~ubiqui-
tin-dependent protein 
catabolic process
4 0.218103 0.181260261 USP7, MAD2L1, USP11, UBA52
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GOTERM_
BP_FAT
GO:0044265~cellular 
macromolecule cata-
bolic process
5 0.272628 0.647055278 USP7, MAD2L1, USP11, HSPA1A, 
HSPA1B, UBA52
GOTERM_
BP_FAT
GO:0043632~modifi-
cation-dependent mac-
romolecule catabolic 
process
4 0.218103 0.682118678 USP7, MAD2L1, USP11, UBA52
GOTERM_
BP_FAT
GO:0019941~mod-
ification-dependent 
protein catabolic 
process
4 0.218103 0.682118678 USP7, MAD2L1, USP11, UBA52
GOTERM_
BP_FAT
GO:0009057~mac-
romolecule catabolic 
process
5 0.272628 0.704462701 USP7, MAD2L1, USP11, HSPA1A, 
HSPA1B, UBA52
GOTERM_
BP_FAT
GO:0051603~proteoly-
sis involved in cellular 
protein catabol-
ic process
4 0.218103 0.711047978 USP7, MAD2L1, USP11, UBA52
GOTERM_
BP_FAT
GO:0044257~cellular 
protein catabolic 
process
4 0.218103 0.714255149 USP7, MAD2L1, USP11, UBA52
GOTERM_
BP_FAT
GO:0030163~protein 
catabolic process
4 0.218103 0.733944826 USP7, MAD2L1, USP11, UBA52
Annotation 
Cluster 37
Enrichment Score: 
0.2301106
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0051173~positive 
regulation of nitrogen 
compound metabolic 
process
5 0.272628 0.552422972 HSP90AB1, YWHAH, HSP90AA1, 
XRCC6, UBA52
GOTERM_
BP_FAT
GO:0031328~positive 
regulation of cellular 
biosynthetic process
5 0.272628 0.601947166 HSP90AB1, YWHAH, HSP90AA1, 
XRCC6, UBA52
GOTERM_
BP_FAT
GO:0009891~positive 
regulation of biosyn-
thetic process
5 0.272628 0.61353288 HSP90AB1, YWHAH, HSP90AA1, 
XRCC6, UBA52
Annotation 
Cluster 38
Enrichment Score: 
0.1812104
Category Term Count % PValue Genes
GOTERM_
CC_FAT
GO:0005743~mi-
tochondrial inner 
membrane
3 0.163577 0.546558222 SDHA, HSPD1, PC
GOTERM_
CC_FAT
GO:0019866~organelle 
inner membrane
3 0.163577 0.586232107 SDHA, HSPD1, PC
GOTERM_
CC_FAT
GO:0031966~mito-
chondrial membrane
3 0.163577 0.684482299 SDHA, HSPD1, PC
GOTERM_
CC_FAT
GO:0005740~mito-
chondrial envelope
3 0.163577 0.716937981 SDHA, HSPD1, PC
GOTERM_
CC_FAT
GO:0031967~organelle 
envelope
4 0.218103 0.720236296 SDHA, MAD2L1, HSPD1, PC
GOTERM_
CC_FAT
GO:0031975~envelope 4 0.218103 0.722291325 SDHA, MAD2L1, HSPD1, PC
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Annotation 
Cluster 39
Enrichment Score: 
0.1597619
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0043549~regula-
tion of kinase activity
3 0.163577 0.641294191 YWHAG, PRDX3, TTN
GOTERM_
BP_FAT
GO:0051338~regu-
lation of transferase 
activity
3 0.163577 0.663635059 YWHAG, PRDX3, TTN
GOTERM_
BP_FAT
GO:0042325~regu-
lation of phosphor-
ylation
3 0.163577 0.77934074 YWHAG, PRDX3, TTN
Annotation 
Cluster 40
Enrichment Score: 
0.0980126
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0016310~phos-
phorylation
5 0.272628 0.722375392 NME2, NME1, CFL1, PRDX4, CAD, 
TTN
GOTERM_
BP_FAT
GO:0006468~protein 
amino acid phosphor-
ylation
4 0.218103 0.776383048 CFL1, PRDX4, CAD, TTN
GOTERM_
BP_FAT
GO:0006793~phos-
phorus metabolic 
process
5 0.272628 0.850266827 NME2, NME1, CFL1, PRDX4, CAD, 
TTN
GOTERM_
BP_FAT
GO:0006796~phos-
phate metabolic 
process
5 0.272628 0.850266827 NME2, NME1, CFL1, PRDX4, CAD, 
TTN
Annotation 
Cluster 41
Enrichment Score: 
0.0808261
Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0016481~negative 
regulation of tran-
scription
3 0.163577 0.772075983 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0010629~negative 
regulation of gene 
expression
3 0.163577 0.815381529 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0045934~neg-
ative regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolic process
3 0.163577 0.822274965 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0051172~negative 
regulation of nitrogen 
compound metabolic 
process
3 0.163577 0.828119239 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0010558~negative 
regulation of macro-
molecule biosynthetic 
process
3 0.163577 0.849825991 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0031327~negative 
regulation of cellular 
biosynthetic process
3 0.163577 0.85973083 YWHAB, YWHAQ, ENO1
GOTERM_
BP_FAT
GO:0009890~negative 
regulation of biosyn-
thetic process
3 0.163577 0.86774819 YWHAB, YWHAQ, ENO1
Annotation 
Cluster 42
Enrichment Score: 
0.0448181
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Category Term Count % PValue Genes
GOTERM_
BP_FAT
GO:0045941~positive 
regulation of tran-
scription
3 0.163577 0.861775234 YWHAH, XRCC6, UBA52
GOTERM_
BP_FAT
GO:0010628~positive 
regulation of gene 
expression
3 0.163577 0.872860499 YWHAH, XRCC6, UBA52
GOTERM_
BP_FAT
GO:0045935~pos-
itive regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolic process
3 0.163577 0.897388829 YWHAH, XRCC6, UBA52
GOTERM_
BP_FAT
GO:0010557~positive 
regulation of macro-
molecule biosynthetic 
process
3 0.163577 0.911844955 YWHAH, XRCC6, UBA52
GOTERM_
BP_FAT
GO:0010604~positive 
regulation of macro-
molecule metabolic 
process
3 0.163577 0.969770046 YWHAH, XRCC6, UBA52
Annotation 
Cluster 43
Enrichment Score: 
0.0082227
Category Term Count % PValue Genes
GOTERM_
MF_FAT
GO:0046872~metal 
ion binding
21 1.145038 0.977996972 CAPNS1, ACACA, FLG2, CAD, 
NPEPPS, TTN, CAPN2, HMCN2, 
BLVRA, NME2, NME1, RYR3, NINL, 
FASN, GLO1, HSPA5, KCNQ2, LRP4, 
UBA52, ENO1, RBM26, PC
GOTERM_
MF_FAT
GO:0043169~cation 
binding
21 1.145038 0.98090612 CAPNS1, ACACA, FLG2, CAD, 
NPEPPS, TTN, CAPN2, HMCN2, 
BLVRA, NME2, NME1, RYR3, NINL, 
FASN, GLO1, HSPA5, KCNQ2, LRP4, 
UBA52, ENO1, RBM26, PC
GOTERM_
MF_FAT
GO:0043167~ion 
binding
21 1.145038 0.984842645 CAPNS1, ACACA, FLG2, CAD, 
NPEPPS, TTN, CAPN2, HMCN2, 
BLVRA, NME2, NME1, RYR3, NINL, 
FASN, GLO1, HSPA5, KCNQ2, LRP4, 
UBA52, ENO1, RBM26, PC
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Resolving the genetic basis of retinal dystrophies.
The retinal dystrophies cone dystrophy (CD), cone-rod dystrophy (CRD), Leber congen-
tial amaurosis (LCA), and retinitis pigmentosa (RP), affect approximately 1/3,000 indi-
viduals, which corresponds to more than 2 million people worldwide.1 Although these 
diseases are described as distinct clinical entities, they are not always easily distinguished2 
and can have overlapping genetic causes.1 Also, many patients with CD may develop pro-
gressive rod dysfunction over the years. In these individuals the CD evolves into CRD.
To date, 74 genes have been associated with the autosomal recessive (ar) forms of these 
diseases and it is expected that more will follow soon, since ~50% of arRP, 90% of arCD, 
60% of arCRD and 30% of arLCA cases still need to be solved.2 Of the 158 identified 
genes implicated in retinal dystrophies, at least 53 (33%) encode proteins that localize to 
the cilium and/or basal body of the cell. In this thesis, new genetic defects were identified 
and new genetic correlations were established in ciliary genes that underlie these retinal 
dystrophies.
Disease genes identification
In the past four years, we have witnessed the evolution of genetic technologies that have 
greatly accelerated the discovery of gene mutations and modifier alleles implicated in 
inherited retinal ciliopathies. In order to identify the genetic defects in individuals af-
fected by isolated or autosomal recessive inherited CD, CRD, LCA, and RP, we have used 
high-density genome-wide single nucleotide polymorphism (SNP) arrays followed by 
copy number variation (CNV) detection and homozygosity mapping3 in combination 
with a positional candidate gene approach (Figure 1, panel A). Below, the notation ‘ar’ 
includes persons with isolated retinal dystrophies. After the advent of next generation 
sequencing technology, our approach shifted to a combination of homozygosity mapping 
with targeted next-generation sequencing (NGS) (Figure 1, panel B), and finally, to exome 
sequencing (Figure 1, panel C).
Copy number variation (CNV)
CNVs are large genomic duplications or deletions (> 1 kb), which change the number 
of DNA copies.4 Recent studies suggest that CNVs account for up to 20% of all genetic 
variants in humans and encompass more than 70% of the variant bases. Altogether, for 
any given individual, structural variants constitute between 9 and 25 Mb of the genome 
(approximately 0.5 to 1%).4,5 With the implementation of high-density SNP microarrays, 
a genome-wide analysis of CNVs has become feasible to screen individuals for pathogenic 
CNVs. Since many CNVs are identified in each affected individual, a selection needs to 
be made of CNVs that could potentially be pathogenic. As a first filtering step, the occur-
rence and frequency of CNVs in cohorts of apparently healthy individuals can be used to 
discriminate between benign and pathogenic variants.
During the past four years our research group analyzed a cohort of 336 individuals diag-
nosed with retinal dystrophies (55 arCRD, 133 arLCA and 148 arRP) by 5.0, 6.0 and 250K 
Affymetrix SNP arrays, and these data were evaluated for the presence of CNVs. The 
CNV data were filtered for heterozygous and homozygous deletions, since such CNVs 
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could lead to gene loss and thus potentially be pathogenic. We identified a total of 67 
deletions with a cut-off larger than 1 kb in 41 patients, and 26 of these CNVs contain 
coding exons of one or more genes. The majority of these CNVs containing coding exons 
are common variants, and the remaining 6 heterozygous deletions were confirmed by 
quantitative PCR. Seven genes (ADAT1, MCC, PLGLA, RGPD3, SLC23A2, ST6GAL2, and 
YSPLZ) were identified in these 6 heterozygous deletions. However, it was not possible to 
identify the second allele in the coding regions of these genes. Possibly, we miss mutations 
in intronic and/or regulatory regions in these genes and further analysis is needed to de-
termine the pathogenicity of the identified heterozygous deletions.
Disadvantages of this approach are the inability to detect balanced rearrangements, and 
the limited resolution, which does not allow the detection of small (base-pair level) inser-
tions or deletions. 
Homozygosity mapping
Homozygosity mapping has proven to be fruitful to identify defects in known and new 
genes implicated in ar retinal dystrophies.6-8 In this thesis, the analysis of a cohort of pa-
tients (described in chapters 3 and 4) by homozygosity mapping enabled the identifica-
tion of new genetic correlations for BBS1 and IQCB1 with non-syndromic RP and LCA 
respectively.9,10 Despite these results, this approach has advantages and disadvantages in 
both consanguineous and non-consanguineous families. In a sporadic patient from a 
consanguineous family there is a high chance that the mutation occurs homozygously, 
but the homozygous regions are large and numerous, making the search of the causative 
genetic defect very challenging. In a genetically heterogeneous disease, several homo-
zygous regions may overlap with known disease-associated genes, which may compli-
cate the search for the causative mutation.11 On the other hand, in affected persons from 
non-consanguineous matings, the chances are lower that an affected individual carries 
homozygous mutations. However, if an individual carries homozygous mutations, the 
chances to find them are higher because of a limited number and smaller size of homozy-
gous regions. Homozygosity mapping is still a relatively efficient method to detect new ge-
netic defects in consanguineous and nonconsanguineous patients, as shown in extensive 
homozygosity mapping analyses of individuals diagnosed with CRD, LCA or RP, where 
homozygous mutations were identified in ~12% of analyzed individuals.6-8
Next generation sequencing (NGS)
When the homozygous regions are large and numerous, which is often the case in consan-
guineous patients (aproximately 10% of their genomes are homozygous),12 searching the 
causative genetic defect can be a very demanding task. In an affected person of a consan-
guineous family, we identified three sizeable homozygous regions, together encompassing 
46 Mb, and harboring more than 260 genes. Analyzing this number of genes by Sanger 
sequencing would be very time-consuming and costly. However, novel NGS technolo-
gies became available during the course of this thesis work and enabled the analysis of 
most coding exons in the homozygous regions. Targeted NGS analysis of the genes in 
these three homozygous regions identified a homozygous nonsense mutation (c.497T>A; 
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[p.Leu166*]) in C8orf37 (Chapter 6A). Additional mutations in this gene were detected in 
three unrelated families, confirming that C8orf37 is a novel retinal ciliopathy gene.
NGS has some clear advantages compared to previous techniques used in this thesis, as 
it has a base-pair resolution, detects most types of genomic variants, and can directly 
identify the causative variants. However, it also raises new challenges for disease gene 
identification, since this technique is not able to detect non-coding variants, it has a cov-
erage variability due to uneven DNA enrichment, it has a limited resolution for structural 
variations, and it can be very challenging to pinpoint the pathogenic variant among the 
large number of variants detected by this technique. Usually nonsense, frameshift, and 
canonical splice site variants are considered to be pathogenic, but the classification of 
missense changes as well as non-canonical splice-site variants is more complicated. There 
are some helpful tools to determine the pathogenicity of these genetic variants, which 
are based on in silico evidence, evolutionary conservation, and population frequencies.13 
Testing the effect of unknown variants will require functional studies, but designing such 
studies often requires significant laboratory efforts, while the results may not be able to 
give a clearcut answer on the involvement of the variant in the disease.
Candidate gene approach
Another approach that can be used to identify retinal dystrophy genes, is a hypothe-
sis-based candidate gene selection, which can be strengthened by combining it with ho-
mozygosity mapping. Genes are selected on the basis of evidence that they might be in-
volved in the disease pathogenesis.14 This evidence can come from previously implicated 
genes, genes associated with similar diseases, or the function of protein products that 
seem relevant to the physiology of the disease.15 This approach has been successful in the 
past, identifying genes involved in for example LCA for which the LCA5 gene was select-
ed based on similarities with CEP290,16 or for Joubert syndrome, where the RPGRIP1L 
gene was analysed based on similarities with RPGRIP1 (a gene known to be implicated 
in LCA).17 Along the same line, mutations were discovered in the Usher syndrome gene 
CLRN1 in individuals affected by nonsyndromic RP,18 and in a functional component of 
the cone phototransduction pathway, PDE6C, in individuals with cone dystrophy.19
A candidate gene approach has some clear advantages. First, if causality is clear, it re-
quires no additional laboratory experiments except for Sanger sequencing. Second, it 
works equally well for any kind of (complex) monogenic disease, and third, it requires 
in principle only a single patient. However, this approach is severely biased towards the 
current biological knowledge and testing only a single gene can be very time-consuming 
when screening a large number of affected individuals.
A successful example of the candidate gene approach in this thesis work was the selec-
tion of genes associated with syndromes involving retinal dystrophy (like ARL13B, BBS1, 
BBS4, BBS7, BBS12, IQCB1, MKS1, NPHP1, NPHP4, PTHB1 and TMEM67) that were 
present in homozygous regions identified in individuals affected by retinal dystrophies. 
This approach allowed us to identify a large homozygous region encompassing the BBS1 
gene in a person with RP, who upon sequence analysis appeared to carry the p.Met390Arg 
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variant in this gene. Subsequently, we performed restriction fragment length polymor-
phism analysis of the p.M390R allele in 2,007 individuals with arRP. This variant was 
detected homozygously in 10 individuals and compound heterozygously in three indi-
viduals affected by RP. The 14 individuals with two BBS1 variants show a broad clinical 
spectrum ranging from non-syndromic RP to full-blown Bardet-Biedl syndrome (BBS) 
(Chapter 4).
Following the same approach in three individuals affected by LCA, we identified large 
homozygous regions on chromosome 3 encompassing the IQCB1 gene, which has pre-
viously been associated with Senior-Løken syndrome (SLNS), characterized by nephro-
nophthisis and retinal degeneration. Mutation analysis of IQCB1 in these three patients 
and a subsequent cohort of 223 additional individuals with LCA identified frameshift and 
nonsense mutations in 12 persons initially diagnosed with LCA.
On the other hand, this approach was not successful in detecting pathogenic variants 
using a candidate gene approach in which we selected genes expressed in the retinal pig-
ment epithelium (RPE) as candidate genes. The RPE is a monolayer of cells that plays a 
key role in the maintenance of the overlaying photoreceptor layer of the neurosensory 
retina.20,21 Several retinal dystrophy genes expressed in the RPE are involved in the reti-
noid cycle.22-29 In a study by Booij et al.,30 39 genes were found to be highly expressed in 
the RPE, and we selected 12 of these genes (CACNAB2, CNDP1, CXCL14, ERMN, ITGB8, 
Figure 1. Flowchart of disease gene identification strategy. The first step is the diagnosis and subsequent exclusion of known 
mutations by Asper chip technology. A. Initially we have used high-density genome-wide single nucleotide polymorphism 
(SNP) arrays followed by copy number variation detection and homozygosity mapping in combination with a candidate gene 
approach. B. After the advent of next generation sequencing technology, our approach shifted to a combination of homozygos-
ity mapping with targeted next generation sequencing (NGS). C. Finally, we shifted to exome sequencing, and envision that in 
the near future whole genome sequencing will be applied.
Chapter 6
146
PDC, PDL5, PLA2G7, RDH10, RPB1, SLC39A12 and STRA6) that were present in signif-
icant homozygous regions of a total of 26 individuals affected by retinal dystrophies (5 
arCD, 9 arCRD, 8 arLCA and 14 arRP). However, we did not identify pathogenic variants 
in these genes that could be associated with retinal dystrophies.
Similar negative results were obtained when we selected genes encoding proteins that are 
part of the Lebercilin interactome.31 Lebercilin is a ciliary protein associated with LCA, 
and is widely expressed throughout development, including the kidney and the brain, 
suggesting that the protein might be involved in other ciliopathies as well. However, the 
phenotype in affected individuals is only confined to the eye, which raises the possibility 
of redundancy in other tissues except the eye.16 MAEA, PGAM5, RANBP9, RANBP10, 
RMND5A, YPEL5, and WDR26  were selected and screened in 20 individuals diagnosed 
with retinal dystrophies (4 arCD, 3 arCRD, 6 arLCA and 7 arRP), who have homozy-
gous regions that encompass these genes. Again, no pathogenic variants were identified 
in these genes.
The lack of pathogenic variants in our series does not necessarily imply failure of the 
candidate gene approach. The size of the individual cohorts in these two studies, 36 and 
20 individuals for RPE-expressed genes and Lebercilin interactors respectively, consid-
erably reduces the chance of finding a mutation. Expansion of the cohort to a similar 
size as in the BBS1 and IQCB1 studies could yield more promising results. Furthermore, 
a different cohort of individuals could be more appropriate for some of these genes. As 
Lebercilin interactors might be involved in other ciliopathies, it may be more effective to 
analyze individuals affected by syndromic ciliopathies like Alström syndrome (ALMS, 
MIM 203800), BBS (MIM 209900), Ellis–van Creveld syndrome (EVC, MIM 225500), 
Joubert syndrome (JBTS, MIM 213300), McKusick–Kaufman syndrome (MKKS, MIM 
236700), Meckel–Gruber syndrome (MKS,MIM 249000), orofaciodigital syndrome type 
1 (OFD1, MIM 311200), SLNS (MIM 266900), and Usher syndrome. For the study of 
preferentially expressed RPE genes, individuals affected by pattern dystrophy of the RPE 
(MIM 169250) could be an interesting cohort to analyze. Pattern dystrophies refer to a 
heterogeneous group of macular disorders, showing a variety of dystrophic patterns of the 
RPE: adult-onset foveomacular vitelliform dystrophy, butterfly-shaped pigment dystro-
phy, reticular dystrophy of the RPE, multifocal pattern dystrophy simulating fundus fla-
vimaculatus, and fundus pulverulentus.32 These disorders are characterized by alterations 
at the level of the RPE, which may eventually lead to photoreceptor degeneration. Most 
patients with pattern dystrophies present in midlife with mild visual disturbances in one 
or both eyes, and may be misdiagnosed as age-related macular degeneration. The RPE 
cells are also affected in another macular disorder: central areolar choroidal dystrophy 
(CACD). It stands to reason that patients with these types of diseases may be more likely 
to carry pathogenic variants in the RPE-expressed genes analyzed in this study.
Are non-syndromic retinal ciliopathies monogenic diseases?
Although non-syndromic retinal ciliopathies are generally considered monogenic, in re-
cent years evidence has emerged suggesting that at least part of these nonsyndromic reti-
nal ciliopathies cannot be defined strictly as monogenetic diseases.
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In nonsyndromic LCA certain retinal appearances and longitudinal changes in visual 
function appear to be gene-specific.33 For the majority of mutations no clearcut geno-
type–phenotype correlation could be established for nonsyndromic retinal ciliopathies. 
However, there are some interesting examples of correlations between the severity of the 
mutation and the occurrence of syndromic features. In TTC8 (BBS8), a splice site muta-
tion leading to the in-frame skipping of a 30-bp retina-specific exon was identified in a 
family with non-syndromic RP, whereas most BBS-associated mutations in this gene are 
predicted to significantly impact mRNA stability and/or protein function.34 Two missense 
mutations in CLRN1 identified in individuals with RP are predicted to have a less severe 
effect on protein function than mutations identified in patients with Usher syndrome.18 
A CEP164 p.*1460Trpext*57 non-stop mutation was identified in an individual affected 
by LCA,35 whereas nonsense mutations in CEP164 cause nephronophthisis-related cil-
iopathies which affect the kidney, retina, brain and liver. A deep intronic mutation in the 
OFD1 gene was identified in a large family with RP, which inserts a cryptic exon into the 
mRNA. Reduced levels of normally spliced gene product remain,36 in contrast to loss-of-
function mutations in this gene which are associated with oro-facial digital syndrome 
and Joubert syndrome.37,38 A similar disease mechanism was previously reported for an 
intronic mutation in CEP290 that causes LCA,39 while loss-of-function mutations cause 
Joubert and Senior-Løken syndromes, suggesting that reduced dosage of correctly spliced 
ciliopathy genes may be a common disease mechanism in retinal degeneration.
A genotype-phenotype correlation is not always apparent by the type of mutation that is 
identified, as nonsense mutations in some cases can lead to a gene product with residual 
function. In individuals with non-syndromic early-onset retinal dystrophy, the CEP290 
nonsense mutation p.Arg151* leads to differential RNA splicing resulting in RNA prod-
ucts lacking exon 7 or exons 7 and 8, both remaining in-frame.46 It was suggested that the 
different splice products are the result of nonsense-associated altered splicing, a putative 
correction mechanism that recognizes an exon with a premature termination codon and 
excludes that exon from the mature mRNA.47
Another mechanism that can complicate a genotype-phenotype correlation is the occur-
rence of a third allele (modifier) that contributes to the severity of the retinal phenotype. 
In three affected individuals of a family with retinal dystrophy a compound heterozygous 
mutation was identified in CEP290 (c.2991+1655A>G and p.Arg151*), and an additional 
MERTK p.Leu394Serfs*3 mutation was heterozygously present in the most severely af-
fected (LCA) individual, while the MERTK mutation was absent in the two more mildly 
affected members of the family.40 Polymorphic alleles in IQCB1 (p.Ile393Asn) and RP-
GRIP1L (p.Arg744Gln) have been associated with severe disease in X-linked RP caused 
by RPGR mutations.41 The contribution of a modifier to the severity of the retinal pheno-
type is supported by the elevated frequency of unaffected carriers of mutations in retinal 
dystrophies genes in the general population.42
Syndromic and non-syndromic forms of retinal ciliopathies are genetically heterogeneous 
and can show considerable clinical and genetic overlap. Interestingly, a deletion in BBS9 
(p.Glu148_Val234del) causes non-syndromic RP in two affected individuals of the family, 
whereas the third affected individual showed all the primary features of BBS,43 suggesting 
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that a modifier may contribute to the extra-ocular clinical features in the latter individual. 
Similarly, a C8orf37 splice-site mutation in individuals with CRD and postaxial polydac-
tyly most likely results in the skipping of exon 2, yielding a frameshift and truncation of 
the 154 carboxy-terminal amino acids (Chapter 6A), effectively resulting in a null allele. 
One could argue that these individuals are more severely affected, however, the age of 
onset of their retinal disease was milder compared to individuals carrying other C8orf37 
mutations. Given that polydactyly is one of the features of BBS, it is unlikely that this is a 
coincidental finding and suggest the contribution of a modulator to the extra-ocular clin-
ical features. This is supported by the interaction of C8orf37 with ciliary proteins NINL 
and CEP164, which are both associated with other ciliopathies like Usher syndrome and 
nephronophthisis, respectively (Chapter 6B). 
Mutations in the BBS1 gene have previously been associated with BBS44 and in one study 
they were associated with RP and variable mild systemic features.45 For a proportion of 
BBS families, a digenic-triallelic inheritance model has been proposed in which inter-
actions between BBS1 and BBS2 or BBS1 and BBS6 were suggested,45-47 although these 
findings could not be confirmed by other studies.48-50 We found that the BBS1 variant 
p.Met390Arg is significantly associated with nonsyndromic RP or mild BBS (Chapter 4). 
Similarly, the BBS3/ARL6 variant p.Ala89Val and the BBS12 variant p.Ser701* have pre-
viously been implicated in both nonsyndromic RP and BBS.51,52. In other studies consid-
erable variations of systemic features have been described in BBS patients.53-55 A digenic/
triallelic model (with a heterozygous trans-acting epistatic allele, such as the MGC1203 
c.430C>T variant) could explain the differential penetrance or expression of BBS, howev-
er, a cis-acting expression regulator model has been proposed.47 In this model, different 
enhancer or promoter variants may modulate the mRNA expression levels of BBS alleles, 
above the expression threshold the disease is expressed as non-syndromic RP or mild 
BBS and below the expression threshold the disease is expressed as full blow BBS (Figure 
2, panel A).
Another genetic model that may explain the variability of disease expression of retinal 
ciliopathies is a trans-acting regulator model (Figure 2, panel B and C). The combination 
and the type of variant in a specific ciliary gene (gene 1) may determine the severity of the 
phenotype. For example, in non-syndromic retinal ciliopathies two hypomorphic alleles 
may cause a mild phenotype, while the combination of a hypomorphic allele and a null 
allele or two null alleles may cause a severe phenotype. A negatively acting trans-acting 
modifier (gene 2) only expressed in the eye may be additive in this model, leading to a 
more severe disease expression (Figure 2, panel B). Since many of these genes are part of 
ciliary protein complexes, and are expressed broadly in different tissues the same model 
could apply to explain the variability of the extra-ocular features in the syndromic forms 
of the disease. The combination and the type of variant in a specific ciliary gene (gene 1) 
can determine the severity of the syndromic phenotype. However, a negatively trans-act-
ing modifier (gene 3) expressed in different organs could be required to trigger the phe-
notype (Figure 2, panel C). 
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Figure 2. Cis- and trans-acting retinal ciliopathies regulator model. (A) In a cis-acting expression regulator model, the 
mRNA expression levels of a specific ciliary gene (gene 1) may be modulated by different enhancer or promoter variants, indi-
viduals carry two hypomorphic variants (mild/mild) on one or two highly (+++) or moderate (++) expressed alleles result in 
non- syndromic or mild syndromic retinal ciliopathies, and low (+/-) expressed alleles result in syndromic retinal ciliopathies. 
In a trans-acting retinal ciliopathies regulator model, (B) in non-syndromic retinal ciliopathies, the combination and the type 
of variant in a specific ciliary gene (gene 1) can determine the severity of the phenotype. For example, two hypomorphic alleles 
(mild/mild) may cause a mild phenotype, while a combination of a hypomorphic allele and a null allele (mild/sev) or two null 
alleles (sev/sev) may cause a severe phenotype. A negatively trans-acting modifier (mod) in a second gene (gene 2) only ex-
pressed in the eye can be added to this model to lead to a more severe disease expression. Since many of these genes are part of 
ciliary protein complexes, and are expressed broadly in different tissues, the same model could apply to explain the variability 
of the extra-ocular features in syndromic forms of the disease. (C) The combination and the type of variant in a specific ciliary 
gene (gene 1) expressed in different organs can determine the severity of the syndromic phenotype. However, a negatively 
trans-acting modifier (gene 3) could be required to trigger the phenotype in different organs. mild, hypomorphic allele; sev, 
null allele; wt; wild type.
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In summary, non-syndromic retinal ciliopathies are genetically heterogeneous, and mu-
tations in some genes associated with these retinal ciliopathies showed a clear phenotyp-
ical variability. Part of this variability has been explained by a digenic/triallelic model of 
inheritance. Due to the fact that many of these genes are ubiquitously expressed, there 
are affected individuals that showed a variable penetrance of a wide spectrum of clinical 
features, making it more difficult to differentiate the syndromic from the non-syndromic 
form of disease. The evidence reviewed above supports the idea that at least part of these 
non-syndromic retinal ciliopathies are not strictly monogenic and could follow a different 
pattern of inheritance like digenic/triallelic or oligogenic.
Translating molecular knowledge to the clinic
Currently, more than 158 genes have been found to be mutated in individuals with retinal 
dystrophies56 (RetNet; http://www.sph.uth.tmc.edu/retnet/). Until recently it was not fea-
sible to screen all genes involved in retinal dystrophies. Therefore, it has been important 
to establish a correct diagnosis in individuals with retinal dystrophies to facilitate the 
search of the genetic defect. Genetic testing can confirm the disease at the molecular 
level, but does not always provide full insight into diagnosis and prognosis of the disease. 
In CEP290-associated diseases - which showed a wide spectrum from non-syndromic 
LCA to MKS - a clear-cut genotype-phenotype model has not yet been established.57 Al-
though one particular intronic CEP290 variant (c.2991+1655A>G) has been associated 
with non-syndromic LCA.39
Identification of the molecular defect sometimes facilitates a proper clinical diagnosis. 
For instance, we found frameshift and nonsense mutations in IQCB1 in 12 individuals 
diagnosed with LCA (Chapter 3). Upon re-inspection of the patients’ disease status, seven 
were found to have developed SLSN, while in five individuals the diagnosis of LCA could 
be maintained as the kidney function remained normal. Because of the mild symptoms 
in the early stages, there is often a delay in the diagnosis of nephronophthisis (NPHP). 
This holds a risk for sudden death resulting from fluid and electrolyte imbalance.58 By 
contrast, individual diagnosed with NPHP receiving kidney transplants had excellent 
outcomes, which were better compared to the general pediatric transplant population.59
Until recently, the most important aspect of establishing a molecular diagnosis in retinal 
ciliopathies was to support genetic counseling, as patients may have considerable worries 
about passing on the mutation(s) to their children. However, the perspective on therapy 
for retinal ciliopathies looks more promising than ever. Therapeutic options have main-
ly focused on gene augmentation by subretinal injection of viral vectors, which appears 
to be safe and successful in long-term restoring of vision in models for non-syndromic 
retinal dystrophies. The successes of gene augmentation studies in a mouse model for 
childhood blindness60 and a RPE65 null canine model61 have led to ongoing clinical trials 
of ocular subretinal delivery of adeno-associated virus (AAV) serotype 2 carrying human 
RPE65 in individuals with RPE65 mutations.62
Promising alternatives for gene augmentation in retinal dystrophies are therapeutic ap-
proaches using either modified U1 small nuclear RNAs or antisense oligonucleotides to 
correct mutation-induced splicing defects. Treatment of fibroblasts derived from indi-
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viduals with X-linked RP who carry splice defects in RPGR with recombinant lentiviral 
vectors has corrected gene function.63 A recent antisense oligonucleotide based approach 
for the most frequent LCA-causative mutation (c.2991+1655A>G), which resulted in the 
inclusion of an aberrant exon in the CEP290 mRNA, has shown to be successful in almost 
completely redirecting normal CEP290 splicing (dose dependent, with a high degree of 
sequence specificity), using immortalized lymphoblastoid cells of individuals carrying tbe 
intronic CEP290 mutation in a homozygous state.64
The identification of genetic defects and the development of cost-effective screening tools 
are necessary to gain a broader understanding of the disease mechanisms in general. Ex-
tensive genotype-phenotype studies may help to predict the prognosis of the disease and 
determine the eligibility of affected individuals for novel therapeutic options. For this 
propose, large efforts are required to register clinical and genetic data of individuals with 
retinal dystrophies. An example is the RP5000 initiative (http://www.rp5000.nl/), which 
aims to build a national infrastructure to clinically document  inherited vision loss in the 
Netherlands. This database can be accessed by all participating centers for a robust and 
accessible storage of detailed clinical data, clinical follow-up data to document the rate of 
disease progression, and genetic data. This type of effort will facilitate multicenter studies, 
such as large-scale genotype-phenotype correlations, will enable the introduction of new 
treatment modalities, and will allow the selection of patients eligible for clinical trials 
exploring new gene-specific treatments.
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Summary
The aim of this thesis was to identify and characterize new genetic defects underlying 
retinal ciliopathies. For this purpose, we initially used high-density genome-wide single 
nucleotide polymorphism (SNP) arrays for homozygosity mapping in combination with 
a positional candidate gene approach. With the advent of next generation sequencing 
(NGS) technology, our approach shifted to a combination of homozygosity mapping with 
targeted NGS, and finally, to exome NGS.
Chapter 1 provides a general introduction to the retinal anatomy, and a brief description 
of the retinal processes like ciliary transport, phototransduction, and the visual cycle. 
At least 21 genes that encode ciliary proteins are implicated in non-syndromic retinal 
dystrophies such as cone dystrophy (CD), cone–rod dystrophy (CRD), Leber congenital 
amaurosis (LCA), macular degeneration or retinitis pigmentosa (RP). 
In Chapter 2, we summarize all genes, mutations and modifier alleles associated with 
non-syndromic retinal ciliopathies, as well as the clinical aspects of these diseases. The 
generation and characterization of vertebrate retinal ciliopathy animal models have re-
vealed insights into the molecular disease mechanisms, which are indispensable for the 
development and evaluation of therapeutic strategies. We provide a review of the recent 
developments regarding gene augmentation, antisense oligonucleotide-based approach-
es, and pharmacological therapies to antagonize retinal degeneration.
Chapter 3 describes mutation analysis of the IQCB1 gene, which has previously been 
associated with Senior-Løken syndrome (SLSN), in 226 individuals affected by LCA. In 
this study we identified frameshift and nonsense mutations in 12 individuals diagnosed 
with LCA. Upon re-inspection of the patients’ disease status, seven were found to have 
developed nephronophthisis, altering the diagnosis to SLSN, while five maintained the di-
agnosis of LCA as the kidney function remained normal. Our results show that the onset 
of renal failure in persons with IQCB1 mutations is highly variable, and that mutations 
are also found in LCA patients without nephronophthisis, rendering IQCB1 a new gene 
implicated in LCA. However, we believe these patients are at high risk to develop renal 
failure, which in early stages is often not recognized and can cause sudden death from flu-
id and electrolyte imbalance. The wide variability in onset, or even absence, of the kidney 
failure suggests the presence of unknown genetic and/or environmental modifier effects 
and factors. We therefore recommend that all LCA patients should be screened for IQCB1 
mutations, in order to follow them more closely for kidney disease.
Another syndrome that involves retinal dystrophy is Bardet-Biedl syndrome (BBS), a 
clinically and genetically heterogeneous disorder characterized by a wide spectrum of 
clinical features including polydactyly, obesity, learning disabilities, hypogonadism, and 
renal abnormalities. In Chapter 4, we investigated DNA samples of 2,007 individuals af-
fected by autosomal recessive or isolated RP and 1,824 ethnically matched controls for 
the presence of the BBS1 p.Met390Arg allele (the most frequent cause of BBS). The BBS1 
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p.Met390Arg variant was detected in a homozygous state in 11 persons with RP and one 
control, in compound heterozygous state in three affected persons, and in heterozygous 
state in five affected individuals and six controls. The 14 affected persons with two BBS1 
variants exhibited a wide spectrum of disease characteristics, ranging from nonsyndrom-
ic RP to classical BBS. The identification of a homozygous p.Met390Arg variant in a con-
trol individual in this study, and in unaffected parents of BBS patients in other studies, 
suggests that cis- or trans-acting modifiers may influence the disease phenotype.
Chapter 5A presents C8orf37 as a new gene involved in autosomal recessive CRD and 
RP. By using homozygosity mapping in an individual with autosomal recessive RP from 
a consanguineous family, we identified three sizeable homozygous regions, together en-
compassing 46 Mb. NGS of all exons, flanking intron sequences, microRNAs, and other 
highly conserved genomic elements in these three regions revealed a homozygous non-
sense mutation (p.Leu166*) in C8orf37, located on chromosome 8q22.1. C8orf37 se-
quence analysis in additional persons with retinal dystrophy carrying conspicuously large 
homozygous regions encompassing the gene, revealed a homozygous splice-site muta-
tion (c.156-2A>G) in two siblings of a consanguineous family, and homozygous missense 
mutations (p.Arg177Trp, p.Gln182Arg) in siblings of two other consanguineous families. 
The missense mutations affect highly conserved amino acids, and in silico analyses pre-
dicted that both variants are probably pathogenic. Immunohistochemical studies local-
ized C8orf37 at the base of connecting cilia of mouse photoreceptors and at the base of 
the primary cilia of cultured human retinal pigment epithelium cells. Clinical assessment 
revealed CRD in four individuals, and RP with early macular involvement in two individ-
uals. The two CRD siblings with the c.156-2A>G mutation also presented with unilateral 
postaxial polydactyly. Given that polydactyly is one of the features of BBS, it is unlikely 
that this is a coincidental finding. Therefore, C8orf37 mutations might also contribute to 
extraocular abnormalities. These results underline the importance of disrupted ciliary 
processes in the pathogenesis of retinal dystrophies.
In Chapter 5B we defined the proteomic network of C8orf37 through tandem affini-
ty purification (TAP) in combination with mass spectrometry. This analysis identified 
94 proteins that may interact directly or indirectly with C8orf37. A clustering analysis 
identified 18 microtubule- and/or cytoskeleton-associated proteins. We further explored 
the interaction between C8orf37 and three ciliary proteins identified by TAP. A dedicat-
ed yeast two hybrid binding assay confirmed direct binding of CEP164 and SPAG5 to 
C8orf37. Staining of ciliated hTERT-RPE1 cells with anti-C8orf37 and ciliary markers 
demonstrated co-localization of endogenous C8orf37, CEP164 and NINL at the base of 
the primary cilium. In adult mouse photoreceptor cells C8orf37 and NINL were found to 
co-localize in the region of the connecting cilium, and more specifically in the basal body. 
In addition, C8orf37 also stains structures at the distal side of the photoreceptor connect-
ing cilium. The interaction of C8orf37 with NINL, along with the presence of C8orf37 in 
the basal body and the tip of the connecting cilium, suggests the involvement of C8orf37 
in ciliary transport of proteins in photoreceptors. This hypothesis is supported by the 
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observed interaction of C8orf37 with IFT74, a protein involved in the anterograde trans-
port complex in photoreceptors and a part of complex B of the intraflagellar transport 
system. Alternatively, the interaction of C8orf37 with CEP164 suggests a possible role in 
DNA damage response. Further studies are needed to define the exact role of C8orf37 in 
photoreceptors.
Chapter 6 is dedicated to the general discussion. The strengths and limitations of our 
disease gene identification approaches are discussed, highlighting the transition from ho-
mozygosity mapping to exome sequencing. 
Cis- and trans-acting regulator models have been proposed that may explain the wide 
variety in disease expression observed for some genes associated with retinal ciliopathies. 
In the cis-acting model, enhancer/promoter variants may modulate the messenger RNA 
expression levels of a mutated gene and thereby determine the penetrance or expression 
of disease. In the trans-acting model, the combination of sequence variants and the type 
of variant in a specific ciliary gene may determine the severity of the phenotype. For ex-
ample, two hypomorphic alleles may cause a mild phenotype, while the combination of a 
hypomorphic allele and a null allele or two null alleles may cause a severe phenotype. A 
negatively acting trans-acting modifier may be additive in this model, leading to a more 
severe disease expression or could be required to trigger the phenotype in different or-
gans. Since many retinal dystrophy genes encode parts of ciliary protein complexes, and 
are expressed broadly in various tissues, the same model could apply to explain the vari-
ability of the extra-ocular features in syndromic forms of the disease.
In conclusion, the studies described in this thesis have led to significant new insights into 
the molecular genetic basis of syndromic and nonsyndromic retinal ciliopathies.
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Samenvatting
Het doel van dit proefschrift was het identificeren en karakteriseren van nieuwe genetische 
defecten die ten grondslag liggen aan retinale ciliopathieën. Om dit te bereiken hebben 
we eerst homozygotie mapping verricht gevolgd door kandidaatgen analyse, met behulp 
van genoomwijde Single Nucleotide Polymorfisme (SNP) arrays. Met de opkomst van 
de “Next Generation Sequencing” (NGS) technologie verschoof de benadering naar een 
combinatie van homozygotie mapping met gerichte NGS analyse, en tenslotte naar exoom 
sequencing. 
Hoofdstuk 1 bevat een algemene introductie van de anatomie van de retina en een korte 
beschrijving van de retinale processen, zoals transport via de cilia, de fototransductie en 
de visuele cyclus.
Minstens 21 genen die coderen voor cilia eiwitten zijn betrokken bij niet-syndromale 
retina dystrofie, zoals kegel dystrofie (CD), kegelstaafdystrofie (CRD), amaurosis con-
genita van Leber (LCA), macula degeneratie of retinitis pigmentosa (RP). In hoofdstuk 2 
worden alle genen, mutaties en modificerende allelen benoemd die geassocieerd zijn met 
niet-syndromale retinale ciliopathieën, met de bijbehorende klinische aspecten van deze 
aandoeningen. Het genereren en karakteriseren van diermodellen voor retinale ciliopa-
thieën heeft geleid tot inzichten in de moleculaire mechanismen die tot de ziekte leiden, 
hetgeen noodzakelijk is voor de ontwikkeling en evaluatie van therapeutische strategieën. 
Dit hoofdstuk bevat een overzicht van de meest recente ontwikkelingen op het gebied van 
verschillende behandelingsopties, zoals het toevoegen van genen, behandeling gebaseerd 
op antisense oligonucleotides, en farmacologische opties om retina degeneratie te stop-
pen.
Hoofdstuk 3 beschrijft de mutatie analyse van het IQCB1 gen, een gen dat voorheen ge-
associeerd was met het Senior-Løken syndroom (SLSN), bij 226 LCA-patiënten. In deze 
studie werden stopmutaties en frame-shift mutaties gevonden bij 12 personen met LCA. 
Bij nadere analyse van het klinische beeld, bleken 7 individuen SLSN ontwikkeld te heb-
ben, terwijl bij de overige 5 individuen de nierfunctie normaal bleef. De resultaten laten 
zien dat de leeftijd waarop nierfalen wordt gediagnosticeerd bij patiënten met IQCB1 
mutaties erg variabel is, en dat mutaties in IQCB1 ook kunnen leiden tot LCA zonder 
nefronoftisis. Hiermee is IQCB1 een nieuw gen geassocieerd met LCA. Deze patiënten 
hebben een hoog risico op nierfalen, een aandoening die vaak niet herkend wordt in een 
vroeg stadium, en kan leiden tot een plotselinge dood door vocht- en electrolyten disbal-
ans. De grote variatie in de leeftijd waarop nierfalen ontstaat, of zelfs het afwezig zijn van 
nierfalen, suggereert dat nog onbekende genetische factoren of omgevingsfactoren een 
modificerende effect kunnen hebben op de aandoening. Daarom wordt aangeraden om 
alle LCA patiënten te laten screenen op mutaties in IQCB1, zodat hun nierfunctie nau-
wkeurig gecontroleerd kan worden. 
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Een ander syndroom geassocieerd met retina dystrofie is Bardet-Biedl syndroom (BBS), 
een klinisch en genetisch heterogene ziekte gekarakeriseerd door een breed spectrum 
van klinische kenmerken, zoals polydactyly, obesitas, leerproblemen, hypogonadisme 
en nierafwijkingen. In hoofdstuk 4 werd het voorkomen van het p.Met390Arg allel (de 
meest voorkomende oorzaak van BBS) getest in BBS1 bij 2007 individuen met autoso-
maal recessieve of geïsoleerd voorkomende RP en in 1824 etnisch gerelateerde controle 
personen. De BBS1 p.Met390Arg mutatie werd homozygoot gevonden bij 11 RP patiënten 
en in 1 controle individu. Daarnaast kwam deze variant samen met andere BBS1 variant-
en voor bij drie patiënten, en heterozygoot bij vijf patiënten en zes controle individuen. 
De 14 patiënten met twee BBS1 varianten vertoonden een breed spectrum van ziektever-
schijnselen, variërend van niet-syndromale RP tot klassieke BBS. De visus was significant 
verlaagd in acht van de 14 patiënten. De identificatie van de homozygote p.Met390Arg 
variant in één controle individu in deze studie, en in niet-aangedane ouders van BBS-pa-
tiënten in andere studies, suggereert dat factoren die in cis of in trans werkzaam zijn als 
modificerende factoren van invloed kunnen zijn op het fenotype.
Hoofdstuk 5A beschrijft C8orf37 als een nieuw gen betrokken bij CRD en RP. Met behu-
lp van homozygotie mapping bij een patiënt met autosomaal recessieve RP uit een con-
sanguine familie werden drie significante homozygote gebieden geïdentificeerd, met een 
totale lengte van 46 Mb. NGS analyse van alle exonen, flankerende intronen, micro-RNA’s 
en andere sterk geconserveerde genomische elementen in deze drie gebieden leidde tot 
de identificatie van een homozygote nonsense mutatie (p.Leu166*) in C8orf37, gelegen 
in het grootste homozygote gebied op chromosoom 8q22.1. C8orf37 sequentie analyse in 
andere patiënten met retina dystrofie met grote homozygote gebieden die C8orf37 om-
vatten, leidde tot de identificatie van een homozygote splice-site mutatie (c.156-2A>G) 
in twee aangedane personen van een consanguine familie, en homozygote missense mu-
taties (p.Arg177Trp, p.Gln182Arg) bij aangedane personen in twee andere consanguine 
families. De missense mutaties betreffen sterk geconserveerde aminozuren, en in silico 
analyse voorspelde voor beide varianten een waarschijnlijk pathogeen effect. Immuno-
histochemische studies toonden aan dat C8orf37 lokaliseert aan de basis van de het con-
necting cilium in gecultiveerde humane pigment epitheelcellen. Klinische analyse toonde 
CRD aan in vier personen met C8orf37 varianten en RP met vroege betrokkenheid van de 
macula bij twee andere personen met mutaties in dit gen. De twee CRD patiënten met de 
c.156-2A>G mutatie hadden ook unilaterale postaxiale polydactylie. Gezien het feit dat 
polydactylie een kenmerk is van BBS, lijkt dit geen toevallige bevinding. Mogelijk leiden 
C8orf37 mutaties ook tot extraoculaire afwijkingen. 
In hoofdstuk 5B wordt het eiwitnetwerk van C8orf37 bestudeerd door middel van ei-
wit-interactie-screens (Tandem Affinity Purification) in combinatie met massa spectrom-
etrie. Deze analyse identificeerde 94 eiwitten die mogelijk direct of indirecte interactie 
hebben met C8orf37. Een cluster analyse toonde 18 microtubuli- en/of cytoskelet-geasso-
cieerde eiwitten aan. Gebaseerd op deze lijst van interactoren hebben we de mogelijkheid 
van directe interactie van C8orf37 met drie ciliaire eiwitten onderzocht met behulp van 
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“yeast two hybrid” assays. Deze analyse bevestigde een directe verbinding tussen CEP164 
en SPAG5 en C8orf37. De interactie van C8orf37 met NINL en CEP164 werd verder uit-
gezocht. Kleuring met anti-C8orf37 en ciliaire markers in gecilieerde hTERT-RPE1 cellen 
bevestigde de localisatie van endogeen C8orf37 aan de basis van het primaire cilium. 
Vergelijkbare resulaten werden gezien bij hTERT-RPE1 cellen die gekleurd waren met 
anti-CEP164 en anti-NINL in combinatie met ciliaire markers zoals boven beschreven, 
hetgeen aantoont dat beide endogene eiwitten, CEP164 en NINL, colocaliseren aan de 
basis van het primaire cilium. De subcellulaire colocalisatie van C8orf37 en NINL in vol-
wassen muis fotoreceptoren werd gezien in de regio van het verbindende cilium, en meer 
specifiek in de basaallichaampjes. Daarnaast kleurt C8orf37 ook structuren aan de prox-
imale uiteinde van het verbindende cilium. De interactie van C8orf37 met NINL, samen 
met de aanwezigheid van C8orf37 in het basaallichaampje en het proximale uiteinde van 
het verbindende cilium suggereert de betrokkenheid van C8orf37 bij cilair transport van 
eiwitten in fotoreceptoren. Deze hypothese wordt ondersteund door de identificatie van 
IFT74 als interactor van C8orf37. Het IFT74 eiwit is betrokken bij het anterograde trans-
port complex in fotoreceptoren en is onderdeel van complex B van het intraflagellaire 
transport systeem. De interactie met CEP164 wijst op een alternatieve rol voor dit eiwit, 
aangezien CEP164 een centrosomaal eiwit is, betrokken bij een respons op DNA schade. 
Aanvullend onderzoek is nodig om de exacte rol van C8orf38 in fotoreceptoren vast te 
stellen.
Hoofdstuk 6 is gewijd aan een algemene discussie. De voor- en nadelen van de gebruikte 
genidentificatie methode worden bediscussieerd, hetgeen de verschuiving benadrukt van 
homozygotie mapping naar exoom sequencing.
Modellen met daarin cis-en trans-werkende regulatoren werden voorgesteld welke de 
grote verscheidenheid verklaren van ziekte expressie voor sommige genen geassocieerd 
met retinale ciliopathies. In het cis-werkende model kunnen enhancer of promoter vari-
anten de messenger RNA expressie moduleren van een gemuteerd gen en daarmee de 
penetrantie van de ziekte. In een trans-werkend regulator model, zal de combinative van 
varianten en het type variant in een specifiek ciliair gen de ernst van het ziektebeeld bep-
alen. Bijvoorbeeld, twee hypomorfe allelen kunnen een mild fenotype veroorzaken, ter-
wijl een combinatie van een hypomorf allel met een eiwit-inactiverend allel of twee eiwit 
inactiverende mutaties aanleiding kunnen geven tot een ernstig fenotype. Een negatief 
in trans-werkende modifier kan een additief effect hebben in dit model, hetgeen leidt tot 
een ernstiger ziektebeeld, of kan leiden tot symptomen in niet-oculaire organen. Omdat 
vele retina dystrofie genen coderen voor onderdelen van het ciliaire eiwit complex, die 
breed tot expressie komen, zou hetzelfde model ook een verklaring kunnen geven voor de 
variable expressive van de ziekte buiten het oog.
Concluderend hebben de studies in dit proefschrift geleid tot significante nieuwe inzicht-
en van de moleculair genetische basis van niet-syndromale retinale ciliopathieën.
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